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Abstract 
Analysis of Expressed Sequence Tags Mapping to the Critical Region of the 
5q- Syndrome 
Amanda J. Strickson 
Doctor of Philosophy 
February 2002 
The 5q- syndrome is a myelodysplastic syndrome characterised by a macrocytic 
anaemia, hypolobulated megakaryocytes, a low risk of transformation to AML, 
and a 5q- chromosome as the sole karyotypic abnormality. The approximate 5Mb 
critical region of gene loss of the 5q- syndrome has been defined in two patients 
with the 5q- syndrome at 5g31-q33, flanked by the genes for FGF1 and IL12ß. 
The frequent loss of genetic material from the long arm of chromosome 5 in 
association with a malignancy has led to the hypothesis that, by analogy with 
other malignancies characterised by genetic loss, the 5q- syndrome is caused by 
loss of function of a gene with tumour suppressor activity. 
A transcript map of the 5q- syndrome critical region was generated with the aim 
of identifying the putative tumour suppressor gene associated with this disease. 
The expressed sequence tag (EST) database, db(EST) was used to isolate novel 
coding sequences mapping to the critical region of gene loss. Ten novel coding 
sequences (C5orf4, AF010242, AF156165, Cdy-17a06, Bda-87b11 195312, 
4885953 / 143772,120101,195971, and 199067) were localised to the YAC contig 
spanning the critical region at 5g31-q33. The ten cDNA clones were sequenced, 
and overlapping clones were identified and sequenced in order to generate 
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complete or partial coding sequences. This included the cloning of novel gene, 
C5orf4, and the identification of the human synaptopodin and dynactin p62 genes. 
In addition, the human homologues of the Drosophila melanogaster RMSA-1 and 
Saccharomyces cerevisiae CDC60 genes, and two known human genes (PP2A and 
HAH1) were localised to the critical region. Expression in human peripheral blood 
leukocytes and CD34+ progenitor cells was investigated for each known and novel 
gene. Genomic localisation, expression patterns and predicted function would 
suggest these known and novel genes represent putative tumour suppressor 
genes. 
Mutation studies were carried out on six known, and two novel candidate genes 
mapping to the narrowed 1.5Mb critical region of gene loss at 5g31.3-q32. No 
mutations were found in the coding regions/exons of these genes, suggesting they 
are not involved in the pathogenesis of the 5q- syndrome. 
Page 4 
Contents 
Acknowledgements 
Abstract 
Contents 
List of tables and figures 
Chapter 1 
Chapter 2 
Chapter 3 
Chapter 4 
Chapter 5 
Chapter 6 
Chapter 7 
Introduction 
Materials and methods 
2 
3 
5 
6 
10 
27 
Identification, localisation, cloning, and mutation 71 
analysis of novel gene C5orf4 
Identification, localisation and analysis of novel cDNAs 105 
mapping to the critical region of the 5q- syndrome 
Analysis of species homologous ESTs mapping to the 148 
critical region of the 5q- syndrome 
Molecular analysis of the SPARC, HAH1, and 176 
Annexin VI genes 
Mutation analysis on five 5q- syndrome candidate genes 208 
by Denaturing High-Performance Liquid 
Chromatography (DHPLC) 
Chapter 8 Conclusion 
Publications 
References 
Appendix Stock solutions and buffers 
264 
272 
273 
304 
Page 5 
List of tables and figures 
Chapter 1 
Figure 1.1 
Chapter 3 
Table 3.1 
Table 3.2 
Figure 3.1 
Table 3.3 
Table 3.4 
Figure 3.2 
Figure 3.3 
Figure 3.4 
Chapter 4 
Table 4.1 
Table 4.2 
Table 4.3 
Table 4.4 
Figure 4.1 
Figure 4.2 
Table 4.5 
Ideogram of chromosome 5 showing some of the genes 19 
localised to 5g31-q33 
MTN blots used in Northern analysis containing a variety 78 
of human tissues 
3' RACE PCR primer conditions for C5orf4 82 
Northern blot analysis of I. M. A. G. E. cDNA clone 469867 88 
Overlapping I. M. A. G. E. cDNA clones identified from 91 
db(EST) homology searches from I. M. A. G. E. 
cDNA clone 469867 
Clones identified from screening the I. M. A. G. E. cDNA 94 
clone collection library with probe 209846 
Transcription map of the critical region of the 5q- syndrome 96 
Nucleotide and predicted amino acid sequence of C5orf4 98 
Mutation analysis by cycle sequencing of patient 3 and 100 
C5orf4 
RACE PCR primer conditions for novel cDNAs A3B02,119 
43911, and 199067 
YAC localisation PCR conditions for novel cDNAs 43911,121 
195312,195971,120101, and 199067 
ESTs identified from the collaboration with Genethon, and 123 
the Human Chromosome 5 GeneMap'98 
ESTs identified from the Human Chromosome 5 124 
GeneMap'99 
Gene dosage analysis of novel cDNA AF156165 125 
Data map of novel ESTs identified from Genethon, the 126 
Human Chromosome 5 Genemaps'98 and '99, and the 
UniGene set 
Expression patterns and transcript sizes of novel cDNAs 128 
mapping to the critical region of the 5q- syndrome, 
identified from Genethon and the Human Chromosome 
5 GeneMap'98 
Page 6 
Table 4.6 
Figure 4.3 
Figure 4.4 
Figure 4.5 
Figure 4.6 
Figure 4.7 
Chapter 5 
Table 5.1 
Figure 5.1 
Figure 5.2 
Figure 5.3 
Figure 5.4 
Figure 5.5 
Chapter 6 
Figure 6.1 
Table 6.1 
Table 6.2 
Table 6.3 
Table 6.4 
Expression patterns and transcript sizes of novel cDNAs 129 
mapping to the critical region of the 5q- syndrome, 
identified from the Human Chromosome 5 GeneMap'99 
Northern blot analysis of I. M. A. G. E. cDNA A3B02, and 130 
I. M. A. G. E. cDNA 240080 
Hybridisation of high-density gridded, foetal brain cDNA 131 
library filters, with cDNA probes Cdy-17a06 and Bda-87b11 
Dot blot analysis following hybridisation with cDNA probe 133 
Cdy-17a06 
Southern blot analysis of I. M. A. G. E. cDNA clone A3B02 135 
3' RACE PCR analysis of I. M. A. G. E. cDNA clone A3B02 137 
ESTs identified from the Human Chromosome 5 162 
GeneMap and UniGene set 
Gene dosage analysis of I. M. A. G. E. cDNA clone 194016 164 
Northern blot analysis of I. M. A. G. E. cDNA clone 33583 165 
(CDC60) 
BlastX analysis of I. M. A. G. E. cDNA clone 33583 and the 166 
yeast cell division cycle gene CDC60 
Sequence alignment of I. M. A. G. E. cDNA clone 145513 and 167 
the Homo sapiens chromosomal protein mRNA (the human 
homologue of the Drosophila RMSA-1 gene) 
Sequence alignment of I. M. A. G. E. cDNA clone 33583 and 169 
the Homo sapiens mRNA for leucyl tRNA synthetase 
(human homologue of the yeast CDC60 gene) 
Ideogram of chromosome 5 illustrating the critical region 182 
of the 5q- syndrome and the position of the SPARC gene 
PCR primer conditions for localisation of the SPARC, 188 
HAH1, and annexin VI genes to the YAC contig 
PCR primer conditions for CD34+ expression analysis in 188 
the SPARC, HAH1, and annexin VI genes 
SPARC exon PCR conditions 
HAH1 and annexin VI RT-PCR conditions 
190 
193 
Table 6.5 HAH1 and annexin VI cycle sequencing PCR conditions 194 
Page 7 
Table 6.6 
Figure 6.2 
Figure 6.3 
Figure 6.4 
Figure 6.5 
Figure 6.6 
Chapter 7 
Table 7.1 
Table 7.2 
Table 7.3 
Table 7.4 
Table 7.5 
Table 7.6 
Table 7.7 
Figure 7.1 
Figure 7.2 
Figure 7.3 
Figure 7.4a 
Figure 7.4b 
Table 7.8 
Table 7.9 
Clinical details of 5q- syndrome patients included in the 196 
study 
Northern blot analysis of I. M. A. G. E. cDNA clone 416547 197 
Physical map of the SPARC, HAH1, and annexin VI genes 199 
CD34+ expression analysis of the annexin VI gene 200 
Sequence analysis of exon 10 of the SPARC gene 201 
BestFit analysis of patient 1 and the published sequence 203 
from fragment 2 of the annexin VI gene 
Clinical details of 5q- syndrome and AML patients 223 
included in the study 
Exon primer conditions for the GSHPx-3 and 224 
ENSG00000145872 genes 
Exon primer conditions for the PDGFRJ3 gene 225 
Exon primer conditions for 15/23 exons of the MEGF1 gene 226 
Exon primer conditions for novel gene ENSG00000086589 227 
5' RACE PCR conditions for candidate gene MEGF1 233 
Genomic PCR primer conditions for candidate gene MEGF1 234 
Agarose gel analysis of the 358bp product of GSHPx-3 238 
exon 1 
Agarose gel analysis of the 449bp PCR product of PDGFRß 239 
exon 23b 
Creation of a mixture of heteroduplexes and homoduplexes 240 
through hybridisation 
Graphical representation of the melting curve of MEGF1 241 
exon 19 
Graphical representation of the temperatures required to 241 
partially denature MEGF1 exon 19 
Temperature predictions for DHPLC analysis on the 243 
WAVETM system, for candidate gene MEGF1 
Temperature predictions for DHPLC analysis on the 244 
WAVETM system, for candidate genes PDGFRJ3 and 
ENSG00000086589 
Page 8 
Table 7.10 
Figure 7.5a 
Figure 7.5b 
Table 7.11 
Table 7.12 
Figure 7.6 
Figure 7.7a 
Figure 7.7b 
Figure 7.8 
Figure 7.9 
Chapter 8 
Figure 8.1 
Temperature predictions for DHPLC analysis on the 245 
WAVE 
TM 
system, candidate genes GSHPx-3 and 
ENSO00000145872 
DHPLC chromatogram of exon 1 of the ENSG00000145872 246 
novel gene 
DHPLC chromatograms of heterozygotes 247 
Frequency of polymorphisms identified from the coding 249 
exons and flanking intronic sequence of candidate gene 
MEGF1, by DHPLC, in patients with the 5q- syndrome/ 
AML and normal controls 
Frequency of polymorphisms identified from the coding 250 
exons and flanking intronic sequence of candidate genes 
GSHPx-3, PDGFRß, and ENSG00000086589 by DHPLC, in 
patients with the 5q- syndrome/AML and normal controls 
Sequence analysis of exon 14 of the MEGF1 gene 251 
DHPLC analysis of exon 23e of the PDGFRß gene 253 
Sequence analysis of exon 23e of the PDGFRß gene 254 
BestFit analysis of patient 13 and the published sequence 255 
from exon 8 of the ENSG00000086589 novel gene 
BlastX analysis of 5' RACE sequence and the Homo sapiens 257 
chromosome 5 working draft sequence, contig AC011374 
Transcription map of the critical region of the 265 
5q- syndrome 
Page 9 
Chapter 1 
Introduction 
1.1 The Myelodysplastic syndromes 
1.2 Molecular pathogenesis of MDS and leukaemia 
1.2.1 Cytogenetic studies 
1.2.1 Molecular studies 
1.3 The 5q deletion in MDS and leukaemia 
1.4 The 5q- syndrome 
1.4.1 Cytogenetic studies 
1.4.1 The 5q- syndrome critical region 
1.5 The Human Genome Project 
1.6 Human Chromosome 5 
1.7 Expressed Sequence Tags 
1.8 I. M. A. G. E. cDNA clones 
1.9 Aims of the study 
Page 10 
1.1 The Myelodysplastic syndromes 
The myelodysplastic syndromes (MDS) are a heterogeneous family of 
haematologic disorders characterised by ineffective haematopoiesis (Gordon, 
1999). These syndromes usually present in the elderly but can be seen in younger 
patients, including children, and are increasingly being recognised as a 
complication of chemotherapy used in the treatment of a variety of human 
malignancies (Passmore et al., 1995). 
MDS is classified into primary MDS (no known cause) and secondary MDS 
(strong association with a leukaemogenic agent). The latter usually have multiple 
chromosome abnormalities in the bone marrow and evolve to acute myeloid 
leukaemia (AML). A central criterion for the classification is the percentage of 
blasts, or primitive leukaemic cells, in the bone marrow. The French-American- 
British (FAB) classification system has developed five categories of disease: (1) 
refractory anaemia (RA), (2) refractory anaemia with ringed sideroblasts (RARS), 
(3) refractory anaemia with excess blasts (RAEB), (4) refractory anaemia with 
excess blasts in transformation (RAEB-t), and (5) chronic myelomonocytic 
leukaemia (CMML). 
For the majority of patients with MDS, no curative option exists. Patients who are 
young enough and have an available matched sibling or matched unrelated donor 
may undergo an allogeneic bone marrow transplant (BMT) with a potential cure 
rate of 30% to 50% (Gordon, 1999). The major issue regarding this approach is the 
relatively high morbidity, or that no overall benefit will occur (relapse). The best 
results in terms of relapse-free survival appear to be in the subset of patients with 
early or low-grade MDS, characterised by RA or RARS. These patients that lack a 
donor for BMT are considered for induction chemotherapy. However, the 
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majority of elderly patients with MDS are not optimal candidates for such an 
approach. As a result, supportive care has a major role for patients with MDS and 
depending on the FAB presentation, may be the preferred approach. 
Erythropoietin, a growth factor, is probably the most commonly used supportive 
care after transfusion. The use of colony-stimulating growth factors to support 
leukopenia is currently under investigation. 
1.2 Molecular pathogenesis of MDS and leukaemia 
MDS is a clonal disorder that affects an early haematopoietic progenitor, giving 
rise to clonally derived neutrophils, erythrocytes and platelets. Evidence that 
MDS is a clonal disorder includes the presence of clonal cytogenetic abnormalities 
and analysis using X-inactivation-based clonality assays. These findings support 
the concept of somatic mutations giving rise to clonal proliferation of myeloid 
lineage cells. However, these studies provide no information about the identity of 
the genes involved in the development of myelodysplasia. The frequent loss of 
genetic material has led to the hypothesis that, by analogy with other malignancies 
characterised by genetic loss (e. g. retinoblastoma, Wilms' tumour, and colon 
cancer), MDS is caused by loss of function of a gene with tumour suppressor 
activity (Legare and Gilliland, 1995). 
1.2.1 Cytogenetic studies 
The reported frequency of karyotypic abnormalities in primary MDS varies 
between one third and one half of all successfully karyotyped cases (Second 
International Workshop on Chromosomes in Leukaemia, 1980). Approximately 
fifty percent of these abnormalities are due to the loss of genetic material as a 
result of whole or partial chromosome loss, specifically chromosomes 5,7,11,12, 
Page 12 
13, and 20 (Mufti, 1992). Monosomies and chromosome deletions have been 
reported in all five MDS subtypes, although some of these karyotypic 
abnormalities occur more frequently in specific subsets of the disease. For 
example, the 5q deletion is the most commonly reported abnormality in RA, and 
has been found in up to 70% of patients (Heim and Mitelman, 1986). This is in 
contrast with monosomy 7 that is found in only 5% of patients with RA, but 30% 
of patients with RAEB and RAEB-t, and 20% with CMML. The llq deletion is 
frequently observed in RARS and is reported in up to 20% of patients. The 12p 
deletion is rarely reported in RA and RAEB, but is a frequent karyotypic 
abnormality in CMML (Mufti, 1992). 
Cytogenetic studies have frequently identified non-random interstitial deletions 
and monosomy of chromosomes 5,7, and 17 in MDS and AML suggesting a 
multistep pathway that culminates in an aggressive clinical course (Castro et al., 
2000). Thus, the unmasking of an oncogene(s) or inactivation of a tumour 
suppressor gene(s) on these deleted chromosomes may have an important role in 
the evolution of MDS to AML when they are mutated. In AML and MDS, 
mutations of the p53 gene are infrequent, less than 10%. However, in a subset of 
patients with "17p- syndrome", the p53 gene is frequently mutated (Lai et al., 
1995). A recent report on this distinct clinical entity demonstrated loss of the p53 
gene by 17p deletion in 14/16 cases analysed by FISH. 
Deletion of the long arm of chromosome 20 (20q-) represents the most common 
chromosomal abnormalities associated with the myeloproliferative disorders 
(MPDs), but is also found in MDS and AML (Bench et al., 2000). Bench et al., have 
recently defined a MPD CDR of 2.7Mb, and a MDS/AML CDR of 2.6Mb. The 
authors localised twenty ESTs to the new MDS critical region of which five were 
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expressed in both human bone marrow and purified CD34+ cells. These genes 
represent candidates for the 20q- MDS/AML gene. 
Partial deletion of the long arm of chromosome 7, or monosomy 7, is a common 
abnormality in the bone marrow cells of patients with MDS or acute non- 
lymphocytic leukaemia (ANLL) (Kere et al., 1987). Molecular studies using DNA 
markers that map to the terminal portion of 7q have shown the deletion to be 
interstitial, although terminal deletions have been reported (Fourth International 
Workshop on Chromosomes in Leukaemia, 1984). As for chromosome 20, studies 
have shown there to be more than one critical region of gene loss of the 7q- 
chromosome. The region 7q22-q34 may contain as many as four distinct minimal 
regions of deletion that are thought to contain one or more myeloid tumour 
suppressor genes (Todd et al., 2001). 
1.2.2 Molecular studies 
The mechanism causing chromosomal deletions in MDS and leukaemia is 
unknown. Huebner et al., (1989) suggested that specific genome 
rearrangements/ deletions may be characteristic of and necessary for many 
differentiating lineages. That is, terminally differentiated cells within a particular 
lineage, rearrange specific chromosome regions in order to switch on or off the 
genes required for differentiation. 
The consistent loss of genetic material in MDS and leukaemia is suggestive of a 
recessive mechanism of pathogenesis and it is probable that the deleted 
chromosome /bands harbour as yet unidentified tumour suppressor genes. 
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The importance of recessive mechanisms of tumourigenesis was first highlighted 
by Knudson in 1971. According to Knudson's 'two-hit' model, dominantly 
inherited predisposition to cancer entails a germline mutation, while 
tumourigenesis requires a second, somatic mutation. Non-hereditary cancer of the 
same type requires the same two hits, but both are somatic. The original tumour 
used in this model, retinoblastoma, involves mutation or loss of both copies of the 
RB1 tumour suppressor gene in both hereditary and non-hereditary forms 
(Knudson, 1971). 
Current molecular studies have identified at least seventeen tumour suppressor 
genes involved in the pathogenesis of cancer, including; p53, adenomatous 
polyposis coli (APC) gene, and the neurofibromatosis type 1 (NFI) gene. A review 
of the existing data about the various tumour suppressor genes and their role in 
disease leads to the conclusions that; the mutation of a single tumour suppressor 
gene can predispose to tumours in multiple tissues, and the products of tumour 
suppressor genes function at many levels within the cell (Skuse and Ludlow, 
1995). For instance, they may be transcription factors, e. g. RB1, they may play a 
part in cytoplasmic signal transduction, e. g. NF1, or they may be cell-surface 
adhesion molecules, e. g. the deleted in colorectal cancer (DCC) gene. In every 
case, the tumour suppressor protein has a role in the normal regulation of cellular 
proliferation or differentiation. Tumours arise when that role is disturbed and cell 
growth becomes unrestrained. 
There are many recent reports suggesting that known tumour suppressor genes 
may be involved in the pathogenesis of MDS and leukaemia. These include the 
p53, p15 and p16 genes. A study by Kaneko et al., (1995) showed 7/57 patients 
with MDS demonstrated p53 mutations within exons 5 to 8. Four of these patients 
progressed to acute leukaemia within seven months of diagnosis, and the 
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remaining three died within seven months without leukaemic transformation. 
These findings suggest that mutations of the p53 gene can be implicated in 
leukaemic transformation and a poor prognosis in MDS (Kaneko et al., 1995). 
Moreover, Adamson et al., (1995) showed that 4/26 MDS patients had deletion of 
the p53 gene in exons 5 to 8. Each case with a mutation was of an advanced MDS 
subtype, suggesting that p53 mutation in these diseases is a terminal genetic event 
in the process of leukaemogenesis. 
In the last five years, two cyclin-dependent kinase inhibitors, known as 
p16(INK4A/MTS1) and p15(INK4B/MTS2), which map to 9q21, have been found 
deleted in a wide range of tumours and mutated in a small number of leukaemic 
patients (Sill et al., 1996). Moreover, recently it has been shown that the p15 gene is 
methylated in MDS. Hypermethylation and homozygous deletions of tumour 
suppressor genes establish a new paradigm of inactivation by lack of expression, 
in contrast to the previously identified tumour suppressors which are 
predominantly inactivated by point mutations followed by loss of the wild-type 
allele. To investigate the time sequence of occurrence of p15 gene methylation in 
MDS and its correlation with leukaemic transformation and survival of patients, 
Tien et al., (2001) analysed the methylation status of the p15 promoter region in 
fifty patients and was serially studied in twenty-two of them. 17/50 (34%) 
patients showed p15 gene methylation, first demonstrated at diagnosis or during 
follow-up. When FAB subtypes at the time of study were used in the analysis, the 
incidence of p15 methylation in each risk group remained stable throughout the 
course: 0% for RA and RARS, and from 23% to 30% for RAEB, RAEB-t and 
CMML. The incidence of p15 methylation rose to 60% at initial study and finally, 
to 75% in cases of AML evolved from MDS. Most patients (69%) with p 15 
methylation showed disease progression to AML. Thus, p15 methylation can be 
detected early at the diagnosis of MDS or acquired during disease progression. It 
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may play an important role in the pathogenesis of some high-risk MDS and is 
related to leukaemic transformation of MDS (Tien et al., 2001). 
The isolation and characterisation of these putative tumour suppressor genes will 
lead to an understanding of molecular mechanisms underlying normal 
haematopoiesis and leukaemic transformation. Several strategies are currently in 
use to clone these genes, including defining a critical region of gene loss using 
molecular studies and FISH (Fluorescent in situ Hybridisation) analysis; 
constructing a YAC (Yeast Artificial Chromosome) contig giving genomic 
coverage of the whole region; isolating novel coding sequences from these YACs 
from appropriate cDNA libraries; screening expressed sequence tag (EST) 
databases; and more recently, using the draft and/or annotated sequence available 
from the Human Genome Project (HGP). The tumour suppressor gene is 
ultimately identified as a result of its frequent inactivation by rearrangement or 
point mutation. To date, however, no tumour suppressor genes have been 
definitively identified from the study of chromosome deletions in MDS or AML. 
1.3 The 5q deletion in MDS and leukaemia 
The 5q deletion is the most frequently reported deletion in MDS and is observed 
in 10-15% of patients (Heim and Mitelman, 1986). The deletion is interstitial, the 
breakpoints are variable, and all thirteen bands between 5q11 and 5q35 have been 
cited as breakpoints. The breakpoints most frequently reported are 5q12-14 
(proximal) and 5q31q33 (distal). There also appears to be breakpoint uniformity 
with respect to the 5q deletion. Johansson et al., (1993) and Pedersen and Jensen, 
(1991) found that the del(5)(q13q33) is the most commonly reported 5q deletion in 
MDS. The proposed location of the critical region of the 5q- chromosome differs 
markedly between cytogenetic studies suggesting the presence of more than one 
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critical region. This has been confirmed by molecular studies that have defined 
more than one critical region of the 5q- chromosome. Boultwood and Fidler, (1995 
review) describe four distinct CDRs between chromosome 5g31-q33 reported in 
the literature. However, the approximate 5Mb CDR reported by Boultwood et al., 
(1994a) was defined by patients with the 5q- syndrome, while Willman et al., 
(1993); Le Beau et al., (1993), and Nagarajan et al., (1994) defined their 5q deletion 
CDRs with MDS, therapy related MDS, and AML patients. Willman et al., defined 
a more centromeric critical region mapping between interleukin 5 (IL5) and the 
granulocyte/macrophage colony stimulating factor (CSF2) centering around the 
interferon regulatory factor 1 (IRF1) gene in a group of patients with MDS and 
AML. Le Beau et al., have defined the critical region of the 5q deletion as the 
approximately 2.8Mb region between the interleukin 9 (IL9) gene and genetic 
marker D5S166 in a range of malignant myeloid disorders. Nagarajan et al., 
defined their critical region between that of Willman and Le Beau, encompassing 
the early growth response (EGR1) gene. This suggests the disease genes causing 
the 5q- syndrome, therapy related MDS and AML may be distinct, and that 
chromosome 5g31-q33 harbours more than one tumour suppressor gene. 
A number of haematopoietic growth factors and receptors have been localised to 
5q an it has been speculated that one or more of them may be critical to the 
pathogenesis of these myeloid disorders. The heamatological role of these genes 
has led to the proposal that loss of one or more of these genes may be critical to 
pathogenesis in those myeloid disorders with a 5q deletion. They include the 
interleukins 3,4,5, and 9, CSF2, receptor for the macrophage colony stimulating 
factor (CSF1R), EGR1, and IRF1 gene, see Figure 1.1. The molecular analysis of 
candidate and newly identified genes mapping within the respective critical 
regions should reveal the nature of the genetic abnormality associated with the 
myelodysplastic syndromes in which these deletions are found. 
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Figure 1.1 
Ideogram of chromosome 5 showing some of the genes localised to 5g31-q33. 
Early studies focused on the EGR1, CSF1R, and putative tumour suppressor gene, 
IRF1, as candidate genes for MDS and AML in association with a 5q deletion. A 
study by Willman et al., (1993) showed IRF1 to be consistently deleted at one or 
both alleles in thirteen cases of MDS/AML with aberrations of 5q31. However, a 
study by Boultwood et al., (1993) showed the IRF1 gene to be retained in patients 
with the 5q- syndrome. The EGR1 gene was also shown to be retained on the 5q- 
chromosome in patients with the 5q- syndrome, thus mapping it outside the 
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critical region of gene loss (Boultwood et al., 1994a). The CSF1R gene is a 
transmembrane glycoprotein with tyrosine kinase activity (Sherr et al., 1985). The 
loss of one CSF1R allele from the 5q- chromosome together with the loss of the 
second allele on the apparently normal homologous chromosome 5 in a 
subpopulation of cells in some patients with MDS was demonstrated by 
Boultwood et al., (1994a). 
1.4 The 5q- syndrome 
The 5q- syndrome was first described by Van den Berghe et al., in 1974 when three 
patients with long-standing idiopathic refractory anaemia and an interstitial 
deletion of the long arm of chromosome 5 were discovered. Two additional 
patients were reported in 1975 by Sokal et al., and a new haematologic syndrome 
was established, the 5q- syndrome. Patients with the 5q- syndrome are typically 
elderly (mean age at presentation is 66 years), predominantly female, present with 
macrocytic anaemia, modest leukopenia, normal or high platelet count, a 
hypercellular bone marrow, hypolobulated megakaryocytes, del (5q) as the sole 
karyotypic abnormality, and a low risk of transformation to acute leukaemia. The 
management of patients with the 5q- syndrome is supportive. The major 
manifestation of the syndrome relates to the refractory anaemia and the need for 
RBC transfusions. Patients with severe anaemia who receive repeated red cell 
transfusions are at risk for the infectious complications of blood transfusions, as 
well as iron overload. 
1.4.1 Cytogenetic studies 
The 5q deletion occurs as the sole karyotypic abnormality in the 5q- syndrome, as 
well as together with other karyotypic abnormalities in the other MDS subtypes 
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RAEB, RARS, secondary MDS, and de novo AML. In contrast to t-MDS and t-AML 
with del(5q), the 5q- syndrome usually has a benign clinical course, with a low 
risk of transformation to acute leukaemia. However, the del(5q) in the 5q- 
syndrome is cytogenetically indistinguishable from the deleted chromosome 5 of 
other myeloid disorders (Jaju et al., 1998). 
The mechanism causing the 5q- syndrome is unknown. The frequent loss of 
genetic material from the long arm of chromosome 5 in association with the 5q- 
syndrome is suggestive of a recessive mechanism of tumourigenesis, and it is 
probable that the deleted chromosome bands harbour a tumour suppressor gene 
(Boultwood et al., 1994a). 
1.4.2 The 5q- syndrome critical region 
The 5q deletion typically encompasses most of the long arm of chromosome 5, 
del(5)(5q13q33), and many known genes are lost as a result (Boultwood et al., 
1994a). However, uncharacteristically small 5q deletions in association with MDS 
have been reported (Van den Berghe et al., 1985). Prior to this study, Boultwood et 
al., had identified two patients with the 5q- syndrome and small 5q deletions, 
del(5)(5q31q33). Loss of heterozygosity (LOH) analysis was carried out on a large 
number of genes localised to this region, with the aim of identifying the gene(s) 
involved in the pathogenesis of the 5q- syndrome. The CDR of 5.6Mb was 
delineated between the gene for fibroblast growth factor acidic (FGF1) and the 
subunit of interleukin 12 (IL12_ß) in these two patients with the 5q- syndrome and 
small deletions. The common region of loss in these two 5q- syndrome patients 
include the glucocorticoid receptor (GRL), adrenergic receptor beta 2 (ADRß2), 
CSF1 R, secreted protein, acidic, and rich in cysteine (SPARC), and glutamate 
receptor (GLUM) genes. These genes were shown to be deleted from the 5q- 
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chromosome in both patients, and thus represent candidates for the 5q- syndrome 
gene. This 5q- syndrome critical region is telomeric to and distinct from the other 
critical regions on 5q associated with MDS and AML. 
1.5 The Human Genome Project 
The Human Genome Mapping Project initiated in 1990 is a thirteen year, $13 
billion effort coordinated by the US Department of Energy (DOE) and the National 
Institute of Health (NIH). The project was originally planned to last fifteen years, 
but rapid technological advances have accelerated the expected completion date to 
2003, as of January 31,2001. The project goals are to: 
- identify the 100,000 genes in human DNA (now believed to be 30,000). 
- determine the sequences of the 3 billion bp that make up human DNA. 
- store this information in databases. 
- develop tools for data analysis. 
- address the ethical, legal and social issues that may arise from the project. 
There are five International Human Genome Project major sequencing sites: DOE 
national laboratories; Baylor College of Medicine Genome Centre; The Sanger 
Centre; The Washington University Genome Sequencing Centre; and The 
Whitehead Institute/MIT Centre for Genome Research. There are twenty-one 
other US Genome Research sites working on individual chromosomes and fifteen 
other International Genome Research Centres from many countries including 
Australia, China, France, Germany, Japan, and Korea. The five major sites (from 
the US and UK) have split the project between them: The Genome Centre at 
Washington University are sequencing chromosomes 1,2,3,4,5,7,8,12,13,14, 
16,22, and X. The Sanger Centre are sequencing chromosomes 1,6,9,10,13,20, 
22, and X. The first major breakthrough was the recent completion of the 33.4Mb 
sequence of chromosome 22 (Dunham et al., 1999). As of November 10 2001, over 
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671,627,342 bp (22%) of the 3 billion bp is finished, high-quality sequence. A 
further 499,693,897 bp (16%) is unfinished sequence. 
1.6 Human Chromosome 5 
Human Chromosome 5 spans 198cM and contains 194Mb of DNA and represents 
approximately 6% of the human genome. It is currently being sequenced by 
Washington University Genome Centre. On April 13 2000, researchers had 
decoded in draft form the genetic information on chromosome 5. As of October 31 
2001,22.4Mb (11.5%) of the 194Mb is finished, high-quality sequence. 
1.7 Expressed Sequence Tags 
Until 1991, the field of human genome research had predominantly concerned 
itself with large-scale mapping and technology development, for example, 
positional cloning and the advent of automated sequencing. Many exciting 
insights have arose from positional cloning: the involvement of trinucleotide 
repeats in the pathophysiology of Fragile X syndrome, Huntington's disease and 
other neurological disorders is a striking example (La Spada et al., 1994). 
However, up until 1995, only approximately forty genes had been cloned by virtue 
of their location in the genome, compared with approximately 36,000 sequences in 
the primate division of GenBank that are the result of functional cloning 
experiments. Thus, in 1991, the introduction of expressed sequence tags (ESTs), 
partial 5' and 3' cDNA sequences (approximately 300-400bp) representing 
expressed human genes, was considered the route to completing the 3 billion 
nucleotide sequence of the human genome. However, it was not until 1994 with 
the advent of the Washington University EST Project, funded by Merck and Co. 
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and the National Cancer Institute, that ESTs gave the public data collections a 
boost. 
The National Centre for Biotechnology Information (NCBI) 
(http: //www. ncbi. nlm. nih. gov) was established on November 4 1988. It is 
located at the National Library of Medicine, on the campus of the NIH. It is 
responsible for building, maintaining, and distributing biomedical databases 
including GenBank, and the NIH genetic sequence database that collects all 
known DNA sequences from scientists worldwide. GenBank 
(http: //www. ncbi. nlm. nih. gov/Genbank/index. html) is the NIH genetic 
sequence database; an annotated collection of all publicly available DNA 
sequences. There are approximately 14,397,000,000 bases in 13,602,000 sequence 
records as of October 2001. One division of GenBank is the EST database db (EST) 
(http: //www. ncbi. nlm. nih. giv/dbEST/index. html). On November 2 2001, the 
number of public entries in db(EST) was 9,407,866, of which 3,876,441 were 
human. db(EST) has had a profound effect on the positional candidate approach 
of gene discovery. As of December 5 1997,91% (83/91) of positionally cloned 
genes mutated in human disease states were represented by exact matches with 
one or more ESTs in db(EST). 
Several research groups have utilised the EST resource in assigning expressed 
genes to specific chromosomes and regions. ESTs that are regionally assigned can 
serve as sequence tagged sites (STSs) for physical mapping projects, and have the 
advantage of representing an expressed gene. Furthermore, when localised, ESTs 
can serve as candidate genes for disease loci in the region. As the human 
expression map becomes denser, the use of ESTs as candidate genes may 
supplement the traditional strategy of positional cloning (Pappas et al., 1995). In 
1993, Sargent et al., identified the gene for glycerol kinase deficiency through the 
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use of EST localisation as well as a traditional positional cloning approach. 
Recently, ESTs have been localised to transcript maps on several chromosomes, 
including chromosome 5, with the aim of identifying candidate tumour 
suppressor genes for cancer and genetic disease. For example, Horrigan et al., 
(1999) constructed a high-resolution map of a 6Mb interval of human chromosome 
5, band 5g31, incorporating 175 STSs, of which 122 were non-redundant ESTs. The 
ESTs were assembled into overlapping transcription units and ordered with 
respect to polymorphic markers in the region, resulting in a comprehensive map. 
This map will facilitate gene discovery efforts for several disorders, including the 
genes deleted in acute myeloid leukaemias and myelodysplasia (Horrigan et al., 
1999). The distal short arm of chromosome 1 (1p) is rearranged in a variety of 
malignancies, and several genetic diseases also map to this region (Jensen et al., 
1997). Jensen et al., constructed an integrated transcript map to precisely define 
the positions of genes and ESTs previously mapped to 1p35-p36. One hundred 
and forty-two ESTs were mapped by PCR against a radiation hybrid panel, with 
the aim of identifying candidate genes for genetic disease mapping to distal 1p. 
1.8 I. M. A. G. E. cDNA clones 
The Integrated Molecular Analysis of Genomes and their Expression (I. M. A. G. E. ) 
consortium at http: //www-bio. llnl. gov/bbrp/image/image. html was initiated in 
1993 by four academic groups on a collaborative basis after informal discussions 
led to a common vision on how to achieve an important goal in the study of the 
human genome. The groups shared high-quality, arrayed cDNA libraries and 
placed sequence map and expression data on the clones in these arrays into the 
public domain. From this information, they re-arrayed the unique clones to form 
a "master array" which they hoped would ultimately contain a representative 
cDNA from each and every gene in the genome. There are five authorised 
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distributors of I. M. A. G. E. clones from either the USA: American Type Culture 
Collection (ATCC); Genome Systems Inc.; Research Genetics; or Europe: UK 
HGMP, Hinxton, England; and Resource Centre of the German Human Genome 
Project, Berlin Germany. The majority of ESTs deposited into db(EST) are from 
the I. M. A. G. E consortium and each one is represented by an I. M. A. G. E. cDNA 
clone. These clones are available to researchers free of any royalties via the world- 
wide-web (www). 
1.9 Aims of the study 
Following the delineation of the critical region of the 5q- syndrome to 
approximately 5Mb at 5g31-5g33, the primary aim of this study was to generate a 
transcript map of the CDR of gene loss, flanked by the FGF1 and IL12ß genes. The 
development of a transcript map should facilitate the identification of candidate 
tumour suppressor genes on 5q. 
As previously mentioned, the majority of genes in the human genome are 
represented by one or more ESTs. We decided to use db(EST) as the primary 
resource to identify novel coding sequences mapping to the critical region of gene 
loss. Molecular analysis including mutation studies was carried out on candidate 
genes, with the ultimate aim of identifying the 5q- syndrome gene. 
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Chapter 2 
Methods 
2.1 Preparation of Granulocyte and T-lymphocyte fractions from whole 
peripheral blood 
2.1.1 Separation of granulocytes and mononuclear cells by density 
gradient centrifugation 
2.1.2 Preparation of mononuclear cells 
2.1.3 Separation of T-lymphocytes by rosetting with sheep red blood cells 
2.2 Extraction of high molecular weight DNA from whole peripheral blood, 
and peripheral blood cell fractions. 
2.2.1 Cell preparation for whole blood 
2.3 Standard restriction enzyme digestion of genomic DNA and gel 
electrophoresis 
2.4 Southern blotting 
2.5 Preparation of probes for hybridisation 
2.5.1 Genomic and cDNA probes 
2.5.1.1 Transformation of competent cells 
2.5.1.2 Plasmid DNA mini-preparation 
2.5.1.3 Recovery of probe from plasmid 
2.5.2 PCR generated probes 
2.6 Probe labelling 
2.7 Filter hybridisation 
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2.8 Filter washing 
2.9 Removal of the probe from the filter 
2.10 Autoradiography 
2.11 Preparation of single-stranded templates for DNA sequencing 
2.11.1 Cloning of the insert from the plasmid into M13 phage 
2.11.1.1 Preparation of insert and vector DNA 
2.11.1.2 Ligation of insert into the M13 vector 
2.11.2 Preparation of competent E. coli for transformation 
2.11.3 Transformation of competent cells with ligated M13 
2.11.4 Preparation of single-stranded templates 
2.12 Automated fluorescent dye sequencing 
2.12.1 Sequencing reactions using a Cy5 labelled primer 
2.12.1.1 Annealing of the primer to a single-stranded template 
2.12.1.2 Sequencing reactions 
2.12.1.3 Annealing of the primer to a double-stranded template 
2.12.1.4 Sequencing reactions 
2.12.2 Sequencing reactions using a Cy5 dATP internal label 
2.12.2.1 Annealing of the primer to a single-stranded template 
2.12.2.2 Sequencing reactions 
2.12.2.3 Annealing of the primer to a double-stranded template 
2.12.2.4 Sequencing reactions 
2.12.3 Preparation of the sequencing gel plates 
2.12.4 Preparation of the gel 
2.13 RACE PCR 
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2.14 Subcloning of RACE PCR products for direct sequencing 
2.14.1 A-Tailing of RACE PCR product 
2.14.2 Ligation of RACE PCR products into the vector 
2.14.3 Transformation of competent cells 
2.15 Localisation of known genes and novel cDNAs to the YAC contig 
2.16 Reverse transcriptase PCR (RT-PCR) analysis 
2.16.1 Purification and quantification of RT-PCR products. 
2.17 CD34+ expression by RT-PCR 
2.18 Cycle sequencing on the ALFexpress automated sequencer 
2.18.1 Preparation of dNTP/Cy5 ddNTP mixes 
2.18.2 Sequencing reactions 
2.18.3 Precipitation of sequencing reactions 
2.18.4 Preparation of the polyacrylamide gel and loading of samples 
2.18.5 Processing the sequence data on the ALFexpress automated 
sequencer 
2.19 Cycle sequencing on the ABI PRISM 3100 Genetic Analyser 
2.19.1 Preparation of sequencing reactions 
2.19.2 Sodium acetate precipitation of sequencing reactions 
2.19.3 Processing the sequence data on the ABI PRISM 3100 Genetic 
Analyser 
The preparation of all reagents used in this Methods section is described in the 
Appendix. 
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2.1 Preparation of Granulocyte and T-lymphocyte fractions from whole 
peripheral blood. 
The method described is for the separation of granulocytes and T-lymphocytes 
from 20mis of peripheral blood. Sample volumes of 40mis were routinely 
separated in 2x 20mis. 
2.1.1 Separation of granulocytes and mononuclear cells by density gradient 
centrifugation. 
1.20mis of peripheral blood was collected into Tri-Sodium EDTA tubes. 
2. The blood was gently layered onto 20mls of Histopaque-1077 (Sigma Aldrich, 
Cheshire, UK) in a 50ml polypropylene conical tube and centrifuged at 
1600rpm (400g, Sorvall RT6000B benchtop centrifuge) for 30 minutes at room 
temperature. 
3. The interface (the mononuclear cell layer) was transferred to a sterile 50ml 
conical tube, using a Pasteur pipette, and processed as described (2.1.2). 
4. The upper (serum) and lower (Histopaque) layers were carefully aspirated 
using a Pasteur pipette and discarded to leave the red blood cell/ granulocyte 
layer. 
5. Phosphate buffered saline (PBS) was added to the red blood cell/ granulocyte 
layer to give a total volume of 50mls and the tube mixed by gentle inversion. 
6. The tube was centrifuged at 1600rpm at room temperature for 10 minutes. 
7. The supernatant was removed using a Pasteur pipette and discarded. 
8. Steps 5,6 and 7 were repeated. 
8. To lyse the red cells, the packed red blood cell/granulocyte layer was 
distributed into conical tubes containing freshly prepared red cell lysis buffer 
(approximately 1ml of red blood cells per 50m1 of red cell lysis buffer), and left 
at room temperature for 15 minutes with occasional mixing. 
Page 30 
8. The tubes were centrifuged at 1600rpm for 10 minutes at room temperature 
and the supernatant poured off. 
8. Each granulocyte pellet was resuspended in approximately 1ml of PBS and the 
pellets pooled into 2 conical tubes. 
8. The tubes were filled to 50mls with PBS and centrifuged at 1600rpm for 10 
minutes at room temperature. The supernatant was poured off. 
8. Step 12 was repeated. 
8. The pellets were pooled into one conical tube and finally resuspended in PBS 
to a total volume of 10mis. 
8. If the cell fraction was for the preparation of high molecular weight DNA, 
DNA was either extracted immediately, see section 2.3 from step 8, or the cell 
suspension was frozen at -20°C for DNA extraction at a later date. 
2.1.2 Preparation of mononuclear cells 
1. PBS was added to the mononuclear cell fraction to a total volume of 50mls, it 
was mixed by gentle inversion and centrifuged at 1600rpm for 10 minutes at 
room temperature. 
2. The supernatant was poured off and the cell pellet resuspended in 50mis of 
PBS and centrifuged at 1600rpm for 10 minutes at room temperature. 
3. The cell pellet was resuspended in 10mls of PBS. 
4. This cell fraction was then either processed further to obtain T-lymphocytes, 
see section 2.1.3, or used for the preparation of high molecular weight DNA, 
see section 2.2 
2.1.3 Separation of T-lymphocytes by rosetting with sheep red blood cells 
This is based on the erythrocyte rosetting method of Kaplan and Clark (1974). 
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1. The mononuclear cell fraction from section 2.1.2 step 3 was diluted with PBS to 
obtain a concentration of 2-6 x 106/ml white blood cells. 
2.1-2 volumes of neuramidase-treated sheep red blood cells (TCS Biologicals, 
Buckingham, UK), 0.5-1 volumes of foetal calf serum (FCS) and 100-300}1 of a 
fresh 1: 30 dilution of a 1% stock solution of polybrene were added to the cell 
suspension. 
3. The suspension was centrifuged at 750rpm for 5 minutes at 4°C and then 
incubated at 4°C for a minimum of 5 hours or maximum overnight. 
4. The supernatant was removed from the packed cell pellet (sheep red blood 
cells and rosetted T-lymphocytes) and 1 volume of PBS added. 
5. The cells were gently resuspended by rotating the meniscus through the cell 
pellet. 
6. The cell suspension was gently layered onto an equal volume of Histopaque 
and centrifuged at 1600 rpm for 30 minutes at room temperature. 
7. The upper layer, interface (non T-cell) and Histopaque layer were aspirated 
and discarded, leaving the sheep red blood cell/T-lymphocyte layer. 
8. PBS was added to 50mls, the tube mixed by gentle inversion and centrifuged at 
1600 rpm for 10 minutes at room temperature. 
9. The supernatant was removed using a Pasteur pipette and discarded. 
10. Steps 8 and 9 were repeated. 
11. To lyse the sheep red blood cells, the cell pellet was distributed into conical 
tubes containing freshly prepared red cell lysis buffer (approximately 1m1 of 
cells per 50m1 of lysis buffer) and incubated at room temperature for 15 
minutes with occasional mixing. 
12. The tubes were centrifuged at 1600 rpm for 10 minutes and the supernatant 
poured off. 
13. The T-cell pellets were treated exactly as the granulocyte pellets from step 11 of 
section 2.1.1. 
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2.2 Extraction of high molecular weight DNA from whole peripheral blood, 
and peripheral blood cell fractions 
Extraction was carried out using the Nucleon® BACC2 Genomic DNA Extraction 
Kit (Nucleon® Biosciences, Scotlab, Lanarkshire, UK). Steps 1-5 were omitted for 
DNA extraction from blood cell fractions. 
2.2.1 Cell preparation from whole blood 
1. Whole peripheral blood was collected in sodium EDTA tubes. 
2. Samples were centrifuged at 2400rpm (1300g) for 10 minutes at room 
temperature and the plasma pipetted off and discarded, taking care not to 
disturb the buffy coat. The sample could be frozen at -20°C at this stage for 
extraction at a later date. 
3. The sample was transferred to a 50m1 polypropylene centrifuge tube and 
Reagent A (Nucleon® Biosciences) added to 40mis. 
4. The sample was vortexed for 4 minutes and centrifuged at 2400rpm for 4 
minutes at room temperature. 
5. The supernatant was discarded without disturbing the pellet. 
6.2mls of Reagent B (Nucleon® Biosciences) was added to the cell pellet and 
vortexed briefly to resuspend the pellet. 
7. The cell suspension was transferred to a 5m1 screw-capped polypropylene 
centrifuge tube (maximum internal diameter 12mm). 
8.500pl of sodium perchlorate (Nucleon® Biosciences) was added and the tube 
inverted 10 times by hand. 
9.2mls of chloroform was added and the tube inverted 10 times by hand to 
emulsify the phases. 
10.300pI of Nucleon® resin was added, and without re-mixing the phases, 
centrifuged at 2400rpm for 3 minutes at room temperature. 
11. The upper phase was transferred to a fresh 15m1 polypropylene centrifuge 
tube without disturbing the Nucleon® resin layer (brown in colour). 
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12. Two volumes of cold absolute ethanol were added to the upper phase and the 
tube inverted several times until the DNA had precipitated. The sample can be 
stored at -20°C for >1 hour to aid precipitation of the DNA if necessary. 
13. The sample was centrifuged at 3000rpm for 5 minutes to pellet the DNA and 
the supernatant discarded. 
14.2mls of cold 70% ethanol was added and the tube inverted several times. The 
sample was re-centrifuged as before, and the supernatant discarded. This step 
can be repeated if necessary. 
15. The pellet was air dryed for 15 minutes and resuspended in an appropriate 
volume of sterile water. The DNA was left to dissolve overnight at 4°C and 
stored at -20°C. 
2.3 Standard restriction enzyme digestion of genomic DNA, and gel 
electrophoresis 
1. Approximately 5pg of DNA was digested in a total volume of 30-50}i1. 
2. The following were added to a 1.5ml microcentrifuge tube; 
i. Sterile distilled water to give the desired total volume. 
ii. The appropriate volume of 10x concentrated enzyme buffer to give a final 
1x concentration. Specific buffers supplied by the enzyme manufacturers 
were used. 
iii. 100mM Spermidine (Sigma Aldrich). 
iv. 5pg of DNA. 
v. 40 units of restriction enzyme. 
3. The contents of the tube were mixed gently and centrifuged briefly at low 
speed to bring the contents to the bottom of the tube. 
4. The mixture was incubated at the optimal temperature for the restriction 
enzyme for a minimum of 4 hours. 
5. In some cases it was necessary to add more enzyme. A total volume of 7-14P1 
of sterile distilled water, 10x enzyme buffer to a final concentration of 1x, 
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100mM Spermidine, and 40-80 units of enzyme was added to the digested 
DNA and steps 3 and 4 repeated. 
6. Digested DNA was either electrophoresed immediately or stored at -20°C until 
required. 
7.1% agarose gels were prepared in a total volume of 300m1 (the appropriate 
volume for the electrophoresis equipment used). 
8. The agarose (Type I: Low EEO, Sigma Aldrich) was dissolved in 300ml of 1x 
TBE buffer and microwaved on high power for approximately 5 minutes or 
until the agarose was dissolved. 
9. The molten agarose was poured into a sealed gel tray, with a 20-toothed comb 
positioned 1.0 cm from one end, and allowed to set. 
10. The comb and tape were removed and the gel tray positioned in the 
electrophoresis tank with 2 litres of 1x TBE buffer. 
11. Loading dye was added to the digested DNA samples (the volume of dye 
added was 1/10 of the volume of the digested DNA sample) and the samples 
loaded into the wells of the gel. 
12. The gel was run at 50 volts overnight. 
2.4 Southern blotting 
1. Following electrophoresis, the gel was stained in ethidium bromide (Sigma 
Aldrich) (10mg/ml in distilled water) for 15 minutes, and then destained in 
distilled water for 10 minutes. 
2. The gel was viewed on a UV transilluminator and a photograph taken 
(Polaroid film type 667, Fahrenheit, Milton Keynes, UK). 
3. The gel was soaked in denaturing solution for 30 minutes and then immersed 
in alkali transfer buffer for 10 minutes. 
4. A capillary blot was set up using alkali transfer buffer; 
i. A glass tray was filled with alkali transfer buffer, to form a reservoir. 
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ii. A glass plate was placed over the tray and a length of Whatman 3mm 
paper, soaked in alkali transfer buffer, was placed over the glass plate so 
that both ends of the paper were immersed in the buffer reservoir. 
iii. The gel was inverted, placed on the Whatman paper and the edges of the 
tray covered in clingfilm to prevent evaporation of the buffer reservoir. 
iv. A piece of Hybond N+ membrane (Amersham Pharmacia Biotech, 
Amersham, UK) was cut to the size of the gel, numbered, soaked in 
distilled water and placed number side up on the gel. 
v. 3 sheets of Whatman 3mm paper, cut to size, were soaked in alkali 
transfer buffer and placed on top of the filter. 
vi. A whole pack of paper towels was placed on top of the Whatman paper 
and finally a second glass tray was inverted on top of the paper towels to 
provide weight. 
5. Transfer was allowed to proceed for 16-24 hours. 
6. The filter was soaked in neutralisation solution for 10 minutes and baked at 
80°C for 10 minutes. 
7. DNA was fixed to the filter by UV cross-linking, it was placed DNA side down 
on a transilluminator (wavelength 302nm) for 1 minute 30 seconds. The UV 
transilluminator was calibrated by cutting a Southern blot of control DNA into 
5 strips and exposing each strip DNA side down on the transilluminator for a 
different length of time, ranging from 30 seconds to 5 minutes. The strips were 
all hybridised together with a suitable labelled probe. Following 
autoradiography, the optimum UV exposure time was evident from the 
strength of the signals. 
2.5 Preparation of probes for hybridisation 
2.5.1 cDNA probes 
cDNA probes were generated from I. M. A. G. E. cDNA clones for use in Southern 
and Northern blot analysis. 
Page 36 
2.5.1.1 Transformation of competent cells 
1. Competent cells (Library Efficiency TM HB101, Gibco Life Technologies, 
Paisley, UK) were thawed on ice. 
2.1}x1 of plasmid DNA (10ng/pl) was mixed with 50}il of competent cells and 
incubated on ice for 30 minutes. 
3. The tube was heat shocked in a water bath at 42°C for 90 seconds and returned 
to ice for 2 minutes. 
4.950}ßl of sterile LB (Luria Bertani) medium was added and the mix incubated at 
37°C for 1 hour. 
5. An appropriate volume (100}zl for 15mm x 100mm plates) was spread onto 
solid LB agar plates containing the appropriate antibiotic. 
6. The plates were inverted and incubated at 37°C overnight. 
7. A single isolated colony was picked from the plate using a sterile loop and 
used to inoculate 10mis of sterile LB containing the appropriate antibiotic. 
8. The bacteria were cultured overnight at 37°C with shaking. 
9. A permanent stock was prepared by adding 0.15m1 of glycerol to 0.85m1 of the 
overnight culture in a sterile microcentrifuge tube, and stored at -70°C 
2.5.1.2 Plasmid DNA mini-preparation 
Plasmid was extracted with the QIAprep® Spin Miniprep Kit (QIAGEN, 
Southampton, UK) using a microcentrifuge. 
1.1.5mls of the overnight 10ml culture containing the appropriate antibiotic was 
transferred to a 1.5m1 microfuge tube. The remaining culture was centrifuged 
for 15 minutes at 4°C to obtain a bacterial pellet, and stored at -20°C. 
2.250}ßl of Buffer P1 (QIAGEN) was added to the bacterial cell pellet and 
vortexed to resuspend the cells. 
3.250}ßl of Buffer P2 (QIAGEN) was added, and the tube inverted 6 times to mix. 
4.350pl of Buffer N3 (QIAGEN) was added, and the tube inverted immediately 
but gently 6 times to mix. 
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5. The sample was centrifuged at 13,000rpm for 10 minutes at room temperature. 
During centrifugation, a QlAprep spin column was placed in a 2ml collection 
tube. 
6. The supernatant from step 5 was pipetted into the QlAprep spin column and 
centrifuged at 13,000rpm for 1 minute at room temperature, and the flow- 
through discarded. 
7. The QlAprep spin column was washed by adding 0.5mls of Buffer PB 
(QIAGEN), centrifuged at 13,000rpm for one minute at room temperature, and 
the flow-through discarded. This step is necessary to remove trace nuclease 
activity when using endA+ strains such as the JM series. Host strains such as 
XL-1 Blue and DH5aTM do not require this additional wash step. 
8. The QlAprep spin column was washed by adding 0.75m1s of Buffer PE 
(QIAGEN), centrifuged at 13,000rpm for 1 minute at room temperature, and 
the flow-through discarded. 
9. The QlAprep spin column was centrifuged as before for an additional 1 minute 
to remove residual wash buffer. 
10. The QlAprep spin column was placed in a fresh 1.5ml microfuge tube. The 
DNA was eluted by adding 50}ßl of sterile water to the centre of the QlAprep 
spin column, left for 1 minute, centrifuged at 13,000rpm for 1 minute at room 
temperature, and stored at -20°C. 
2.5.1.3 Recovery of the probe from the plasmid 
The probe was recovered from the plasmid with the Wizard® PCR Preps DNA 
Purification System (Promega, Madison, WI). 
1.15}ßl of plasmid DNA was digested with the enzyme(s) required to excise the 
insert, (see section 2.4 for digestion of DNA). 
2. A 1% Low Melting Temperature agarose gel was made using a comb which 
could accommodate the larger volumes of plasmid digests. The duration of 
electrophoresis was dependent on the sizes of fragments to be separated. 
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3. The digested plasmid DNA solution was mixed with loading dye and loaded 
into the gel. A DNA molecular weight marker was loaded on one side. 
4. Following electrophoresis, the gel was viewed on a UV transilluminator. 
5. The band which corresponded to the correct size of the plasmid insert was cut 
from the agarose (approximately 300pl (300mg)) using a scalpel blade. 
6. The 300pl (300mg) agarose slice was transferred to a 1.5m1 microcentrifuge 
tube and incubated at 70°C until the agarose had completely melted. 
7.1ml of resin was added to the melted agarose slice and mixed thoroughly for 
20 seconds by inverting. 
8. One Wizard® Minicolumn was prepared. The plunger from a 3ml Luer-Lok® 
syringe (Becton Dickinson & Co., Oxford, UK) was removed and set aside. The 
syringe barrel was attached to the Luer-Lok® extension of each Minicolumn. 
9. The resin/DNA mix from step 7 was pipetted into the syringe barrel. The 
syringe plunger was inserted slowly and the slurry gently pushed into the 
Minicolumn. 
10. The syringe was detached from the Minicolumn, and the plunger removed 
from the syringe. The syringe barrel was reattached to the Minicolumn. 2mls 
of 80% isopropanol was pipetted into the syringe to wash the column. The 
syringe plunger was inserted into the syringe, and the isopropanol was gently 
pushed through the Minicolumn. 
11. The syringe was removed and the Minicolumn transferred to a 1.5ml 
microcentrifuge tube. The Minicolumn was centrifuged at 5500rpm for 2 
minutes at room temperature to dry the resin. 
12. The Minicolumn was transferred to a new microcentrifuge tube. 50}1 of sterile 
water was applied to the Minicolumn and allowed to stand for 1 minute. The 
Minicolumn was centrifuged at 5500rpm for 20 seconds to elute the bound 
DNA fragment. 
13. The Minicolumn was removed and discarded, and the purified DNA 
quantified on a 1% TAE agarose gel and stored at -20°C. 
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2.5.2 Oligonucleotide probes 
The oligonucleotide probes were generated by PCR amplification using primer 
sets designed from the obtained sequence data for Southern and Northern blot 
analysis. 
1. For each 100pl PCR reaction the following were added to a sterile 0.6m1 thin- 
walled tube; 
sterile distilled water 
10x reaction buffer 
50mM MgC12 
dNTP mix (1.25mM) 
primer 1 (100pmol) 
primer 2 (100pmol) 
template DNA (=200ng) 
up to 1001x1 
101x1 
61x1 
81x1 
11x1 
11x1 
1}zl 
Taq polymerase (2.0-2.5 units) 1}zl 
The buffer, MgC12, and Taq polymerase were manufactured by Bioline, London, 
UK). The dNTP mix (Amersham Pharmacia Biotech) was prepared by mixing 
12.5pl of each of the 100mM dNTPs with 950pl of sterile distilled water and 
storing in 1ml aliquots. The volume of 50mM MgC12 stated was a standard 
starting point, if necessary a MgC12 titration was performed to determine the 
optimal final concentration. The template DNA was total genomic DNA obtained 
from the peripheral blood of normal healthy individuals. 
2. The tubes were mixed gently and centrifuged briefly to bring the contents to 
the bottom of the tube. 
3. Approximately 60 l of mineral oil was added to each tube, to prevent any 
evaporation, and the tubes centrifuged briefly again. 
4. The tubes were placed on the thermal cycler (Biometra Trio Thermoblock, 
Anachem, Luton, UK) and subjected to the appropriate thermal profile. Each 
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primer set had an optimal annealing temperature and the thermal profile 
selected for each primer set was essentially as shown below, but the optimal 
annealing temperature was substituted for the annealing temperature shown. 
Initial denaturation 95°C for 5 minutes 
35 cycles of; 94°C denaturation for 30 seconds 
60°C primer annealing for 30 seconds 
72°C primer extension for 1 minute 
Final extension 72°C for 8 minutes 
Hold temperature 4°C 
5. The mineral oil was removed from the tubes and a small aliquot of the reaction 
(usually 5}ßl) was run on a mini agarose gel. The concentration of the agarose 
was dependent on the size of the PCR product. 
6. The gel was stained in ethidium bromide and visualised on a UV 
transilluminator. If a single band of the expected size was observed, then the 
remainder of the PCR product was purified. Purification was achieved by the 
use of the Wizard® PCR Preps DNA Purification System. 
7. The purified product was quantified and stored at -20°C for use as a probe. 
2.6 Probe labelling 
Probes were labelled to high specific activity (approximately 2x109 dpm/pg) with 
High Prime (Roche Products Ltd., East Sussex, UK) and radioactive dCTP 
(Amersham Pharmacia Biotech) using random oligonucleotide primers. 
1.25-40ng of probe, in distilled water to a final volume of 13}zl, was denatured by 
boiling for 7 minutes and then quenched on ice for 3 minutes. For 
simultaneous hybridisation with two probes, the two probes were mixed in the 
desired ratio in a total volume of 13}ßl and the procedure followed as for a 
single probe. 
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2. The following were added to the denatured probe; 
i. 4iil of High Prime solution. 
ii. 3}xl of [a32P]dCTP, 3000Ci/mMol, aqueous solution. 
3. The mixture was incubated at 37°C for 10 minutes. 
4. Non-incorporated deoxyribonucleoside triphosphate was removed by 
chromatography through a Sephadex G-100 column. Columns were prepared 
using a 1m1 syringe, plugged with a small ball of glass wool. TE buffer was 
passed through the column, followed by Sephadex G-100 slurry (Sigma 
Aldrich). Care was taken not to introduce air bubbles. Sephadex was added 
until there was no further settling. 
5. The column was placed into a 15m1 sterilin tube and centrifuged at 1000rpm 
for 5 minutes at room temperature. The fluid collected in the sterilin tube was 
discarded. 
6.100}x1 of TE was added to the column and step 5 repeated. 
7. The column was placed into a clean sterilin tube. 80pl of TE was added to the 
labelled probe mixture and the new volume pipetted into the column. 
8. This was centrifuged at 1000rpm for 5 minutes at room temperature. The 
column was discarded and the fluid collected in the sterilin tube, containing 
the labelled probe, was transferred to a 1.5ml microcentrifuge tube. 
9. The labelled probe was used immediately or stored at -20°C. 
2.7 Filter Hybridisation 
Filter hybridisation was carried out in a hybridisation oven (Biometra). The 
hybridisation chambers were bottles that were clamped in a rotisserie and 
continuously rotated. 
1. The filter was soaked in 2x SSC, placed on an appropriately sized piece of 
hybridisation mesh and positioned in a hybridisation bottle containing 5-10ml 
of 2x SSC. The bottle was placed in the rotisserie in the oven at 65°C. 
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2. The SSC was poured from the bottle and replaced with hybridisation buffer, 
10ml/large bottle and 5ml/small bottle. The hybridisation buffer contained 
salmon sperm DNA (Sigma Aldrich) at a concentration of 10mg/mi, denatured 
by boiling for 7 minutes and quenched on ice for 3 minutes. The bottle was 
returned to the oven and the filter was prehybridised at 65°C for 1-12 hours. 
For probes containing multiple repeat sequences, human placental DNA, 
denatured by boiling for 7 minutes and quenched on ice for 3 minutes, was 
added to the hybridisation buffer at a concentration of 50pg/ml. 
3. The labelled probe was denatured by boiling for 7 minutes, quenched on ice 
for 3 minutes and added to 5m1 or 10ml (depending on bottle size) of fresh 
hybridisation buffer. 
4. The prehybridisation buffer was poured from the bottle and replaced with the 
labelled probe and fresh hybridisation buffer. The bottle was returned to the 
oven and the filter hybridised at 65°C for 16-24 hours. 
2.8 Filter Washing 
1. The filter was removed from the bottle and rinsed by immersing in 1 litre of 4x 
SSC, 0.1% SDS. 
2. The filter was transferred to 11 of 1x SSC, 0.2% SDS and incubated at 65°C for 
30 minutes. 
3. The filter was transferred to a second hot wash of 11 of 0.2x SSC, 0.2% SDS and 
incubated at 65°C for 5-30 minutes. The length of time incubated was 
determined by regular monitoring of the filter. The filter was periodically 
removed from the wash solution and monitored using a Geiger counter. When 
a background reading of 2-5 counts per second was obtained, the filters were 
regarded as adequately washed and were removed from the solution. 
4. The filter was wrapped in Saranwrap (Fahrenheit) and placed between two 
sheets of X-ray film (Fuji, Genetic Research Instrumentation, Essex, UK), 
between intensifying screens at -70°C, in order to obtain an autoradiographic 
image. The top sheet of film was developed after 1-3 days and the lower sheet 
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of film developed 1-14 days later, depending on signal intensity on the first 
exposure. 
2.9 Removal of the probe from the filter 
Filters were kept wrapped in Saranwrap at -70°C to prevent dehydration. Prior to 
rehybridisation the filter was stripped of the probe from the previous 
hybridisation. 
1. The filter was washed in 0.4M NaOH for 20 minutes at 45°C. 
2. The filter was then transferred to a neutralising solution, 0.1x SSC, 0.1% SDS 
and 0.2M Tris HCl pH7.5, for 15 minutes at 45°C. 
2.10 Autoradiography 
Autoradiographic signal intensities were quantitated using an LKB 2222-020 
Ultrascan XL Laser Densitometer, according to the manufacturer's instructions. 
2.11 Preparation of single-stranded templates for DNA sequencing 
2.11.1 Cloning of the insert from the plasmid into M13 phage 
2.11.1.1 Preparation of insert and vector DNA 
1. Approximately lpg of plasmid DNA was digested with the appropriate 
restriction enzymes to release the insert. The enzymes were selected because 
they were present in the multiple cloning site of both the plasmid and the M13 
vector strain used. The plasmid was digested in a total volume of 50}xl, with 
5pl of 10x buffer, 5pl of 0.1% bovine serum albumin (BSA), 5}x1 of 0.1% Triton 
X-100 (Sigma Aldrich) and 40 units of each restriction enzyme. Sterile distilled 
water was added to make the total volume 50-pl. 
2. The digest was incubated at 37°C for at least 2 hours (up to overnight). 
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3. Following digestion the plasmid DNA was electrophoresed on a 1% LMT (low 
melting temperature) agarose gel, prepared with 1x TAE buffer. 
4. The plasmid insert was excised and purified using Wizard® columns. It was 
stored at -20°C and used as required. 
5. Approximately 5pg of M13 vector was digested with the appropriate 
restriction enzymes as described, and run on a 1% LMT agarose gel. The 
digested M13 vector was excised and purified using Wizard® columns and 
stored at -70°C and used as required. 
2.11.1.2 Ligation of the insert into the M13 vector 
1. Two ligation reactions were set up for each insert to be cloned, in order to 
create two insert: vector ratios. Each ligation reaction was set up in a total 
volume of 10}xl, with 1ix1 of ligation buffer, 1}x1 (N20ng) of M13 cut with the 
appropriate restriction enzymes, 0.5p1 of T4 DNA ligase (Roche Products) and 
insert DNA to give an insert: vector ratio of 2: 1 or 0.5: 1. Sterile distilled water 
was added to make the total volume 10pl. 
2. Ligation reactions were incubated at 16°C for at least 1 hour and up to 
overnight. 
3. Prior to transformation, the required volume (2-10}x1) of each ligation reaction 
was transferred to a sterile 14m1 transformation tube (Falcon, Becton 
Dickinson, Oxford, UK). 
4. A ligation control was also set up in order to check that the vector had been 
correctly prepared, this was as described, but without the insert DNA. 
2.11.2 Preparation of competent E. coli for transformation 
The preparation of competent E. coli is based on the method of Hanahan et al., 1991. 
1. JM101 cells were stored in glycerol at -70°C; prior to use the cells were streaked 
onto a minimal media plate and incubated overnight at 37°C. The minimal 
plate was then stored at 4°C, the cells were viable for several weeks. 
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2. A colony was picked from the minimal plate, streaked onto a SOB plate and 
incubated at 37°C overnight. 
3. A few colonies were lifted from the SOB plate and used to inoculate 50m1 of 
sterile SOB media in a sterile 500m1 conical flask. 
4. The inoculated media was incubated at 37°C with shaking, until the OD550 
reached 0.3-0.4. 
5.5mls of the culture was taken for the lawn. It was added to 5mls of fresh SOB 
media and incubated further at 37°C without shaking to give a dense culture. 
6. The remaining culture was divided between 2 pre-cooled 50m1 conical tubes 
and cooled on ice for 15 minutes. 
7. The culture was centrifuged at 2500rpm for 10 minutes at 4°C. The 
supernatant was poured off and the tubes inverted and tapped sharply on 
tissue, in order to remove as much SOB as possible. 
8. The cell pellets were resuspended in 1/3 volume TFB, that is, 1/3 of the 
original culture volume (for a 50ml culture this was 16.6m1,8.3m1 per tube). 
The cells were resuspended by gentle swirling of the TFB over the pellet and 
incubated on ice for 10 minutes. 
9. The cells were centrifuged for 10 minutes at 4°C and the supernatant removed 
as previously. The cell pellets were resuspended in 1/12.5 volume TFB (i. e. 
4m1 total, 2ml per tube) and the tubes pooled. 
10.28}ßl of nitrogen-purged, top grade DMSO (dimethyl sulfoxide) (Sigma 
Aldrich) per 10ml of original starting culture (i. e., 140it for a 50m1 culture) was 
added and the cells incubated on ice for 10 minutes. 
11.28pl of 2.2M DTT (Sigma Aldrich) in 10mM KOAc pH6.2 per 10ml of initial 
culture was added and the cells incubated on ice for 10 minutes. 
12. Step 10 was repeated with an incubation of 5 minutes instead of 10 minutes. 
The cells were now competent. 
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2.11.3 Transformation of competent cells with ligated M13 
1.200pl of competent cells were added to each 14m1 transformation tube 
containing 2-10}ßl of a ligation reaction (section 2.11.1.2) and incubated on ice 
for 40 minutes. 
2. The cells were heat-shocked at 42°C for 2 minutes and then returned to ice. 
3. JM101 lawn cells (section 2.12.2, step 5) were mixed with 2x YT soft agar 
(melted and held at 45°C) in the proportions 2m1 of lawn cells per 35ml of soft 
agar. 945µl of 2% X-gal in dimethylformamide and 450}11 of 2% IPTG (in 
water) per 35ml of agar were added. 
4.4ml of the agar mix was added to each tube of heat shocked cells. This was 
mixed by rolling and poured immediately onto 100mm 2x YT agar plates. 
5. The plates were allowed to set at room temperature, inverted and incubated at 
37°C overnight. 
6. Control transformations on duplicate plates were also carried out with; cut 
vector at lOng/plate, ligation control at 10ng /plate and uncut vector at 
1ng/plate. 
2.11.4 Preparation of single-stranded templates 
1.100ml of 2x YT was inoculated with 1ml of an overnight standing culture of 
JM101 cells in 2x YT. 
2. This was dispensed in 1.5ml aliquots into sterile 50m1 conical tubes. 
3. Each tube was inoculated with a colourless plaque using sterile 1-10Pl pipette 
tips. The pipette tip was used to stab the plaque and was then dropped into 
the tube. It was removed after a few minutes. 
4. The tubes were shaken at 37°C for 6 hours. 
5. The culture was transferred into a 1.5ml microcentrifuge tube and centrifuged 
at 13000 rpm for 5 minutes at room temperature. 
6. The supernatant was decanted into a fresh tube containing 200PI 20% 
PEG/2.5M NaCl. It was mixed well and incubated at room temperature for 20 
minutes. 
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7. The tubes were centrifuged at 13000 rpm for 5 minutes at room temperature 
and the supernatant discarded. 
8. They were centrifuged for a further 2 minutes and all traces of PEG carefully 
removed using a drawn out Pasteur pipette. 
9. The viral pellet was resuspended in 200pl of sterile distilled water. 
10. When the pellet was fully dissolved, 200il of phenol was added, the mix 
vortexed for 5-10 minutes and then centrifuged for 5 minutes. 
11. The upper aqueous layer was removed to a fresh microfuge tube. 
12.200}ßl of chloroform was added, the mix vortexed for 2 minutes and 
centrifuged for 2 minutes. 
13. Steps 11 and 12 were repeated. 
14. The upper aqueous layer was removed to a fresh microfuge tube and the single 
stranded template precipitated by adding 20pl of 3M sodium acetate and 600}zl 
of 100% ethanol and incubating at -20°C overnight. 
15. The template was pelleted by centrifuging at 13000rpm for 10-15 minutes. The 
supernatant was discarded and the pellet washed in 70% ethanol. 
16. The pellet was dried, redissolved in 25}zl of sterile distilled water and stored at 
-20°C 
2.12 Automated fluorescent dye sequencing 
The sequencing reactions were carried out using the Cy5 Autoread sequencing kit 
(Amersham Pharmacia Biotech) which incorporates the fluorescent dye Cy5 
Amidite and all sequencing reactions were run on the ALFexpress automated DNA 
sequencer (Amersham Pharmacia Biotech). Two slightly different methods were 
used for the sequencing of single-stranded templates, the first used a Cy5 labelled 
primer and the second used Cy5 dATP for internal labelling. All reagents for the 
sequencing reactions, including Cy5 labelled M13 universal and reverse primers, 
were provided in the Autoread sequencing kit, with the exception of the Cy5 
dATP (Amersham Pharmacia Biotech) which was purchased separately. 
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2.12.1 Sequencing reactions using a Cy5 labelled primer 
2.12.1.1 Annealing of the primer to a single-stranded template 
1. Using sterile distilled water, the concentration of the template was adjusted so 
that 13pl contained 1-2 ig of DNA. 
2. The following were added to a 0.6m1 thin-walled tube: 
Template DNA 13pl 
Cyanine-labelled Primer (2-10 pmol) 2}il 
Annealing buffer 2}11 
Total volume 17-VI 
3. The tube was vortexed gently, centrifuged briefly and incubated at 60°C for 10 
minutes. 
4. The tube was incubated at room temperature for at least 10 minutes and then 
centrifuged briefly. 
5.1pl of extension buffer was added to the annealing reaction and the sequencing 
reactions performed immediately. 
2.12.1.2 Sequencing reactions 
1. During the incubation steps of primer annealing, the sequencing mixes and T7 
DNA polymerase were prepared for sequencing. Four wells of a microtitre 
plate were labelled 'A', 'C', 'G' and 'T' respectively and 2.5pl of the 'A' mix, 'C' 
mix, 'G' mix and 'T' mix were pipetted into the appropriate well. The 
dispensed sequencing mixes were stored on ice until required and just prior to 
use the microtitre plate was placed on the hot block and the sequencing mixes 
warmed to 37°C. The required amount of T7 DNA polymerase was diluted 
with enzyme dilution buffer to the appropriate concentration, 3 units/ 2}il for 
single-stranded sequencing. 
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2.2}ßl of diluted T7 polymerase was added to the annealing reaction and mixed 
thoroughly with a pipette tip. 4.5pl was immediately pipetted into each of the 
prewarmed sequencing mixes. 
3. The reactions were incubated at 37°C for 5 minutes exactly. 
4.5iil of stop solution was added to each reaction and mixed gently using a 
pipette tip. 
5. The reactions were stored on ice (or at -20°C if the gel was to be run at a later 
date), until the sequencing gel was ready for loading. Just prior to loading the 
reactions were heated to 85-90°C for 2-3 minutes and then quenched on ice. 
6pl was loaded into the appropriate wells of a sequencing gel. 
2.12.1.3 Annealing of the primer to a double-stranded template 
1. Using sterile distilled water, the concentration of the template was adjusted so 
that 16V1 contained 5-10pg of DNA. 
2. The following were added to a 0.6m1 thin walled tube; 
Template DNA 16}1 
2M NaOH 8p l 
Distilled Water 16}ßl 
Total volume 40}1 
3. The tube was vortexed gently, centrifuged briefly and incubated at room 
temperature for 10 minutes. 
4.7pl of 3M sodium acetate (pH 4.8) and 4}ßl of dH2O were added. 
5.120pl of 100% ethanol was added, mixed, and placed on dry ice for 15 minutes. 
(Alternatively, the tubes were incubated at -70°C for >_30 minutes). The 
precipitated DNA was collected by centrifugation for 15 minutes. The 
supernatant was carefully removed and discarded, and the pellet rinsed with 
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70% ethanol, recentrifuged for 10 minutes, and the supernatant carefully 
removed. The pellet was dried at 37°C for 5 minutes. 
6. The pellet was resuspended in 10}ßl of distilled water. 
7. The following were added to the tube containing the resuspended template; 
Template DNA 10Pl 
Cyanine-labelled Primer (4-10 pmol) 2}ßl 
Annealing Buffer 2l 
Total Volume 14}i1 
8. The tube was vortexed gently, centrifuged briefly and the annealing reaction 
preheated at 65°C for 5 minutes. The reaction was immediately placed at 37°C 
and incubated for 10 minutes. The tube was removed and placed at room 
temperature for at least 10 minutes, then centrifuged briefly. 
9.1}il of Extension Buffer and 3}il of DMSO were added and the sequencing 
reactions performed immediately. 
2.12.1.4 Sequencing reactions 
1. The sequencing mixes and T7 DNA polymerase were prepared for sequencing, 
exactly as described above (section 2.12.1.2), with the exception that the 
enzyme was diluted to a concentration of 6-8 units/ it for double-stranded 
sequencing. 
2.2}xl of diluted T7 polymerase was added to the annealing reaction and mixed 
thoroughly with a pipette tip. 4.5pl was immediately pipetted into each of the 
prewarmed sequencing mixes. 
3. The reactions were incubated at 37°C for 5 minutes exactly. 
4.5pl of stop solution was added to each reaction and mixed gently using a 
pipette tip. 
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5. The reactions were stored on ice (or at -20°C if the gel was to be run at a later 
date), until the sequencing gel was ready for loading. Just prior to loading the 
reactions were heated to 85-90°C for 2-3 minutes and then quenched on ice. 6p1 
was loaded into the appropriate wells of a sequencing gel. 
2.12.2 Sequencing reactions using a Cy5 dATP internal label 
This protocol enables the use of unlabelled primers. 
2.12.2.1 Annealing of the primer to a single-stranded template 
1. The template was adjusted so that 12pl contained 1-2pg of DNA. 
2. The following were added to a 0.6m1 thin-walled tube; 
Template DNA 12pl 
Primer (4-400pmol) 2}x1 
Annealing buffer 2}xl 
Total volume 16}ßl 
The primers used were custom made commercially. 
3. The tube was vortexed gently, centrifuged briefly and incubated at 65°C for 10 
minutes. 
4. The tube was allowed to cool to less than 30°C over a period of 45 minutes and 
then centrifuged briefly. The sequencing reactions were performed 
immediately. 
2.12.2.2 Sequencing reactions 
1. During the slow cool of the annealing reactions the sequencing mixes and T7 
DNA polymerase were prepared for sequencing, exactly as described above 
(section 2.12.1.2), with the exception that 3pl of each of 'A' mix, 'C' mix, 'G' mix 
and 'T' mix were dispensed into the appropriate wells of the microtitre plate. 
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2.1}zl of Cy5 dATP labelling mix was added to the annealed template and mixed 
with a pipette tip. 
3.2pl of diluted T7 polymerase was added to each reaction and they were 
incubated at room temperature for exactly 5 minutes, (the addition of T7 
polymerase was staggered to allow time for pipetting at the next stage). 
4. When the incubation was almost complete, the dispensed sequencing mixes 
were pre-warmed to 37°C for at least 1 minute. 
5.1pl of extension buffer was added to each reaction and 4.5}ßl was immediately 
added to each of the pre-warmed sequencing mixes. 
6. The reactions were incubated for 5 minutes. 
7.5pl of stop solution was added to each reaction and mixed by gentle agitation. 
8. Immediately prior to loading the sequencing gel, the reactions were heated to 
85°C-90°C for 2-3 minutes and then quenched on ice. 6-8}ßl of each reaction 
was loaded into the appropriated wells of a sequencing gel. 
2.12.2.3 Annealing of the primer to a double-stranded template 
The standard annealing of primer to double-stranded template was prepared, 
exactly as described above (section 2.12.1.3), with the exception that the pellet was 
resuspended in 12}zl of distilled water. 
2.12.2.4 Sequencing reactions 
The sequencing mixes and T7 DNA polymerase were prepared for sequencing, 
exactly as described above (section 2.12.2.2), with the exception that the enzyme 
was diluted to a concentration of 6-8 units! }zl for double-stranded sequencing; 
3.5pl of DMSO was added to each reaction; 5.4pl immediately added to each of the 
pre-warmed sequencing mixes, and 6}ßl of Stop Solution was added to each 
reaction. 
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2.12.3 Preparation of the sequencing gel plates 
The gel plates were cleaned using Kimwipe tissues (Kimberley Clark, Merck, 
Hertfordshire, UK), as these tissues are free of dyes that may cause interference 
when excited by the laser. 
1. The gel plates were cleaned using a soft brush and a detergent, which did not 
fluoresce (Synerphonic N, Merck) and rinsed thoroughly with distilled water. 
The spacers and comb were rinsed in distilled water only. 
2. Each item was wiped dry using lint-free tissues. 
3. The two gel plates were cleaned again with lint-free tissue soaked in sterile 
distilled water, by wiping from the bottom of the plate to the top. This was 
repeated with 100% ethanol. 
4. The top 1-2cm of each plate was wiped with diluted bind silane (Amersham 
Pharmacia Biotech) solution. This was left to dry for a few seconds and then 
polished with a lint-free tissue. 
5. The plates were polished with ethanol, from bottom to top, taking care not to 
spread bind silane elsewhere on the plates. 
6. The spacers were wiped with 100% ethanol and positioned on the thermoplate 
(bottom plate), and gentle pressure was applied to secure them to the silicone 
rubber seals. The top plate was lowered into position on the thermoplate and 
the two plates clamped together, using specially designed clamps. 
7. The comb was wiped with 100% ethanol and placed in position at the top of 
the plates, ensuring it rested flush with the left hand side of the gel cassette. 
8. The apparatus was levelled to ensure even distribution of the gel. 
2.12.4 Preparation of the gel 
All reagents used in the preparation of the gel were ALF grade (Amersham 
Pharmacia Biotech). 
1. The following reagents were mixed together in a clean 250ml conical flask; 
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ALF grade urea 27g 
Long Ranger polyacrylamide gel mix 9mis 
(JT Baker, London, UK) 
10x TBE (ALF grade) 11.25m1s 
Sterile distilled water up to 75mis 
2. The mix was filter sterilised through a 0.2211 Falcon bottle top filter (Falcon, 
Becton Dickinson). 
3.37.5pl of temed (Sigma Aldrich) and 375pl of 10% ammonium persulphate 
(ALF grade) (Amersham Pharmacia Biotech) were added to the gel mix, it was 
mixed and poured into a 50ml syringe (with the plunger removed). 
4. The plunger was placed back in the syringe and the gel solution was applied in 
an even motion, back and forth along the lower lip of the glass plate. Capillary 
action drew the solution front upward to fill the entire space between the 
plates. 
5. The gel was left to polymerise for 3 hours. 
2.12.5 Loading the gel 
1. The gel cassette was placed in the ALFexpress and the top and bottom 
chambers filled with 0.6x TBE buffer. It was correctly linked to the cooling 
system. 
2. The comb was removed and the wells flushed out with buffer using a needle 
and syringe. 
3. The ALFexpress was programmed with the appropriate running details and the 
laser and temperature left to equilibrate. 
4. The denatured sequencing reactions were loaded into the appropriate wells of 
the gel, the electrodes connected and the machine started. 
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2.13 RACE PCR 
RACE PCR was carried out using Marathon-ReadyTM cDNAs (Clontech, 
Basingstoke, UK). 
1. Gene-Specific Primers (GSPs) were designed: 23-28 nucleotides in length, had a 
GC content of 50-70%, and a Tm of at least 65°C. The GSPs should be designed 
approximately 100-200bp towards the end of the 5' and/or 3' end of the 
sequence depending on whether 5' and / or 3' RACE is to be performed. 
2. The following reagents were added to a 0.6m1 thin walled tube; 
Marathon-ReadyTM cDNA 5pl 
AP1 primer (10pM) (Clontech) 1p1 
GSP1 (10pM) 1}i1 
Master Mix 43}ßl 
Total volume 50Pl 
For the positive control, the Marathon-ReadyTM cDNA was replaced with 5}zl of 
G3PDH cDNA, and the GSP replaced with 1 }zl of the Control 5' and/or 3' 
G3PDH primer. For the negative control, the Marathon-ReadyTM cDNA was 
replaced with 5}ßl distilled water. 
3. The PCR MasterMix was prepared from the following reagents; 
10x PCR reaction buffer 5}il 
dNTP mix (2mM) 5pl 
AmpliTaq GoldTM DNA Polymerase (2.5U) 0.5iil 
Distilled water 32.5pl 
Total volume 43}il 
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4. The Tm of the GSP determined whether a 2-step (Touchdown) PCR 
amplification, or a standard 3-step PCR amplification was carried out. The 
thermal profile selected for each GSP primer was essentially as shown below, 
but the optimal annealing temperature and program was substituted for the 
annealing temperature shown. 
4a. Touchdown thermal profile: 
Pre-Incubation/Activation Step 
5 cycles of; 
5 cycles of; 
20 cycles of; 
(25 cycles in nested reaction - 
see 5). 
Final extension 
Hold temperature 
4b. 3-step thermal profile: 
Pre-Incubation /Activation Step 
30 cycles of, 
(35 cycles in nested reaction-see 
5. ) 
Final extension 
Hold temperature 
95°C for 10 minutes 
94°C denaturation for 30 seconds 
72°C primer annealing/ extension for 
4 minutes 
94°C denaturation for 30 seconds 
70°C primer annealing/ extension for 
4 minutes 
94°C denaturation for 30 seconds 
68°C primer annealing/ extension for 
4 minutes 
68°C for 7 minutes 
4°C 
95°C for 10 minutes 
94°C denaturation for 30 seconds 
65°C primer annealing for 30 
seconds 
72°C primer extension for 4 minutes 
72°C for 7 minutes 
4°C 
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5.3pl of first-round PCR product was removed from the tubes and added to a 
new sterile 0.6m1 thin walled tube. For each 50pl nested PCR reaction, the 
following reagents were added to the first-round PCR product; 
First-round PCR product 3pl 
AP2 Primer (10}iM) (Clontech) l VI 
GSP2 Primer (lOpM) 1 PI 
Master Mix 45pl 
Total volume 50}zl 
6. The tubes were mixed gently and centrifuged briefly to bring the contents to 
the bottom of the tube. 
7. Approximately 60pl of mineral oil was added to each tube, to prevent any 
evaporation, and the tubes centrifuged briefly again. 
8. The Tubes were placed on the thermal cycler (Biometra Trio Thermoblock) and 
subjected to the appropriate thermal profile. Each GSP2 primer, like GSP1, had 
an optimal annealing temperature, which determined whether a 2-step 
(Touchdown) PCR amplification, or a standard 3-step PCR amplification was 
carried out (see 4a and 4b). 
9. The mineral oil was removed from the tubes and 5pl was run on a 1% mini 
agarose gel. 
10. The gel was stained with ethidium bromide and visualised on a UV 
transilluminator. If a single band of size >100bp was observed, more often in 
each tissue, then the remainder of the PCR product was purified. Purification 
was achieved by the use of Wizard® PCR preps as previously described in 
section 2.5.1.3. 
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2.14 Subcloning of RACE PCR products for direct sequencing 
The purified PCR products were cloned into the pGEM®-T Easy Vector System II 
(Promega). 
2.14.1 A-Tailing of RACE PCR products 
For each A-Tailing reaction, the following were added to a sterile 0.6m1 thin- 
walled tube; 
10x reaction buffer 
50mM MgCl2 
dATP (1: 100) 
Purified PCR product 
Taq polymerase (2.5U) 
Sterile distilled water 
and incubated at 70°C for 30 minutes. 
1P1 
0.5p1 
2}zl 
2-6}zl 
0.5}zl 
up to 10Pl 
2.14.2 Ligation of RACE PCR products into the vector 
Two insert: vector ratios (2: 1 and 1: 2) for each A-tailed PCR product were used 
when ligating into the pGEM®-T Easy Vector. For each PCR product ratio, 
including positive and background controls, the following were added to a 0.6ml 
sterile thin walled tube; 
2x Rapid Ligation Buffer 
pGEM®-T Easy Vector (50ng) 
PCR product 
Control Insert DNA (positive control only) 
T4 DNA Ligase (3 Weiss units/pi) 
Sterile distilled water 
5V1 
1P1 
2pl / 0.5}zl 
1Pl 
1Pl 
up to 10Pi 
and ligated at room temperature for >_ 1 hour or overnight at 4°C. 
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2.14.3 Transformation of competent cells 
50}ßl of JM109 High Efficiency Competent Cells were added to each 10Pl ligation 
reaction and incubated on ice for 20 minutes. The cells were then heat-shocked for 
50 seconds at 42°C and immediately returned to ice for 2 minutes. 950Pl of room 
temperature SOC medium was added to each transformation tube, and incubated 
for 1.5 hours at 37°C with shaking (N150rpm). Following incubation, 200}ßl of each 
transformation culture was plated onto LB / ampicillin / IPTG / X-Gal plates. 
Alternatively, to increase the number of colonies, the cells were pelleted by 
centrifugation at 1,000 xg for 10 minutes, resuspended in 200}ßl of SOC medium 
and plated out. The plates were then incubated overnight (16-24 hours) at 37°C. 
2.15 Localisation of known genes and novel cDNAs to the YAC contig 
1. Gene specific primer pairs were designed for each known gene or novel cDNA. 
The primers were approximately 50% GC and at least 19 bases in length. 
Additionally, the primers contained either aG or C residue as the last 3'-base, 
and did not have any regions that could self-anneal or form "hair pin" loops. 
The primers were dissolved in distilled water to a final concentration of 
10Opm/i1. 
2. For each 100pl PCR reaction the following were added to a sterile 0.6ml thin 
walled tube; 
Sterile distilled water up to 100}zl 
10x reaction buffer 10}1 
50mM MgC12 6pl 
dNTP mix (1.25mM) 8pl 
Primer 1 (100pmol/pl) 1pl 
Primer 2 (100pmol/pl) 1p1 
YAC template DNA (=200ng) 1}ßl 
Taq polymerase (2.0-2.5 units) 0.5}ßl 
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The buffer, MgC12, and Taq polymerase were manufactured by Bioline. The dNTP 
mix (Amersham Pharmacia Biotech) was prepared by mixing 12.5}ßl of each of the 
100mM dNTPs with 950}1 of sterile distilled water and storing in 1ml aliquots. 
The volume of 50mM MgCl2 stated was a standard starting point, if necessary a 
MgC12 titration was performed to determine the optimal final concentration. The 
template was YAC DNA from the YAC contig spanning the critical region of the 
5q- syndrome (Kostrzewa et al., 1998). 
3. The tubes were mixed gently and centrifuged briefly to bring the contents to 
the bottom of the tube. 
4. Approximately 60pl of mineral oil was added to each tube, to prevent any 
evaporation, and the tubes centrifuged briefly again. 
5. The tubes were placed on the thermal cycler (Biometra Trio Thermoblock) and 
subjected to the appropriate thermal profile. Each primer pair had an optimal 
annealing temperature, and the thermal profile selected for the primer set was 
as shown below: 
Initial denaturation 95°C for 5 minutes 
35 cycles of; 95°C denaturation for 30 seconds 
60°C primer annealing for 30 seconds 
72°C primer extension for 1 minute 
Final extension 72°C for 8 minutes 
Hold temperature 4°C 
6. The mineral oil was removed from the tubes and 5pl was run on a 1.5% mini 
agarose gel. 
7. The gel was stained in ethidium bromide and visualised on a 
UV 
transilluminator. 
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2.16 Reverse transcriptase PCR (RT-PCR) analysis 
RT-PCR analysis was carried out using the Reverse--iTTM One-step PCR kit 
(ABgene, Surrey, UK). 
1. RT-PCR primer pairs were designed flanking the coding region of known 
genes and novel cDNAs. The primers were approximately 50% GC and at 
least 19 bases in length. Additionally, the primers contained either aG or C 
residue as the last 3'-base, and did not have any regions that could self-anneal 
or form "hair pin" loops. The primers were dissolved in RNase-free water to a 
final concentration of 100pm/pl. 
2. The following were added to a 0.5m1 RNase-free microfuge tube; 
2x Reddy-Load Master Mix 251xl 
Sense primer (10pM) 11x1 
Anti-sense primer (10pM) 11x1 
Reverse Transcriptase Blend 1}x1 
RNA template (1pg/pl) 11x1 
RNase-Free Water 21pl 
Total volume 50}1 
For the positive control, 1pl of MS2 positive control template and 1}ßl of MS1 and 
MS2 primers was substituted for the experimental RNA template and primers, 
respectively 
3. The tubes were mixed gently and centrifuged briefly to bring the contents to 
the bottom of the tube. 
4. The tubes were placed on the thermal cycler (Hybaid PCR sprint, Hybaid, 
Middlesex, UK) and subjected to the appropriate thermal profile. Each primer 
pair had an optimal annealing temperature and the thermal profile selected for 
the primer set was as shown below: 
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1St strand synthesis 47°C for 30 minutes 
RTase inactivation and 
initial denaturation 94°C for 2 minutes 
40 cycles of; 94°C denaturation for 20 seconds 
63°C primer annealing for 30 seconds 
72°C primer extension for 1 minute 
Final extension 72°C for 5 minutes 
Hold temperature 4°C 
2.16.1 Purification and quantification of RT-PCR products 
1.1}xl of purified template, 1pl of Bromophenol Blue loading dye, and 3}x1 of 
distilled water to a final volume of 5pl was added to a 0.5m1 microcentrifuge 
tube. 
2. The tubes were mixed gently and centrifuged briefly to bring the contents to 
the bottom of the tube. 
3. All 5pl was run on a 1% Low EEO Agarose gel in 1x TAE buffer at 100V for 
approximately 40 minutes. The purified product should be seen as a high 
quality, single band. 
4. A small aliquot of the reaction (5izl) was run on a 1% mini agarose gel. 
5. The gel was stained in ethidium bromide and visualised on a UV 
transilluminator. 
2.17 CD34+ expression by RT-PCR 
Total RNA was obtained from CD34+ cells with the Total RNA Isolation Kit (AMS 
Biotechnology (Europe) Ltd., Oxfordshire, UK). RT-PCR was carried out using the 
Reverse--iTTM One-step PCR kit (ABgene) as previously described (2.16 steps 2-4). 
1. RT-PCR primer pairs were designed flanking the coding regions of each novel 
cDNA/gene. The primers were dissolved in RNase-free water to a final 
concentration of 100pm/pl. 
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2. CD34+ RNA (O. lpg/ml) was used as the template in the RT-PCR reaction. For 
the positive control, 1pl of a Total RNA mononuclear fraction from a healthy 
individual was substituted for the CD34+ RNA template. 
2.18 Cycle sequencing on the ALFexpress automated sequencer 
All cycle sequencing reactions were carried out using the Thermo SequenaseTM 
CyTM5 Dye Terminator Kit (Amersham Pharmacia Biotech), for use on the 
Alfexpress automated sequencer (Amersham Pharmacia Biotech). 
2.18.1 Preparation of dNTP/Cy5 ddNTP mixes 
All mixes were prepared on ice. 
1.4 tubes were labelled "A Mix", "C Mix", "G Mix", and "T Mix respectively for 
preparation of the dye terminator mixes. 
2.4}x1 of 1.1mM dNTP, 2pl of the appropriate Cy5 ddNTP, and 16pl of distilled 
water to a final volume of 22}xl was added to each "Mix". These volumes are 
sufficient for 10 sequencing reactions. 
3. The mixes were vortexed and centrifuge briefly to collect the contents at the 
bottom of each tube. 
4. The dNTP/Cy5 ddNTP mixes were stored on ice, in the dark, until needed. 
2.18.2 Sequencing reactions 
All sequencing reactions were prepared on ice. 
1. Four sterile 0.6m1 thin walled tubes "A", "C", "G", and "T" were labelled for 
each template (1-10), respectively. 
2.2}ßl of the "A Mix", "C Mix", "G Mix", and "T Mix" (prepared in 4.2.15.4) were 
dispensed into the corresponding tubes "A", "C", "G", and "T" respectively. 
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3. A Master Mix was prepared for each template (set of 4 reactions; A, C, G, and 
T), by combining the following in a 0.5m1 microcentrifuge tube; 
Template DNA# 1.0-20.5pl 
Primer (4pmol)* 2}ßl 
Reaction buffer 3.5}zl 
Thermo Sequenase DNA polymerase (10U/pl) 1}zl 
Distilled water to a final volume of 27pl 
# Generally, 1-4}x1 of template was used in the sequencing reaction if a clean, 
bright band was seen on an agarose gel. 10pl was used if the band was faint. 
Anything over 10pl did not give a sufficient quality sequence. 
* Nested primers were designed a few base pairs internally to the amplification 
primers for the sequencing reactions as they produced a better sequence run due 
to the added specificity. The primers were diluted in distilled water to a final 
concentration of 2pmol/pl. 
4. The tubes were vortexed and then centrifuged briefly to bring the contents to 
the bottom of the tube. 6pl of each template Master Mix was aliquoted into 
each of its "A", "C", "G", and "T" mixes. The reactions were mixed by gently 
pipetting up and down. The reactions were overlayed with 10}x1 of mineral oil 
if a non-heated lid thermal cycler was used. 
5. The tubes were placed on the thermal cycler and subjected to the appropriate 
thermal profile. Each primer had an optimal annealing temperature, and the 
thermal profile selected for both primers was as shown below: 
30 cycles of; 95°C for 30 seconds 
61 °C primer annealing for 30 seconds 
72°C primer extension for 1 minute 20 
seconds 
4°C hold 
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2.18.3 Precipitation of sequencing reactions 
Precipitation of all sequencing reactions was carried out on ice. 
1. If a non-heated lid thermal cycler was used, each sequencing reaction was 
transferred from underneath the mineral oil to a new 0.5m1 microcentrifuge 
tube. 
2.2}ßl of 7.5M ammonium acetate was added directly to each reaction. 
3.2pl of glycogen solution was added to each tube. 
4.30}ßl of ice-cold absolute ethanol was added to each tube. 
5. The samples were vortexed and incubated on ice for 20 minutes. Alternatively, 
they were incubated overnight at -20°C. 
6. The reactions were centrifuged at full speed (10,000-16,000xg) in a 
microcentrifuge for 15 minutes at 4°C to pellet the DNA. 
7. The supernatant was removed, making sure the pellet was not touched. 200pl 
of ice-cold 70% ethanol was added to each pellet. 
8. The reactions were centrifuged at full speed for 5 minutes at 4°C. 
9. The supernatant was removed carefully, firstly with a 20-200pl pipette tip, then 
with a 0.5-10pl pipette tip. Any ethanol remaining in the tube was removed 
with a clean, lint and dye free tissue, making sure the pellet was not disturbed. 
The pellets were left to dry for no longer than 10 minutes, as overdrying made 
the pellets difficult to resuspend. In addition, the pellet turned from being 
bright white to transparent if it was left to dry for too long, making it less 
visible. 
10. The pellet was resuspended in 8}ßl of Stop solution by pipetting slowly up and 
down. 
2.18.4 Preparation of the polyacrylamide gel and loading of samples 
1. The glass gel plates were cleaned twice with distilled water. Kimwipe tissues 
were used at all times for cleaning the gel plates. Kimwipe tissues were used 
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because they contain no dye, and therefore prevent contaminating 
fluorescence. 
2. The glass gel plates were cleaned twice with Absolute ethanol. 
3. The top inch of both plates was wiped with Bind-Silane. 
4. The glass gel plates were cleaned again with Absolute ethanol. 
5. Two 0.5mm glass spacers were cleaned with Absolute ethanol and placed 
securely on the bottom Thermoplate (Amersham Pharmacia Biotech). The top 
plate was placed on top and secured with clips. 
6. The 0.5mm comb was cleaned with Absolute ethanol and placed between the 
two plates. 
7. ReproGelTM High Resolution gel mix (Amersham Pharmacia Biotech) Solution 
B was added to Solution A. The polyacrylamide was mixed by inverting the 
bottle 5 times. The gel mix was loaded directly onto the gel plates. 
8. The gel plates were placed directly under the ReproSetTM (Amersham 
Pharmacia Biotech) and the gel mix left to polymerise for 10 minutes under the 
UV light. 
9. The samples were denatured at 72°C for 3 minutes, then immediately placed 
on ice. If the samples were denatured at the normal 95°C, the signal from the 
larger dye-terminated fragments would be degraded. 
10. The entire volume of each reaction (8il) was loaded into the appropriate well 
of the sequencing gel and electrophoresed under the appropriate conditions. 
2.18.5 Processing the sequence data on the ALFexpress automated sequencer 
Each clone (1-10) was processed using the Extended Shift Function available in 
ALFwinTM Sequence Analyser 2.10 software (Amersham Pharmacia Biotech). This 
process overcomes the effect known as "smiling" that is produced when samples 
in the first and last lanes move more slowly than those in the middle lanes. The 
data was always processed after the run had completed. The software never 
processed the data as a post-run action. 
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2.19 Cycle sequencing on the ABI PRISM 3100 Genetic analyser 
All cycle sequencing reactions were carried out using the ABI PRISM® BigDYETM 
Terminator Cycle Sequencing Ready Reaction Kit v2.0 (Applied Biosystems UK, 
Warrington, Cheshire) for use on the ABI PRISM 3100 Genetic analyser (Applied 
Biosystems). 
2.19.1 Preparation of sequencing reactions 
Preparation of sequencing reactions was carried out at room temperature. 
1. Sixteen sterile 0.6m1 thin-walled tubes were labelled for each of the 8 
templates: (1-8 for Forward primer; 9-16 for Reverse primer). 
2. A Master Mix was prepared for each primer (9 reactions each) by combining 
the following in a 1.5ml microcentrifuge tube; 
Template DNA* 1.0-2.0}i1 
Primer (3.2 pmol) 1}zl 
5x Sequencing buffer 2pl 
Terminator Ready Reaction Mix 4pl 
Distilled water to a final volume of 20}ßl 
* Generally, l-2pl of a 1: 10 dilution of the genomic DNA PCR product was used as 
the template in the sequencing reaction if a clean, bright band was seen on an 
agarose gel. 
3. Each Master Mix was vortexed to mix. 19}ßl of Master Mix was added to 1}ßl of 
template. The reactions were vortexed and then centrifuged briefly to bring 
the contents to the bottom of the tube. 
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4. The tubes were placed on the Hybaid PCR Sprint thermal cycler (Hybaid 
Limited, Middlesex, UK) and subjected to the appropriate thermal profile: 
25 cycles of; 96°C for 10 seconds 
50°C primer annealing for 5 seconds 
60°C primer extension for 4 minutes 
4°C hold 
2.19.2 Sodium acetate precipitation of sequencing reactions 
Precipitation of all sequencing reactions was carried out at room temperature. 
1.2pl of 3M sodium acetate (pH 4.6) was added directly to each reaction. 
2.50pl of 95% ethanol was added to each tube. 
3. The samples were vortexed and then centrifuged briefly to bring the contents 
to the bottom of the tube. 
4. The reactions were incubated at room temperature for 15 minutes. 
5. The reactions were centrifuged at full speed (10,000-16,000 x g) in a 
microcentrifuge for 20 minutes to pellet the DNA. 
6. The supernatant was removed, making sure the pellet was not touched. 250}zl 
of 70% ethanol was added to each pellet. 
7. The reactions were vortexed briefly and centrifuged at full speed for 5 
minutes. 
8. The supernatant was removed carefully, firstly with a 20-200pl pipette tip, 
then with a 0.5-10pl pipette tip. The pellets were left to dry for no longer than 
20 minutes, as overdrying made the pellets difficult to resuspend. 
9.20}zl of Template Suppression reagent (TSR) was added to each reaction. The 
tubes were vortexed and centrifuged briefly to bring the contents to the 
bottom of the tube. 
10. The samples were denatured at 95°C for 2 minutes, then immediately chilled 
on ice. 
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2.19.3 Processing the sequence data on the ABI PRISM 3100 Genetic analyser 
All sequence data was collected using the ABI PRISM Data Collection Software 
version 1.0, and processed using the ABI PRISM DNA Sequencing Analysis 
Software version 3.6 NT. 
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3.1 Introduction 
3.1.1 Identification of disease genes 
The choice of strategy for identifying a disease gene is dependent on the resources 
(animal models, chromosomal abnormalities, clone libraries, etc. ) available, and on 
how much is known about the pathogenesis of the disease. Several strategies 
initially identify a number of candidate genes, which then are tested individually 
for evidence that implicates them as the disease locus. A number of different 
methods have been used to identify candidate genes, but mapping the disease to a 
specific sub-chromosomal localisation is generally the most productive first step. 
3.1.2 Positional candidate gene approach 
Once a disease has been mapped, it is now possible to use database searches to 
identify candidate genes. With increasingly more human genes being mapped to 
specific sub-chromosomal regions, positional candidate gene approaches are now 
dominating the field. 
3.1.3 Chromosome 5 mapped genes 
Human chromosome 5 contains an estimated 194 million bases, or approximately 
6% of the human genome. A number of disease-linked genes have been mapped 
to chromosome 5. They include those for colorectal cancer, dwarfism, severe 
combined immunodeficiency, schizophrenia, basal cell carcinoma, deafness, atrial 
septal defect, asthma, and acute myelogenous leukaemia (HGP Information, April 
2000 (http: //www. ornl. gov/hgmis)). Several genes have been assigned in 
particular to 5q including many haematopoietic growth factors, for example the 
interleukin genes (Le Beau et al., 1989), and the interferon regulatory factor 1 
(IRF1) gene (Itoh et al., 1991). Chromosome 5 is currently being sequenced by the 
Department of Energy's Joint Genome Institute in Walnut Creek, California as part 
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of the HGP. The draft sequence of chromosome 5, along with chromosomes 16 
and 19 was released to the public on April 13,2000. At this time it was believed 
that these three chromosomes contain an estimated 10,000-15,000 genes (HGP 
Information, April 2000). By February 2001,24577kb was finished sequence 
(12.7%), represented by 152 contigs. The GeneMap of chromosome 5 from Entrez 
at NCBI 
(http: / /www. ncbi. nlm. nih. gov/cgi-bin/Entrez/maps. cgi? ORG=hum&CHR=5) 
showed there were 331 known genes as of November 12,2000, of which 47 map to 
the critical region of the 5q- syndrome at 5g31.3-q33. 
3.1.4 Isolating expressed sequence tags (ESTs) from the critical region of the 
5q- syndrome 
Until the draft sequencing and annotation of the human genome was reported in 
February 2001, the most recent and advanced technique for the isolation of novel 
coding sequences has been the use of ESTs (Expressed Sequence Tags). ESTs are 
partial sequences, approximately 300-400bp, of the 3' and 5' ends of cDNAs. It is 
probable that the majority of the 30-40,000 genes in the human genome are now 
represented by one or more ESTs. On November 2,2001 the number of public 
entries in the EST database db(EST) 
(http: //www. ncbi. nlm. nih. gov/dbEST/index. html) was 9,407,866, of which 
3,876,441 were human. Moreover, there were over 1,000 separate entries 
comprising of EST clusters assigned to chromosome 5. ESTs representing novel 
genes can be accessed from the National Centre for Biotechnology Information 
(NCBI) website through The Human Gene Map 
(http: //www. ncbi. nlm. nih. gov/genome/guide/HsChr5. shtml), and UniGene 
(http: / /www. ncbi. nlm. nih. gov/UniGene/Hs_DATA/ChromLists/Chr5. html). 
The former enables a specific sub-chromosomal region between specific markers 
to be accessed for ESTs represented as unidentified transcripts. 
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We selected ESTs for analysis that had been mapped to the region by two 
independent groups and contained sequences derived from cDNA libraries of 
haematological tissue, e. g. foetal liver spleen. The UniGene site has clusters that 
contain sequences that represent a unique gene. Each cluster contains a number of 
EST sequences with added information. We selected ESTs for analysis that either 
possessed a poly-adenylation signal; were novel; had similarity to known proteins 
of particular interest (after translation); contained a mapped sequence-tagged site 
(STS); or its clone source was a CGAP (Cancer Genome Anatomy Project) library. 
CGAP is an interdisciplinary program established and administered by the 
National Cancer Institute (NCI) to generate the information and technological 
tools needed to decipher the molecular anatomy of the cancer cell (CGAP 
homepage). This and other projects will form the basis for human genome 
research during the next few years, as the complete reference sequence becomes 
available to underpin the next phase of human biology and genetics. 
Therefore, the EST database was used to identify novel cDNAs mapping to the 
critical region of gene loss, with the ultimate aim of isolating the putative tumour 
suppressor gene associated with the development of the 5q- syndrome. 
Page 75 
3.2 Materials and Methods 
3.2.1 ESTs 
The Human Gene Map of chromosome 5 was accessed to identify ESTs assigned 
between the DNA markers D5S410 and D5S487 that span the critical region of the 
5q- syndrome at 5g31.3-q33. One of the EST clusters identified revealed an 
unidentified transcript represented by 21 ESTs from the Soares foetal liver spleen 
1NFLS library; the Soares melanocyte 2NbHM library; the Soares multiple 
sclerosis 2NbHMSP library; the Soares pregnant uterus NbHPU library; the 
Stratagene fibroblast (937212) library; and the Stratagene lung (937210) library. A 
transcript was selected that had no homology to any known genes and had ESTs 
from cDNA libraries of haematological origin. 
Two ESTs were selected for further analysis based on their cDNA library source 
(Soares pregnant uterus NbHPU Homo sapiens library and the Soares foetal liver 
spleen 1NFLS library), and having no significant homology to any known human 
gene (i. e., representing novel genes). 
3.2.2 I. M. A. G. E. cDNA clones 
I. M. A. G. E. cDNA clones from which the two ESTs were derived were obtained 
from the Human Genome Mapping Project Resource Centre (HGMP-RC), 
Hinxton, Cambridge as stabs in agar. Single colonies were obtained by plating 
onto LB (Luria Bertani) ampicillin (50mg/ml) plates. A single colony was then 
inoculated into a 10ml LB culture containing ampicillin. Plasmid DNA was 
obtained using the QIAprep® Spin Miniprep Kit (QIAGEN). Both inserts were 
excised with the restriction enzymes Notl and EcoRI. 
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3.2.3 Samples 
Six patients with the classical features of the 5q- syndrome, including a 5q deletion 
as the sole karyotypic abnormality were included in the study. Granulocyte and 
mononuclear cells were separated from 40mis of peripheral blood by ficoll 
gradient centrifugation (Boyum, 1984). The granulocytes showed a high level of 
purity (? 95%). Mononuclear cells (specifically T-lymphocytes) were isolated by 
erythrocyte rosetting and showed a purity of ? 90%. High molecular weight DNA 
was obtained from the fractionated blood leukocytes by Nucleon® extraction 
(Nucleon® Biosciences, Scotlab). Granulocyte DNA fractions from the peripheral 
blood of healthy individuals were used as controls. High molecular weight DNA 
was obtained from a human/mouse hybrid cell line with human chromosome 5 as 
its only human complement (GM11714, Coriell Cell Repositories, Camden, NJ). 
3.2.4 Gene dosage analysis 
Gene dosage analysis was used to confirm that the cDNA mapped to the critical 
region of the 5q- syndrome and to quantitatively assess the allelic loss of the 
I. M. A. G. E. cDNA clone. Gene dosage compares the hybridisation signal intensity 
from the gene of interest with the signal intensity from the gene on an uninvolved 
chromosome, and expresses it as a ratio. This ratio is obtained for each patient 
and is compared with the ratio obtained in the control group. 
Granulocyte and mononuclear fractions were obtained from the peripheral blood 
of the three 5q- syndrome patients that define the 5q- syndrome critical region, 
and normal controls. The DNA was digested with the restriction enzyme EcoRI, 
size fractionated through 1% agarose gels and Southern blotted. Two probes were 
simultaneously hybridised to the filters; the insert from the I. M. A. G. E. cDNA 
clone and a 1.9 kb genomic EcoRI-Sstl fragment from the renin gene. The renin 
gene is localised to chromosome 1, uninvolved in the 5q- syndrome, and thus acts 
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as an internal hybridisation control. Following autoradiography, the ratio of the 
two signals in the patients was compared with the ratio of the two signals in the 
normal controls. Gene dosage experiments were carried out on two separate 
occasions. 
3.2.5 Northern analysis 
One of the I. M. A. G. E. cDNA clone inserts was hybridised to Multiple Tissue 
Northern (MTN) blots (Clontech) to determine the tissue expression pattern and 
transcript size of the cDNA. The blots contained 2pg Poly-(A)+ RNA from a 
variety of human tissues (Table 3.1). Probes were labelled with 32P-dCTP by 
random priming, as previously described (Chapter 2 section 2.6). Filters were 
prehybridised for 30 minutes and hybridised for 1 hour at 68°C using Expresshyb 
(Clontech), containing salmon sperm DNA, as previously described (Chapter 2 
section 2.7). Filters were first washed in 2XSSC/0.5% SDS for 30 minutes at room 
temperature with continuous agitation and three changes of wash solution; and 
then in 0.1XSSC/0.1% SDS for up to 40 minutes at 50°C with continuous agitation 
and one change of wash solution. Autoradiography was carried out, as previously 
described (Chapter 2 section 2.10). 
Table 3.1 MTN blots used in Northern analysis containing a variety of 
human tissues 
MTN blot Human tissues included 
1 heart, brain, placenta, lung, liver, skeletal 
muscle, kidney, pancreas 
2 spleen, lymph node, thymus, peripheral blood 
leukocytes, bone marrow, foetal liver 
Page 78 
3.2.6 Southern analysis 
Granulocyte DNA fractions were obtained from six 5q- syndrome patients and 
healthy individuals. The DNA was digested with restriction enzymes EcoRI, PstI, 
Hindlll, PvuII, and EcoRV; size fractionated through a 1% agarose gel and Southern 
blotted. Two Southern blot filters were prepared and hybridised with the 
I. M. A. G. E. cDNA clone insert used in the gene dosage and Northern analysis, to 
screen for gene rearrangements. Southern analysis was carried out on two 
separate occasions. 
3.2.7 Direct sequencing 
I. M. A. G. E. cDNA clones were sequenced as either single-stranded or double- 
stranded templates by the dideoxy chain termination method (Sanger et al., 1977), 
as previously described (Chapter 2 section 2.12.1). Clones were sequenced using 
the Cy5 Autoread sequencing kit (Amersham Pharmacia Biotech), which 
incorporated a single fluorescent label, Cy5 Amidite. Reactions were loaded onto 
the Alfexpress automated sequencer (Amersham Pharmacia Biotech). Data was 
generated for analysis using Alfwin Sequence Analyser 2.10 software (Amersham 
Pharmacia Biotech). Each I. M. A. G. E. cDNA clone was sequenced in full, and then 
subjected to a GenBank search for homology with known genes and overlapping 
clones to generate the full-length cDNA. 
3.2.8 Overlapping cDNA clones 
Sequence data from I. M. A. G. E. cDNA clones was subjected to a homology search 
against the EST database db(EST) to obtain overlapping cDNA clones to generate 
the full-length cDNA. The criteria for overlapping clones was to; have a 100% 
match over a _100bp region, and to possess an 
insert size large enough to extend 
the cDNA at either the 5' or 3' end. In addition, UniGene was accessed as it is 
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updated weekly with new EST sequences and bimonthly with new characterised 
sequences. Overlapping cDNA clones were obtained as before (3.2.2) and 
sequenced. If the overlapping clone matched the criteria, its sequence was added 
to the original data and the 'new' sequence submitted to db(EST) as before. 
3.2.9 cDNA library screening 
If no overlapping clones were identified from db(EST) or UniGene, the cDNA 
clone insert was screened against I. M. A. G. E. cDNA libraries from the 
collaboration with the Resource Centre of the German Human Genome Project at 
the Max-Planck-Institute for molecular genetics (RZPD (http: //www. rzpd. de)). 
The probe was hybridised to gridded I. M. A. G. E. cDNA library filters containing a 
number of tissues including; liver, spleen, whole brain, skin, eye, ovary, lung, 
tonsil, melanocyte, pregnant uterus, heart, colon, prostate, kidney, thyroid, 
pancreas, and adrenal gland. Positive clones were obtained and sequenced, and 
the 'new' sequence submitted to db(EST) as before. 
3.2.10 RACE PCR 
The technology of RACE (Rapid Amplification of cDNA Ends) PCR, as described 
in Chapter 2 section 2.13 was used to generate 'new' sequence when no 
overlapping clones were identified from screening db(EST) and cDNA libraries. 
RACE PCR is used to amplify the 5' and/or 3' ends of cDNAs to clone the full- 
length cDNA without constructing or screening a cDNA library. RACE PCR was 
performed using Marathon-ReadyTM cDNAs (Clontech UK Ltd. ). Marathon- 
ReadyTM cDNAs are premade libraries of adaptor-ligated double-stranded cDNA 
ready for use as templates (Chenchik et al., 1996). The libraries chosen were tissue- 
specific to the gene of interest. 
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1. The Gene-Specific Primers (GSPs) were designed only from the 5' end of the 
cDNA as the 3' Poly-A+ tail had been obtained. Details of the primers, 
including their annealing temperatures and choice of thermal profile are 
shown in Table 3.2. 
2. The Marathon-ReadyTM cDNA templates used in the 25pl RACE PCR reaction 
included; human foetal liver, lung, bone marrow, pituitary gland, small 
intestine, foetal skeletal muscle, testis, foetal brain, foetal spleen, 
hypothalamus, and foetal thymus. 
3. The RACE PCR products were subcloned and prepared for sequencing as 
previously described (Chapter 2 section 2.14). 
3.2.11 Localisation to the YAC contig 
The cDNA was sublocalised by PCR screening to the YAC contig encompassing 
the critical region of the 5q- syndrome (Kostrzewa et al., 1998) as previously 
described (Chapter 2 section 2.15). 
A PCR primer pair; Forward 1 (5'-GCTGGCACAAATGAAATGGG-3'), and 
Reverse 1 (5'TTGAACATGGTGTCAGTCCC-3') was designed from the cDNA 
sequence. PCR was performed under the following conditions: 95°C for 30 
seconds, 60°C for 30 seconds, and 72°C for 1 minute. A product size of 140bp was 
expected. 
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3.2.12 Database analysis using the Genetics Computer Group (GCG) software 
package 
The GCG® (Genetics Computer Group) was founded in 1982 at the Department of 
Genetics at the University of Wisconsin-Madison. The Wisconsin Package Version 
10.1 is an integrated package of over 130 programs that allows the manipulation 
and analysis of nucleic acid and protein sequences. 
3.2.12.1 FastA 
FastA uses the method of Pearson and Lipman, (1988) to search for similarities 
between a query sequence and a group of sequences of the same type (nucleic acid 
or protein). The 3051bp sequence of the novel cDNA was submitted to a FastA 
search in the GenEMBL group of sequence databases. 
3.2.12.2 BLAST 
BLAST (Basic Local Alignment Search Tool) uses the method of Altschul et al., 
(1990) to search one or more nucleic acid or protein databases for sequences 
similar to one or more query sequences of any type. The novel cDNA was 
submitted to a BLAST search in the SWISS-PROT protein sequence database. 
3.2.12.3 Frames 
Frames displays open reading frames for the six translation frames of a DNA 
sequence. The open reading frame of the novel cDNA was determined using the 
X-Windows graphics display software run on 'eXodus' for the Apple Macintosh. 
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3.2.12.4 Translate 
Translate translates nucleotide sequences into peptide sequences. A translation 
was carried out to determine the coding region of the cDNA in the correct open 
reading frame. 
3.2.12.5 Motifs 
Motifs looks for sequence motifs by searching through proteins for the patterns 
defined in the PROSITE Dictionary of Protein Sites and Patterns. A Motif search 
was carried out on the translated region of the novel cDNA. 
3.2.12.6 GenBank submission 
GenBank (http: //www. ncbi. nlm. nih. gov/GenBank/index. html) is the NIH 
genetic sequence database, an annotated collection of all publicly available DNA 
sequences. There are approximately 15,850,000,000 bases in 14,976,000 sequence 
records as of December 2001. Many journals require submission of sequence 
information to a database prior to publication so that an accession number may 
appear in the paper. NCBI has a www form called Banklt 
(http: //www. ncbi. nlm. nih. gov/Banklt/index. html), for convenient and quick 
submission of sequence data. 
3.2.13 Mutation analysis of C5orf4 
The method of choice for mutation analysis on the translated sequence of novel 
gene C5orf4 was cycle sequencing using the Thermo SequenaseTM CyTM5 Dye 
Terminator Kit (Amersham Pharmacia Biotech) on the Alfexpress automated 
sequencer (Amersham Pharmacia Biotech). This was due to the small coding 
region of the gene (432bp) which could be cycle sequenced in one fragment only. 
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As C5orf4 was novel, the genomic structure of the gene was unknown, therefore a 
Reverse Transcriptase (RT-PCR) was performed to generate the cDNA template. 
The cDNA template was then combined with a gene-specific unlabelled primer, 
Thermo Sequenase DNA polymerase, Cy5 labelled ddNTPs, and dNTPs. Thermo 
Sequenase gives an even incorporation of the nucleotides and generates very 
uniform signal peaks. 
3.2.13.1 Samples 
Ten patients with the 5q- syndrome were included in the study. Granulocyte and 
mononuclear cells were separated from 40mis of peripheral blood by ficoll 
gradient centrifugation (Boyum, 1984). The granulocytes showed a high level of 
purity (>_95%). Mononuclear cells showed a purity of >_90%. Total RNA was 
obtained from the granulocyte fractions with the Total RNA Isolation Kit (AMS 
Biotechnology (Europe) Ltd. This method is based on the disruption of cells in 
guanidinium thiocynate/cationic detergent solutions, followed by the organic 
extraction and alcohol precipitation of the RNA. Granulocyte total RNA fractions 
from the peripheral blood of healthy individuals were used as controls. 
3.2.13.2 Reverse Transcriptase PCR (RT-PCR) 
RT-PCR was carried out using the Reverse--iTTM One-step PCR kit (ABgene) as 
previously described in Chapter 2 section 2.16. 
An RT-PCR primer pair; Forward 3 (5'-TGCAGATGGTCAGGATGG-3'), and 
Reverse 3 (5'-TCTGACCAGCCTCCAGTC-3') was designed flanking the coding 
region of C5orf4. The primers were approximately 50% GC and at least 19 bases in 
length. Additionally, the primers contained either aG or C residue as the last 3'- 
base, and did not have any regions that could self-anneal or form "hair pin" loops. 
The primers were dissolved in RNase-free water to a concentration of 100pm 
/ ul. 
Page 85 
The RT-PCR primers annealed to the template at 63°C. A product size of 550bp 
was expected. 
3.2.13.3 Cycle sequencing 
Cycle sequencing reactions were carried out as described in Chapter 2 section 
2.18. 
Cycle sequencing primers; Forward 4 (5'-AAATGTGTGAGGCTGGCAC-3'), and 
Reverse 4 (5'-TCTGGGGAGCTGTGTTTTC-3') were designed internal to the RT- 
PCR primers, but still flanking the coding region of novel gene C5orf4. Both 
primers annealed to the template at 61 °C in the sequencing reaction. 
3.2.14 Database analysis using the Genetics Computer Group (GCG) software 
package 
Sequence data from each patient and control from novel gene C5orf4, was 
compared with the sequence data submitted to GenBank using BestFit analysis. 
3.2.14.1 BestFit analysis 
BestFit makes an optimal alignment of the best segment of similarity between two 
sequences. Optimal alignments are found by inserting gaps to maximise the 
number of matches using the local homology algorithm of Smith and Waterman. 
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3.3 Results 
3.3.1 ESTs 
The Human Gene Map of chromosome 5 between DNA markers D5S410 and 
D5S487 at NCBI contained an unidentified transcript, Hs. 10235 represented by 21 
ESTs. Two of these ESTs (GenBank Accession Numbers: AA029816 and N73983) 
were selected for analysis. 
3.3.2 I. M. A. G. E. cDNA clones 
I. M. A. G. E. cDNA clones 469867 and 296617 from GenBank Accession Numbers 
AA029816 and N73983 respectively were obtained as stabs in agar from the 
HGMP-RC. cDNA clone 469867 was identified from the Soares pregnant uterus 
NbHPU Homo sapiens cDNA library while cDNA clone 296617 was identified from 
the Soares foetal liver spleen 1NFLS cDNA library. 
3.3.3 Gene dosage analysis 
Gene dosage analysis with cDNA clone 469867 and the renin gene showed both 
probes hybridised to a single fragment. An approximate 50% reduction in the 
dosage of clone 469867 in the granulocyte patient DNA, compared with normal 
controls confirmed the deletion of one allele, and therefore, co-localisation to 5q. 
3.3.4 Northern analysis 
Northern analysis showed I. M. A. G. E. cDNA clone 469867 to possess a single 
transcript of 3.0kb and to be ubiquitously expressed with a high level of 
expression in foetal liver, see Figure 3.1. 
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Figure 3.1 
Representative Northern blot analysis of I. M. A. G. E. cDNA clone 469867. MTN 
blot (a) included 2pg of Poly-(A)+ RNA from; heart (1), brain (2), placenta (3), lung 
(4), liver (5), skeletal muscle (6), kidney (7), and pancreas (8). MTN blot (b) 
included 2pg of Poly-(A)+ RNA from; spleen (1), lymph node (2), thymus (3), 
peripheral blood leukocytes (4), bone marrow (5), and foetal liver (6). Sizes of 
RNA marker bands (kb) are indicated approximately. 
3.3.5 Southern analysis 
No rearrangements were observed in the granulocyte fractions of six patients with 
the 5q- syndrome digested with restriction enzymes EcoRI, Pstl, HindIll, Pvull, and 
EcoRV, following hybridisation with cDNA clone 469867. 
12345678 123456 kb 
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3.3.6 Direct sequencing 
3.3.6.1 I. M. A. G. E. cDNA clone 469867 
Direct sequencing of I. M. A. G. E. cDNA clone 469867 as a single-stranded template 
generated 332bp of sequence from the 3' end that included an 18bp Poly-(A)+ tail. 
The 280bp EST sequence was found within the cDNA clone as expected. 
3.3.6.2 I. M. A. G. E. cDNA clone 296617 
Direct sequencing of I. M. A. G. E. cDNA clone 296617 as a double-stranded 
template generated 1500bp of sequence from the 3' end that included an 18bp 
Poly-(A)+ tail. The 261bp EST sequence was not found within the cDNA as 
expected, suggesting the clone was incorrect. Clone 296617 was discarded from 
this point. 
3.3.7 Overlapping cDNA clones 
A db(EST) search using the sequence of 469867 identified two overlapping cDNA 
clones (I. M. A. G. E. No.: 982453, GenBank Accession No.: AA523234; I. M. A. G. E. 
No.: 935769, GenBank Accession No.: AA523935) from the db(EST) homology 
search. They were derived from the metastatic prostate bone lesion 
NCI_CGAP_Pr12 and the colon NCI_CGAP_Co3 cDNA libraries respectively. 
These two clones had the potential to add to the sequence of clone 469867 and 
contribute to the construction of the full-length cDNA. 
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3.3.7.1 I. M. A. G. E. cDNA clone 982453 
The db(EST) search with cDNA 469867 revealed a 100% match with clone 982453 
at the 3' end immediately preceding the Poly-(A)+ tail. Direct sequencing of clone 
982453 as a double-stranded template generated 221bp of sequence at the 3' end 
within the 332bp sequence of clone 469867. Therefore, no further sequence could 
be added to cDNA 469867. 
3.3.7.2 I. M. A. G. E. cDNA clone 209846 
The db(EST) search on overlapping clone 982453 (3.3.7.1) identified one 
overlapping clone, recently deposited, (I. M. A. G. E. No.: 209846, GenBank 
Accession No.: H67084) from the Soares foetal liver spleen 1NFLS cDNA library to 
be matching 100% with cDNA 469867 at the 3' end, immediately preceding the 
Poly-(A)+ tail. Information data on clone 209846 showed it to possess a large 
insert size of 1391bp that would extend cDNA clone 469867 a further 1059bp. 
Direct sequencing of clone 209846 as a single-stranded template generated 1259bp 
of sequence, and the EST data was found within the sequence. The sequence 
overlapped with 469867 with 100% homology over 332bp. Thus, clone 209846 
added a further 927bp to the cDNA. A second db(EST) search identified a further 
four overlapping clones (I. M. A. G. E. No. s.: 280058,292429,241086, and 203279) 
which would potentially extend the 1259bp cDNA, see Table 3.3. 
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3.3.7.3 I. M. A. G. E. cDNA clone 280058 
The information on clones 280058,292429,241086, and 203279 did not include 
insert sizes, therefore inserts were cut out using the appropriate restriction 
enzymes. Clone 280058 possessed the largest insert with a size of 1300bp, and was 
thus chosen for further analysis. Direct sequencing of cDNA 280058 as a single- 
stranded template showed it to overlap 100% at the 5' end from nucleotide 82, 
with the cDNA sequence. However, the clone was not large enough to add any 
further sequence data to the cDNA, and was thus discarded at this point. 
3.3.7.4 False positive I. M. A. G. E. cDNA clones 935769 and 251760 
The db(EST) search with cDNA 469867 revealed clone 935769 to be matching 100% 
with cDNA 469867 at the 3' end immediately preceding the Poly-(A)+ tail. Direct 
sequencing of clone 935769 as a single-stranded template showed it did not 
contain its EST sequence, and thus did not overlap with cDNA 469867, confirming 
it was the wrong clone. The cDNA was discarded from this point. The db(EST) 
homology search on the 'new' 1259bp sequence (469867 + 209846) revealed one 
overlapping clone that would potentially complete the full coding sequence (cds). 
The search showed clone 251760 to be matching 100% over its 567bp EST sequence 
at the 3' end immediately preceding the Poly-(A)+ tail. Direct sequencing of the 
double-stranded template showed it did not contain its EST sequence, and thus 
did not overlap with the cDNA. Clone 251760 was discarded from this point. 
3.3.8 cDNA library screening 
The collaboration with the Resource Centre of the German Human Genome 
Project came into effect when a db(EST) homology search failed to identify 
overlapping clones. Thirty-four potential positive clones were identified with 
probe 209846 (3.3.7.2), see Table 3.4. Direct sequencing of the clones identified 15 
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positive clones out of 28 analysed, see Table 3.4. Eight clones were not screened 
because their insert sizes were less than 500bp. None of the positive clones added 
any further sequence to the cDNA. 
3.3.9 RACE PCR 
RACE PCR was used to extend the cDNA after db(EST) homology searches, 
UniGene, and cDNA library screening failed to produce any further clones. 
Firstly, 3 GSPs were designed (R3-R1) approximately 200bp from the 5' end of the 
sequence. A 294bp RACE PCR product was generated from the human foetal 
brain cDNA library. The product was purified, subcloned, and the plasmid 
extracted. Direct sequencing of the double-stranded template showed it to have a 
100% match with the cDNA, in a 129bp overlap, and extend the sequence by 
165bp. No overlapping clones were identified from db(EST) and UniGene 
homology searches. Therefore, RACE PCR primers were designed from the 'new' 
sequence. The second RACE PCR product was generated from the human foetal 
brain cDNA library also. It had a 100% match with the cDNA, overlapped by 
76bp, and extended the sequence by 164bp. The transcript sequence generated 
was now 1588bp. 
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Table 3.4 Clones identified from screening the I. M. A. G. E. cDNA clone 
collection library with probe 209846 
Clone RZPD Clone 
ID 
Approx insert 
size 
Clone Status Overlap with 
cDNA 
Al M0978Q2 900bp Positive Yes (900b ) 
A2 K1479Q2 924bp Positive Yes (924b ) 
A3 J17114Q2 1000bp Positive Yes (1000b ) 
A4 B19370Q2 926bp Positive Yes (926b ) 
A5 P11389Q2 997bp False positive No 
A6 E01393Q2 759bp Positive Yes (759b ) 
B1 M21395Q2 2700bp False positive No 
B2 E20396Q2 700bp Positive Yes (700b ) 
B3 M14409Q2 ? False positive Yes 
B4 M15409Q2 1259bp Positive Yes (1259b ) 
B5 A03414Q2 CLONE NOT SCREENED 
B6 B08414Q2 735bp False positive No 
C1 B09414Q2 732bp False positive No 
C2 C03414Q2 1238bp NOT SCREENED 
C3 C08414Q2 723bp NOT SCREENED 
C4 D03414Q2 962bp NOT SCREENED 
C5 J01414Q2 ? False positive No 
C6 J03414Q2 ? False positive No 
D1 G21463Q2 1000b Positive Yes (1000b ) 
D2 G09516Q2 1200bp RECOMBINANT CLONE 
D3 G14517Q2 1706bp False positive No 
D4 A07520Q2 1000b Positive Yes (1000b ) 
D5 F18528Q2 CLONE NOT SCREENED 
D6 G15528Q2 2329bp False positive No 
D7 L19536Q2 1489bp False positive No 
D8 F15608Q2 1033bp Positive Yes (1033b ) 
D9 J13654Q2 CLONE NOT SCREENED 
D10 B17656Q2 CLONE NOT SCREENED 
D11 B04536Q2 900bp Positive Yes (900b ) 
D12 L24657Q2 1200b Positive Yes (1200b ) 
D13 M02662Q2 1000b Positive Yes (1000b ) 
D14 F14608Q2 1705BP False positive No 
D15 N12651Q2 CLONE NOT SCREENED 
D16 G03535()2-4 - 826bp Positive Yes (826b ) 
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3.3.10 I. M. A. G. E. cDNA clone 435297 
The db(EST) homology search on the 1588bp sequence identified an overlapping 
clone (I. M. A. G. E. No.: 435297, GenBank Accession No.: AA699911) derived from 
the Soares foetal liver spleen 1NFLS_S1 cDNA library. Restriction enzyme 
digestion showed the insert size to be approximately 1.4kb. This clone would 
complete the full cds. However, the 100% overlap of clone 435297 with the cDNA 
was only 52bp. The ideal overlap is between 80-100bp to confirm the clone is part 
of the cDNA. 
Southern and Northern data to confirm the clone was part of the cDNA was 
inconclusive. RACE PCR primers (R10-R12) were designed. The 144bp RACE 
product showed 100% homology with cDNA clone 435297, confirming the clone 
was part of the cds. Direct sequencing of clone 435297 as a double-stranded 
template with internal primers generated a 1428bp fragment that completed the 
full-length cDNA. I. M. A. G. E. cDNA clones 1654025 (GenBank Accession No.: 
A1084848), and 121027 (GenBank Accession No.: T96312), both from the Soares 
foetal liver spleen 1NFLS cDNA library and possessing insert sizes of 653bp and 
1058bp respectively were directly sequenced as double-stranded templates to 
confirm the sequence of clone 435297 and erase any sequencing ambiguities. 
3.3.11 Localisation to the YAC contig 
Novel gene C5orf4 was sublocalised by PCR screening to YAC 914A10 from the 
YAC contig spanning the critical region of the 5q- syndrome (Kostrzewa et al., 
1998), see Figure 3.2 
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Figure 3.2 
Transcription map of the critical region of the 5q- syndrome. The map shows 
known genes (boldface) and novel gene C5orf4 (italics) cloned in this study. The 
three 5q- syndrome patients that define the critical region of gene loss are also 
shown. C5orf4 is shown to map to YAC 914A10 from the YAC contig 
encompassing the critical region of the 5q- syndrome (Kostrzewa et al., 1998). C, 
denotes chimaeric YAC. 
3.3.12 Database analysis using the Genetics Computer Group (GCG) software 
package 
GCG was accessed via telnet at the National Centre for Supercomputing 
Applications (NCSA), and locally at the Oxford University Bioinformatics centre. 
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3.3.12.1 FastA analysis 
The FastA nucleotide homology search utilised all databases (GenEMBL). The 
3051bp cDNA showed no known homology with any gene, identifying it as 
completely novel. 
3.3.12.2 BlastX analysis 
The BlastX protein homology search from the SWISS-PROT database showed the 
3051bp cDNA to have no known protein homology with any known gene. 
3.3.12.3 Frames analysis 
Frames was carried out on the novel cDNA to determine the open-reading frame 
(ORF) for the sequence. The figure indicated it to be in ORF +1 as this frame 
showed the longest stretch of translated sequence. 
3.3.12.4 Translation of the novel cDNA 
Confirmation of the Frames prediction was achieved by translating the cDNA. 
Translation was carried out on all three ORFs starting from nucleotides 1,2, and 3 
respectively to determine the 5' and 3' untranslated regions (UTRs), and the 
coding region of the novel cDNA. Translation in ORF 1 revealed a Methionine 
(M) at nucleotide position 993 (amino acid position 1) and a Stop codon (*) at 
nucleotide position 1425 (amino acid position 475). This indicated a putative 
coding region of 432 nucleotides (144 amino acids) in Frame 1, see Figure 3.3. 
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1 aaggaagtttgcctctggtaccaccttgggactaagtgtatacccaactaagtcccttca 60 
61 tctccctggaccctgccttcaatcatccctcctcttgcaggtctccaacatgctaccggt 120 
121 gatagtgggcccattagtaatgggctcccacttgtcctccatcaccatgtggttttcctt 180 
181 ggccctcatcatcaccaccatctcccactgtggctaccaccttcccttcctgccttcgcc 240 
241 tgaattccacgactaccaccatctcaagtaaggaccttctccccacaatgggtccctagg 300 
301 caacaaccatcaccctccctccttaagcttctgatagcaggcactggtatctcagtttac 360 
361 atgtgagtgctagttggggaagaggtctgatggctgggaaaataaccacactgggatgac 420 
421 cttactcttttccttctgaaattgggtcctcctccaactgggggttttaaacctatattt 480 
481 ggactctgggccctttgaataagctctggacattctctttagaaaagtacatatatgcat 540 
541 aaaactcctgcaggcaatcacaagtaagtcatgtatctctgaaagccccagactttttca 600 
601 agtgtagtctacaaacctcctataccagaatcacctgagatgcttgtttaaaatataggc 660 
661 tcttgaattccactccaaatatgctgaactaaggtatctgggggagcagggcctggaaac 720 
721 ctgcattttagttaagtgttccaggggattctgatgctggtgatctcatacctgaagaag 780 
781 cctagttctgctagagattctcagactgtgggcatcaatcacatagcaagcttttcaaag 840 
841 gaggactccagatacggcaaattgcaggtttggagtggcccccgggagatgcattggtag 900 
901 caactccccagcttattctgatgcagatggtcaggatggtggtgacaggtgtggggtagg 960 
961 agggctgagaaatgtgtgaggctggcacaaaýaaatgggatctgcacggaagcctccag 1020 
MKWDLHGSLQ 
1021 catgggcactgcagtgccgtcctctctcttctaggttcaaccagtgctatggggtgctgg 1080 
HGHCSAVLSLLGSTSAMGCW 
1081 gtgtgctggaccacctccatgggactgacaccatgttcaagcagaccaaggcctacgaga 1140 
VCWTTSMGLTPCSSRPRPTR 
1141 gacatgtcctcctgctgggcttcaccccgctctctgagagcatcccagactccccaaaga 1200 
DMSSCWASPRSLRASQTPQR 
1201 ggatggagtgagagacagcctaagtgtcatcctggctgtccctcagccatgggatgcaga 1260 
GWSERQPKCHPGCPSAMGCR 
1261 cacggcttcctgattgcacctaacaatttgcctccttcggccacacgccctaatgatggc 1320 
HGFLIAPNNLPPSATRPNDG 
1321 accaccagggtagagggaaggtcggcttcccggaaaagcagggccaaggatgaggctttc 1380 
TTRVEGRSASRKSRAKDEAF 
1381 ttcaaactactgcccttgatgtccctcaatgggatcaggagttagcttaagaaaaaggaa 1440 
FKLLPLMSLNGIRS* 
1441 aacacagctccccagactggaggctggtcagagggaggagacccctggtcctctgctgtg 1500 
1501 gaaggagaggggttcagccccagataactcctttgtggcctgggcaggatgcagagaatg 1560 
1561 acaaggctgaaaggagggggactggaggctgcctggctccagcgagagctccttctggga 1620 
1621 ccagagggtgggacggccaggtatcactttgccccttcctgccccaaaaggctttcacat 1680 
1681 acccgactcaggccagagccaagacaccctggcaaatcattataggtctcaattcatgac 1740 
1741 ataccagatgccagtcgccacttcacccaacacacacacaaacatacacacaccaaacac 1800 
1801 tctgagtgagtggtaaaggccccgtttttactctggcccaccgcaaacaaaaggtttccc 1860 
1861 tctgtgggggagaaaaagaaatccaggagctcctccctggattaaaaccaacgaggtgca 1920 
1921 gaccaaactttaacacctttagccttatgtggaaaccaaaaaccaactgctgggaaactg 1980 
1981 tgaaaagcccttttacccacaaggggaggggtcaaagttgctgccctttggggacacccg 2040 
2041 agacccctaattagcctatctgaatgaggaccaaaggttagagccctctttctccccgaa 2100 
2101 gaaagagcccggaaaaacatggcagagcaaagagcaaaatcctttctcccccgaatgctt 2160 
2161 taccagtttctcagcaacatttattcaagatgatttttaccaggaaccttatcaaaggca 2220 
2221 aaaccacagctgcttgggttgaagtccccatcctggcctcctctcagccgccagacatgg 2280 
2281 ccaggaaccctgtggttcccaagaacaatttaaagatcactctttgatttgaaagaccac 2340 
2341 cattatcattttactaaattcttatatatacttgtgccttttccaactttcagttctctt 2400 
2401 aagaaaaacatccactgtagctttataaaataccttagtatcagctaggtccaagtctcc 2460 
2461 aggcaggactatcaaaatggactccttcttcctatcagctctagaaccccagaggacttg 
2520 
2521 cccagtaggccagctgagcacttaccaggcagcatctccctggccttccacagtctcgcc 
2580 
2581 tgtctgtctctggccttggtggacctggctccctccctaggaggcttttgccctcagctt 2640 
2641 gaatacagttcctggtgcatcaaagctgtaagttctcagctgctggcctgcactcatcac 
2700 
2701 ctcttcctacaaataaacatttggaaaaaagtccatcttcaatatgcttaaagagaaggg 
2760 
2761 taggagataaggagaaagaacagatacggtttttttcccctttaaggcctttagattttg 2820 
2821 aggtactgtaaggggcctagaaggacaaaaggctttcattccctcttccttttggcaggc 
2880 
2881 aggttatcagtccttggcagaagggcccagccctatccttttctgtatcaaacaaaatcc 
2940 
2941 ttgaggttggtatacaagttaaggctgaaaaaaggccttaaattcccagtaaagaatgtg 3000 
3001 aaagcaagcatgtaaaataaactggtcttcatgaaaaaaaaaaaaaaaaaa 
3051 
Figure 3.3 Nucleotide and predicted amino acid sequence of C5orf4. The cDNA 
contains a 144 amino acid ORF. Numbers indicate nucleotide positions. 
The 
predicted translational start codon (ATG), the predicted translational stop codon 
(TAG), and the putative polyadenylation signal (AATAAA) are underlined. 
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3.3.12.5 Motif search 
A motif search was carried out on the 144 amino acid protein sequence of the 
cDNA. No significant motif sequences were found. 
3.3.12.6 GenBank submission 
The novel cDNA was assigned the name C5orf4 based on its chromosomal 
localisation (C5) and being the next one in the series (orf4) by the Human Gene 
Nomenclature Committee, The Galton Laboratory, University College London, 
UK (http: //www. gene. ucl. ac. uk/nomenclature/). The data was submitted using 
the www Banklt form at NCBI, and released on the public database on January 1, 
2000. 
3.3.13 Mutation analysis of C5orf4 
No mutations were found in the 432bp coding region of novel gene C5orf4 in 8 
patients with the 5q- syndrome included in the study, see Figure 3.4. 
It is therefore unlikely that novel gene C5orf4 is the tumour suppressor gene 
associated with the development of the 5q- syndrome. 
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44 
468 aaatgtgtgaggctggcacaaatgaaatgggatctgcacggaagcctcca 419 
970 aaatgtgtgaggctggcacaaatgaaatgggatctgcacggaagcctcca 1019 
418 gcatgggcactgcagtgccgtcctctctcttctaggttcaaccagtgcta 369 
1020 gcatgggcactgcagtgccgtcctctctcttctaggttcaaccagtgcta 1069 
368 tggggtgctgggtgtgctggaccacctccatgggactgacaccatgttca 319 
1070 tggggtgctgggtgtgctggaccacctccatgggactgacaccatgttca 1119 
318 agcagaccaaggcctacgagagacatgtcctcctgctgggcttcaccccg 269 
IIIIIIIIIIIIIIIillillillllllllllllllllllllllllllll 
1120 agcagaccaaggcctacgagagacatgtcctcctgctgggcttcaccccg 1169 
268 ctctctgagagcatcccagactccccaaagaggatggagtgagagacagc 219 
1170 ctctctgagagcatcccagactccccaaagaggatggagtgagagacagc 1219 
218 ctaagtgtcatcctggctgtccctcagccatgggatgcagacacggcttc 169 
1220 ctaagtgtcatcctggctgtccctcagccatgggatgcagacacggcttc 1269 
168 ctgattgcacctaacaatttgcctccttcggccacacgccctaatgatgg 120 
1270 ctgattgcacctaacaatttgcctccttcggccacacgccctaatgatgg 1319 
119 caccaccagggtagagggaaggtcggcttcccggaaaagcagggccaagg 70 
11111111111111111111111111111111111111111111111111 
1320 caccaccagggtagagggaaggtcggcttcccggaaaagcagggccaagg 1369 
69 atgaggctttcttcaaactactgcccttgatgtccctcaatgggatcagg 20 
1370 atgaggctttcttcaaactactgcccttgatgtccctcaatgggatcagg 1419 
19 agttagcttaagaaaaag 2 
IIIIIIIIIIIIIIIIII 
1420 agttagcttaagaaaaag 1437 
T 
Figure 3.4 
Representative mutation analysis by cycle sequencing of patients with the 5q- 
syndrome, and normal controls. Alignment of patient 3 (top line) and C5orf4 
(bottom line) from the 432 bp coding region of the novel gene. The arrows 
indicate the translational start codon (atg) and the translational stop codon (tag). 
Patient 3 has 100% homology with the C5orf4 gene indicating no mutations were 
found. 
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3.4 Discussion 
The EST database db(EST) was used as the resource to identify novel genes 
mapping to the critical region of the 5q- syndrome at 5g31.3-q33. The Human 
Chromosome 5 Gene Map was accessed between DNA markers D5S410 and 
D5S487 that span the critical region of gene loss. An unidentified transcript 
represented by 21 EST sequences was identified. Novel gene C5orf4 was cloned 
from three cDNA clones and two RACE PCR products. The cloning of C5orf4 has 
contributed to the HGP in the identification of the estimated 80-100,000 (now 
believed to be 30-40,000) disease genes in the human genome, and represents a 
candidate gene for the putative tumour suppressor gene associated with the 
development of the 5q- syndrome. 
3.4.1 Molecular studies 
Novel gene C5orf4 was shown to map to the critical region of gene loss by gene 
dosage analysis, and then sublocalised by PCR screening to YAC 914A10 from the 
YAC contig encompassing the critical region of the 5q- syndrome (Kostrzewa et al., 
1998). Northern analysis showed C5orf4 to possess a single transcript of 3.0kb and 
to be ubiquitously expressed with a high level of expression in foetal liver, 
suggesting a possible role in early haematopoiesis. The Wilms' tumour gene, WT1, 
which is essential for kidney development, and mutated in some Wilms' tumours 
is an example of a gene thought to play a role in early haematopoiesis. Studies 
have shown WT1 to have a high level of expression in progenitor cells 
(namely 
CD34+), to be downregulated during the differentiation of leukaemic cell lines, 
and high levels of WTI expression to cause cell-cycle arrest, and/or apoptosis 
(Pritchard-Jones and King-Underwood, 1997). This may reflect a role in the 
control of normal haematopoiesis, which can be altered by mutations 
in the gene 
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and form part of the pathway towards leukaemogenesis. The foetal liver 
expresses WTI at a time when it is a site of active haematopoiesis. Another 
example is the GATA-1 transcription factor that is expressed in early 
haematopoiesis. In vitro experiments suggest that its transcription is activated by 
two specific enhancers only in haematopoietic cell lines, thus involved in 
haematopoietic-specific regulation (Wu et al., 1995). 
Therefore, the localisation, expression pattern, and function hypothesis would 
suggest novel gene C5orf4 to be a candidate for the putative tumour suppressor 
gene associated with the development of the 5q- syndrome. 
3.4.2 Translation of C5orf4 
The full coding sequence of novel gene C5orf4 was generated by sequencing 
overlapping I. M. A. G. E. cDNA clones, screening cDNA libraries, and RACE PCR. 
Translation of C5orf4 defined a 990bp 5' UTR; predicted a 144 amino acid protein 
with a Methionine START codon and a STOP codon, and a 1626bp 3' UTR 
including a putative polyadenylation site. No sequence motifs were found in the 
C5orf4 predicted protein following a database search of the PROSITE dictionary of 
protein sites. 
C5orf4 has a small open reading frame of 144 amino acids. However, there are 
other novel genes with a similar size coding region cited in the literature. One 
example is the novel transcript INE 1 (Inactivation Escape 1) which has been 
localised to chromosome interval Xp21.1-pll. 23, and escapes X-inactivation. This 
cDNA defines a complete sequence of 941bp with a predicted protein of 52 amino 
acids including a Methionine START codon and a STOP codon (Esposito et al., 
1997). The complete sequence of novel gene C5orf4 was submitted to GenBank 
and assigned the Accession No. AF159165 (Boultwood et al., 2000). 
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3.4.3 Mutation analysis of C5orf4 
To investigate the proposal that novel gene C5orf4 may be mutated in the 5q- 
syndrome, we cycle sequenced DNA samples from eight patients with the 5q- 
syndrome for mutations in the coding region of C5orf4. No mutations were found 
in the coding region of the C5orf4 gene in the eight patients included in the study. 
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3.5 Conclusion 
The EST resource has been successfully used to identify novel gene C5orf4 that 
maps to the critical region of the 5q- syndrome at 5g31.3-q33. Database searches 
showed C5orf4 had no protein homology to any known eukaryotic gene, 
identifying it as completely novel. However, its expression in CD34+ cells, and its 
high expression in foetal liver suggests a possible role in early haematopoiesis. 
C5orf4 was therefore screened for mutations by cycle sequencing in eight patients 
with MDS and a 5q deletion. No mutations were observed in the coding region of 
novel gene C5orf4, suggesting it was unlikely to be the tumour suppressor gene 
involved in the development of the 5q- syndrome. 
Since this study was completed, a new patient with MDS and the 5q- syndrome 
has been identified. Boultwood and Fidler et al., (in press) identified a fourth 
patient with the 5q- syndrome and a small deletion to refine further the critical 
deleted region. This resulted in the narrowing of the CDR at the distal breakpoint 
at 5q32 to approximately 1.5Mb at 5g31.3-5g32, flanked by the DNA marker 
D5S413 and the glycine receptor (GLRA1) gene. The distal breakpoint of the new 
critical region of the 5q- syndrome now excludes novel gene C5orf4, and thus 
confirms that C5orf4 is unlikely to be the tumour suppressor gene associated with 
the development of the 5q- syndrome. 
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4.1 Introduction 
4.1.1 Identifying novel genes implicated in disease 
The identification of novel coding sequences in the human genome has been 
important in the discovery of genes implicated in cancer and disease. Current 
strategies including linkage analysis, cytogenetic analysis (cloning a chromosome 
translocation), and LOH have been used to identify some of these novel genes. An 
example of a novel gene identified by linkage analysis is the APC gene. Familial 
adenomatous polyposis (FAP) is an autosomal dominant condition characterised 
by diffuse intestinal polyposis, specific gene mutation, and predisposition for 
developing colon cancer. DNA from sixty-one unrelated patients with FAP was 
examined for mutations in three genes (DPI, SRP19, and DP2.5) located within a 
100kb region deleted in two of the patients (Groden et al., 1991). Four mutations 
were found by single-strand confirmation polymorphism (SSCP) analysis in the 
exons of the DP2.5 gene. Analysis of the DNA from the parents of one of these 
patients showed that this 2bp deletion is a new mutation. Moreover, the mutation 
was transmitted to two of his children. These data have established that DP2.5 is 
the APC gene. 
Familial cases of MDS are rare. Mandla et al., (1998) identified a kindred with 
three affected individuals, with early age of onset MDS, suggesting a possible 
inherited predisposition to this disease. Mandla et al., examined whether band 
5q31, a chromosomal region frequently associated with sporadic MDS, was 
involved in familial expression of MDS in this pedigree. Linkage analysis using 
polymorphic microsatellite DNA markers demonstrated that 5q31 did not 
cosegregate with MDS in this family. To date, only one family with familial MDS 
and a 5q- abnormality has been identified. Grimwade et al., (1993) describe two 
sisters, both of whom had MDS and an interstitial deletion of 5q. The tracking of 
maternal and paternal polymorphisms in this study proved uninformative, 
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suggesting linkage analysis is not a viable strategy in the identification of the 5q- 
syndrome gene. 
Novel genes identified from cloning chromosome translocations include the BCL9 
gene. Abnormalities of chromosome 1q21 are common in B-cell malignancies, and 
the nature of the involved gene(s) remains unknown (Willis et al., 1998). A cell- 
line from a patient with B-cell ALL, which exhibited a t(1; 14)(g21; g32), was used to 
identify the gene involved in the translocation. Novel gene BCL9 was identified 
from sequencing full-length cDNA clones obtained from a normal human foetal 
brain cDNA library. Willis et al., suggested that BCL9 may be the target of 
translocation in some B-cell malignancies with abnormalities of 1q21, and that 
deregulated BCL9 expression may be important in their pathogenesis. More 
recently, novel gene TCL6 (T-cell leukaemia/lymphoma) was isolated from the 
breakpoint cluster region on chromosome 14q32.1 (a region often involved in 
chromosomal translocations and inversions in T-cell lymphoproliferative diseases) 
(Saitou et al., 2000). The TCL6 gene was found to be expressed in T-cell leukaemia 
carrying a t(14; 14)g11; g32.1) chromosome translocation. However, like other T- 
cell genes, namely TML1 and TCL1, TCL6 was not expressed in normal T-cells, 
suggesting this novel candidate gene may be involved in leukaemogenesis (Saitou 
et al., 2000). 
There are several reports of chromosome translocations involving 5q (including 
5q31) in MDS and myeloid leukaemia. For example, Borkhardt et al., (2000) 
isolated the human GRAF gene (for GTPase regulator associated with the focal 
adhesion kinase pp125 (FAK)) from its fusion with the mixed-lineage leukaemia 
(MLL) gene in a unique t(5; 11)(g31; g23) in an infant with juvenile myelomonocytic 
leukaemia, while Jaju et al., (1999) describe a recurrent translocation at 5g35 , 
t(5: 11)(g35; p15.5) in childhood AML. Moreover, the translocation at 5q33, 
t(5; 12)(g33; p13) is a recurrent chromosomal abnormality in a subgroup of myeloid 
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malignancies including MDS. To date, there are no reported translocations 
breaking in the critical region of the 5q- syndrome at 5g31.3-q32. 
Loss of heterozygosity at several chromosomal loci is a common feature of the 
malignant progression of human tumours. These regions are thought to harbour 
one or more putative tumour suppressor gene(s) playing a role in tumour 
development (Baffa et al., 2000). Frequent LOH has been found at 17p in 3% to 4% 
of MDS and AML cases (Soenen et al., 1998). Soenen et al., found a strong 
correlation in AML and MDS between a 17p deletion and a typical form of 
dysgranulopoiesis containing pseudo-Pelger-Huet hypolobulation and the 
presence of small vacuoles in granulocytes. The authors also found a strong 
correlation between the 17p deletion and a p53 mutation, suggesting that MDS and 
AML with a 17p deletion constitute a new morphologic-cytogenetic-molecular 
"entity" in those disorders ("17p- syndrome"). Soenen et al., studied seventeen 
cases of AML and MDS with a 17p deletion. In 14/17 cases, FISH showed a 17p 
deletion of variable extent but that always included deletion of the p53 gene. All 
fourteen patients had typical dysgranulopoiesis, and all but one had p53 mutation 
and/or overexpression. These findings reinforce the morphologic, cytogenetic, 
and molecular correlation found in the 17p- syndrome and suggest a pathogenetic 
role for inactivation of tumour suppressor gene(s) located in 17p, especially the 
p53 gene. 
The identification of other novel coding sequences that may be implicated in 
cancer and disease has relied on a number of different molecular techniques over 
the last decade. These include screening zoo blots that were used to discover four 
novel genes in the class II region of the human major histocompatability complex 
(Hanson et al., 1991); and using YACs for hybridisation against cDNA libraries. 
More recently, the strategies of exon trapping and direct selection have been used. 
However, more rapid process has been made by the screening of EST databases. 
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4.1.2 Techniques for isolating novel coding sequences 
4.1.2.1 Exon trapping 
Exon trapping is a technique that exploits mRNA splicing to discover genes 
directly from genomic DNA capturing complete internal exons (Buckler et al., 
1991), or 3'-terminal exons (Krizman et al., 1993). It has been successfully used to 
isolate the novel Huntington's disease (HD) gene (The Huntington's Disease 
Collaborative Research Group, 1993). Exon trapping was also the primary 
technique used to search for the tumour suppressor gene(s) on chromosome 5q 
that may play an important role in the progression of lung cancer (Hosoe, 1996). 
4.1.2.2 Direct selection 
Direct selection is an expression-based gene identification technique that can 
rapidly identify cDNAs within large genomic regions (Del Mastro and Lovett, 
1997). The technique involves the hybridisation of a cDNA library to a genomic 
clone. cDNAs homologous to the target are selected and subsequently enriched 
by PCR amplification. As with exon trapping, direct selection has been used 
successfully to isolate novel coding sequences associated with disease. One study 
isolated five novel genes from the cri-du-chat critical region at 5p15.2 using 
cosmids from the LANL chromosome 5 specific cosmid library (Simmons et al., 
1995). 
4.1.2.3 YAC hybridisation 
The YAC hybridisation method involves the hybridisation of a radiolabeled YAC, 
containing the genomic DNA of interest, to a cDNA library that has been 
transformed into bacteria and replicated onto nitrocellulose filters (Fidler and 
Boultwood, 1997). A number of groups have successfully used this technique to 
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isolate novel coding sequences. Wallace et al., (1990) used it to identify part of the 
NF1 gene, and Snell et al., (1993) isolated seven novel cDNAs mapping to the 
candidate region of the Huntington's gene. The YAC hybridisation method was 
also the primary technique used to isolate novel coding sequences from the critical 
region of the 5q- syndrome (Boultwood et al., 1997). 
All the above methods, although successful in identifying novel coding sequences, 
have not made a major impact on genome research. The turning point came 
recently with the arrival of ESTs that were conceived as a shortcut to the finish line 
(Adams et al., 1991; Boguski, 1995). ESTs are 5' and 3' terminal sequence reads 
from cDNA clones that are thought to represent nearly all genes in the human 
genome as well as other species, e. g. mouse, Drosophila, and Caenorhabditis elegans. 
4.1.3 Database searching and ESTs 
Database searching is now the primary technique for the isolation of novel coding 
sequences. The field of EST research began tentatively in 1991 with the large-scale 
sequencing project being undertaken predominantly by the private sector. The 
public data collection was boosted with the launch of the Washington University 
Human EST project in October, 1994. This had a goal to provide up to 400,000 
ESTs for the public domain by March 31,1996 (Boguski and Schuer, 1995). This 
number has increased dramatically since then. The number of public entries on 
January 12,2001 was 6,994,862, of which 2,953,517 were human. These ESTs are 
available to the public in the form of their I. M. A. G. E. cDNA clones. The clones are 
from three hundred and sixty different human cDNA libraries and available free 
of any royalties. Over 3.8 million distinct cDNA clones are now arrayed; from 
which over 2.3 million 5' and/or 3' sequences have been deposited into db(EST). 
A variety of methods all indicate that the I. M. A. G. E. collection is likely to 
represent over 60,000 distinct human genes at this time (I. M. A. G. E. Consortium 
home page, January, 2001). 
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Due to this rapid progress, we decided to use I. M. A. G. E. cDNA clones derived 
from ESTs as our primary resource to identify novel coding sequences mapping to 
the critical region of the 5q- syndrome. 
4.1.4 Isolating novel genes mapping to the critical region of the 5q- syndrome 
The Chromosome 5 Human Gene Maps at NCBI (GeneMap'98 and '99) have 
identified approximately one hundred and fifty cDNA sequences, of which forty- 
six are represented by known genes, and one hundred and four are represented as 
ESTs, mapping to the interval between DNA markers D5S410 and D5S487. Each 
interval on the GeneMap illustrates the number of known genes and unidentified 
transcripts (ESTs), and represents their position relative to each other on the 
transcript map. The GeneMaps therefore served as the primary source for 
selecting ESTs within the critical region of the 5q- syndrome. Despite the use of 
normalised libraries to produce these ESTs, there is a considerable degree of 
redundancy in the data. To overcome this, the UniGene set was created as another 
source for selecting ESTs. The UniGene set comprises a non-redundant set of 
unique human 3' UTRs that are divided into clusters of sequences that are most 
likely to be derived from the same gene. In January, 2001, there were over one 
thousand separate entries of ESTs for human chromosome 5 at UniGene, each 
represented by at least one sequence, with some transcripts represented by ninety- 
Haze sequences. 
We selected ESTs from both the Human chromosome 5 GeneMaps and from 
UniGene (as unidentified transcripts), with the aim of identifying novel coding 
sequences mapping to the critical region of the 5q- syndrome. I. M. A. G. E. cDNA 
clones from which these ESTs were derived were used for analysis. A third source 
of ESTs came from the collaboration with Professor Charles Auffray at Genethon. 
Auffray et al., (1995) derived 26,938 ESTs from skeletal muscle and infant brain 
cDNA clones. Of these ESTs, two thousand five hundred were assigned to 
human 
Page 112 
chromosomes, one hundred and thirty of these binned to chromosome 5, and six 
ESTs localised to the critical region of the 5q- syndrome at 5g31-q33. In total, 
twenty-three cDNAs were included in this study to identify the putative tumour 
suppressor gene associated with the 5q- syndrome. 
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4.2 Materials and Methods 
4.2.1 EST identification 
A collaboration with Professor Charles Auffray at Genethon was established to 
identify ESTs mapping to the YAC contig spanning the approximate 5Mb critical 
region of the 5q- syndrome at 5g31-q33, flanked by the genes FGF1 and IL12ß. The 
ESTs were localised by PCR amplification. Two ESTs were isolated from the 
Stratagene skeletal muscle cDNA library, and 4 ESTs were isolated from the 
normalised infant brain cDNA library. 
Following the reduction of the 5q- syndrome critical region to approximately 3Mb, 
the Human Chromosome 5 GeneMap'98 was accessed for ESTs between the DNA 
markers D5S410 and D5S487 at 5g31.3-q33, flanked by the genes ADRß2 and IL12ß. 
ESTs were selected following certain criteria; they were mapped independently by 
more than one group, and were expressed in haematological tissues. Five 
transcripts were identified matching the aforementioned criteria. Two ESTs 
representing each transcript were selected for further analysis. 
The updated Human Chromosome 5 GeneMap'99 was also accessed for ESTs 
between the DNA markers D5S410 and D5S487 which span the critical region of 
the 5q- syndrome at 5g31.3-q33. Twelve transcripts were identified from the 
GeneMap'99. Two ESTs representing each transcript were selected for further 
analysis. 
In total, twenty-three transcripts were identified from Genethon, the GeneMap'98, 
and GeneMap'99, and selected for further analysis. 
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4.2.2 I. M. A. G. E. cDNA clones 
I. M. A. G. E. cDNA clones from the ESTs of which they were derived, were obtained 
from Professor Charles Auffray at Genethon or the UK HGMP-RC as stabs in agar. 
Single colonies were obtained by plating onto LB ampicillin (50mg/ml) plates. A 
single colony was then inoculated into a 10ml LB culture containing ampicillin. 
Plasmid DNA was obtained using the QlAprep® Spin Miniprep Kit. The insert 
was excised using the appropriate restriction enzymes and purified for use as a 
probe with the Wizard® PCR Preps DNA Purification System. 
4.2.3 Samples 
Ten patients with the classical features of the 5q- syndrome, including a 5q 
deletion as the sole karyotypic abnormality were included in the study. 
Granulocyte and mononuclear cells were separated from 40mis of peripheral 
blood by ficoll gradient centrifugation (Boyum, 1984). The granulocytes showed a 
high level of purity (>_95%). Mononuclear cells (specifically T-lymphocytes) were 
isolated by erythrocyte rosetting and showed a purity of >_90%. High molecular 
weight DNA was obtained from the fractionated blood leukocytes by Nucleon® 
extraction. Granulocyte DNA fractions from the peripheral blood of healthy 
individuals were used as controls. High molecular weight DNA was obtained 
from a human/mouse hybrid cell line with human chromosome 5 as its only 
human complement. 
4.2.4 Gene dosage analysis 
Gene dosage analysis was used to confirm the localisation of the EST (cDNA 
clone) to chromosome 5; and to determine the loss or retention of the clone in the 
patient granulocyte DNA (Chapter 3 section 3.2.4). Gene dosage experiments 
were carried out on at least two separate occasions. 
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4.2.5 Northern analysis 
cDNA clones which hybridised to a single fragment in hybrid 5 DNA and showed 
a 50% dosage reduction were hybridised to Multiple Tissue Northern (MTN) blots 
(Clontech) (Chapter 3 section 3.2.5 and Table 3.1). 
4.2.6 Southern analysis 
cDNA clones which hybridised to a single fragment in hybrid 5 DNA and showed 
a 50% dosage reduction were hybridised to Southern blots to screen for 
rearrangements (Chapter 3 section 3.2.6). Granulocyte DNA fractions from eight 
5q- syndrome patients and DNA from control samples were digested with 
restriction enzymes EcoRI, PstI, Hindlll, BglII, PvuII, and EcoRV. Southern blot 
filters were prepared and hybridised separately with the three novel cDNAs. 
4.2.7 Direct sequencing 
I. M. A. G. E. cDNA clones representing each novel cDNA were sequenced as either 
single-stranded or double-stranded templates, as previously described, by the 
dideoxy chain termination method (Sanger et al., 1977) (Chapter 2 section 2.12.1). 
Clones were sequenced using the Cy5 Autoread sequencing kit (Amersham 
Pharmacia Biotech) (Chapter 3 section 3.2.7). Each I. M. A. G. E. cDNA clone was 
sequenced in full and then subjected to a GenBank search for homology with 
known genes and overlapping clones to generate the full-length cDNA. 
4.2.8 Overlapping cDNA clones 
Sequence data from each I. M. A. G. E. cDNA clone was subjected to a homology 
search against the EST database db(EST) at NCBI for overlapping cDNA clones to 
generate the full-length cDNA (Chapter 3 section 3.2.8). Sequence data from the 
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overlapping clone was added to the sequence from the I. M. A. G. E. cDNA clone, 
and the 'new' sequence submitted to db(EST). 
4.2.9 cDNA library screening 
If no overlapping clones were identified from db(EST) or UniGene, the cDNA 
clone insert was screened against cDNA libraries. In the first instance, a foetal 
brain cDNA library was selected as this tissue expresses a wide variety of genes. 
Seven high-density gridded cDNA filters were used in the study. In addition, a 
collaboration with RZPD was established (Chapter 3 section 3.2.9). Positive 
clones were sequenced and the 'new' sequence submitted to db(EST). 
4.2.10 Dot blot analysis 
If more than 5 'positive' clones were identified from screening the foetal brain 
cDNA library filters, the clones were first analysed by Dot blot analysis. Dot blot 
analysis was used to select strongly positive clones from those identified from 
screening the foetal brain cDNA library filters. 
2cm x 2cm squares were drawn on Hybond N+ membrane to form a grid. Each 
square represents each cDNA clone to be tested. Two squares are added on to the 
bottom of the grid for the positive and negative controls. Each cDNA clone to 
be 
tested is spotted onto the membrane to form a circle approximately 0.7cm 
in 
diameter. The original cDNA clone acts as the positive control. Genomic 
DNA 
from another region on chromosome 5, e. g. from a YAC which does not contain 
the cDNA sequence was used as the negative control. 
Following autoradiography, the signal intensity of each cDNA clone was 
compared with the signal intensity of the positive control. 
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4.2.11 RACE PCR 
The technology of RACE PCR was used to generate 'new' sequence when no 
overlapping clones were identified from screening db(EST) and cDNA libraries 
(Chapter 2 section 2.13). The libraries chosen were tissue-specific to the gene of 
interest. 
1. Gene-Specific Primers were designed from the 5' and / or 3' end of the cDNA of 
interest dependent on whether 5' or 3' RACE was to be performed. Details of 
the primers, including their melting temperature (Tm), and choice of thermal 
profile are shown in Table 4.1. 
2. The Marathon-ReadyTM cDNA templates used in the 25 it RACE PCR reaction 
included; human foetal liver, lung, bone marrow, pituitary gland, small 
intestine, foetal skeletal muscle, testis, foetal brain, foetal spleen, hypothalamus, 
and foetal thymus. 
3. The RACE PCR products were subcloned and prepared for sequencing as 
previously described (Chapter 2 section 2.14). 
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4.2.12 Localisation to the YAC contig 
Each cDNA was sublocalised by PCR screening to the YAC contig encompassing 
the critical region of the 5q- syndrome (Kostrzewa et al., 1998) as previously 
described (Chapter 2 section 2.15). PCR primer pairs were designed from the 
cDNA sequence. Details of the primer conditions are shown in Table 4.2. 
4.2.13 Expression analysis 
cDNA clones were analysed by RT-PCR analysis for expression in RNA extracted 
from CD34+ cells, as previously described (Chapter 2 section 2.17) 
4.2.14 Database analysis using the Genetics Computer Group (GCG) software 
package 
The sequence generated from each novel cDNA clone was subjected to a FastA 
nucleotide, and BLAST protein search as previously described (Chapter 3 sections 
3.2.12.1,3.2.12.2). The sequence was then submitted for submission at GenBank as 
previously described (Chapter 3 section 3.2.12.6). 
Page 120 
N 
d+ 
cu 
P--4 ý 
H 
CD 
, -, 
o 
, -, 
_ 
* * .. ý 
c Q Q + 
Cý 
ý Q :, 
00 
ý 
00 
N N4 N 
> 
G) 
> Co ý o o ý 
V 
"0 
0 4) 
P., n. ýz 
-0 
c14 cz 
Q .. -4 Ö N Ö Co 
ä 
c ä U U U U U 
Eý., 
ý ý ý ° ° 
\°o 
U U U 
U U 
U Cý U Cý 
Ü 
aý C7 
ý < Ü 
., E. U < H U U U 
Ü 
.. I 
F, I U ý Ü < < 
ý 
E H 
"ý U < 
Ü ý ý < U Ü 
ý 
H ý ý < U 
H Ü Cý 
ý Ü 
V 
U 
Ü 
< 
Ü 
E--4 
< 
ý Ü 
0 0 0 7 
C. 7 
< 
E -i E E ý 
ý 
< 
ý 
ý 
ý U 
C7 
Ü 
U 
ý 
ý 5 
r-+ r+ 
ý ý N N ö 
r-I 
ö 
r--4 
1,0 o 'Z 0 " 
ßl 
ý a h a> LO ý ý ý N ° ý ON 
rý rý 
m 
ö 
Cf) LO LO C> o cq 
ý 
4.3 Results 
4.3.1 EST identification 
Six ESTs from the collaboration with Professor Charles Auffray at Genethon, were 
localised to the YAC contig mapping to the approximate 5Mb critical region at 
5g31-q33, by PCR amplification, see Table 4.3. A further 17 novel cDNAs were 
identified from the Human Chromosome 5 GeneMaps'98 and '99, and the 
UniGene set, see Tables 4.3 and 4.4. I. M. A. G. E. cDNA clones from which each EST 
was originally derived were obtained. 
4.3.2 Gene dosage analysis 
Gene dosage analysis was carried out on 12/23 novel cDNAs, see Figure 4.1. Ten 
out of twelve (83%) cDNA clones were shown to map to the critical region of the 
5q- syndrome at 5g31.3-q33. Probe 1ja10 was shown to hybridise to 4 fragments in 
the granulocyte DNA from the patients and controls, but 1 fragment in Hybrid 5. 
This suggested cDNA 1ja10 to be a recombinant gene or a member of a gene 
family. Direct sequencing of cDNA 1ja10 as a single-stranded template generated 
1344bp of sequence. The 365bp EST sequence was not found within the cDNA as 
expected, suggesting the clone was incorrect. cDNA 1ja10 was discarded 
from this 
point. 
The remaining 9 novel cDNAs were selected for further analysis, see 
Figure 4.2. 
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Table 4.4 ESTs identified from the Human Chromosome 5 GeneMap '99 
I. M. A. G. E. GenBank D marker Tissue source I. M. A. G. E. 
clone name Accession No. interval (cDNA library) clone 
insert size 
197258 R86964 D5S402- Soares foetal 1067bp 
D5S2090 liver spleen 
1NFLS 
110211 T71275 D5S436- Soares foetal 1105bp 
D5S413 liver spleen 
1NFLS 
485953 AA040631 D5S410- Soares pregnant 787bp 
D5S487 uterus NbHPU 
192250 H41167 D5S470- Snares foetal 1627bp 
D5S410 liver spleen 
1NFLS 
30879 R41775 D5S410- Soares infant 2007bp 
D5S487 brain 1NIB 
277516 N56962 D5S434- Soares multiple 550bp 
D5S2013 sclerosis 
2NbHMSP 
327361 W02135 D5S410- Soares foetal 623bp 
D5S487 heart 
NbHH19W 
141271 R67401 D5S470- Soares placenta 1023bp 
D5S410 Nb2HP 
265726 N22851 D5S470- Soares 1743bp 
D5S410 melanocyte 
2NbHM 
341099 W58211 D5S410- Soares foetal 490bp 
D5S487 heart 
NbHH19W 
143772 R76720 D5S410 Soares pregnant 1187bp 
uterus NbHPU 
240080 H82404 D5S410- Soares foetal 2344bp 
D5S487 liver spleen 
1NFLS 
Page 124 
12345678 
nrr ,... mom renin 
eow AF156165 
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Figure 4.1 
Representative gene dosage analysis of novel cDNA AF156165. DNA obtained 
from the granulocyte fractions of 4 patients (lanes 1,3,5 and 7) and healthy 
controls (lanes 2,4,6 and 8) was digested with EcoRI and simultaneously 
hybridised to a probe for AF156165 and a probe for the renin gene. ++ indicates 
the presence of two copies of the AF156165 gene and +- indicates the deletion of 
one copy of the gene. 
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4.3.3 Northern analysis 
The 9 cDNAs from the gene dosage analysis plus the remaining 11 cDNAs were 
analysed for their tissue expression and transcript size. cDNA clone 197258 was 
excluded from the study as it was not expressed in human bone marrow, see Table 
4.6. Eight cDNAs possessed large transcripts _7.5kb, see Tables 4.5 and 4.6. The 
original I. M. A. G. E. cDNA clone from each transcript was sequenced in full for 
each of the large eight cDNAs. A db(EST) search using the sequence of each 
cDNA clone failed to identify any large (i. e. _>1kb) overlapping clones. 
The remaining 7 cDNAs were shown to be expressed in bone marrow and to 
possess a transcript size <_4.4kb, see Tables 4.5 and 4.6. These cDNAs were 
selected for further analysis. cDNA clone A3B02 was shown to be highly 
expressed in human bone marrow, see Figure 4.3 (a), while clone 248808 was 
highly expressed in foetal liver, see Figure 4.3 (b). 
4.3.4 cDNA library filter hybridisation 
Two of the cDNAs (Cdy-17a06 and Bda-87b11) which showed the deletion of one 
allele from gene dosage analysis were screened against high-density gridded, 
foetal brain cDNA library filters, see Figure 4.4. Twenty clones for each cDNA 
were selected for further analysis. Each clone was identified by x, y co-ordinates 
and obtained from the Reference Library Database, Berlin, Germany as stabs in 
agar. Dot blot analysis was carried out to determine the true positive clones. 
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Table 4.6 Expression patterns and transcript sizes (kb) of novel cDNAs 
mapping to the critical region of the 5q- syndrome, identified from 
the Human Chromosome 5 GeneMap'99 
MTN 2 (size in kb) 
Novel cDNA s In t pbI bm fl 
265726 9.5 9.5 9.5 9.5 9.5 9.5 
141271 7.5 7.5 7.5 7.5# 7.5 7.5# 
327361 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 
277516 7.5 7.5 7.5 7.5 7.5 7.5 
30879 7.5 7.5 7.5 7.5 7.5 7.5 
110211 4.4,8.5 4.4,8.5 4.4,8.5 4.4,8.5 4.4,8.5 4.4,8.5 
192250 4.4,7.5 4.4,7.5 4.4,7.5 4.4,7.5 4.4,7.5 4.4,7.5 
197258 smear smear smear smear smear smear 
485953 2.5 2.5 2.5 2.5 2.5 2.5 
240080 2.4 2.4 2.4 2.4 2.4* 
341099 3.5,4.5 3.5,4.5 3.5,4.5 3.5,4.5 3.5,4.5 3.5,4.5 
143772 3.0,4.4 3.0,4.4 3.0,4.4 3.0,4.4 3.0,4.4 3.0,4.4 
s- spleen, In - lymph node, t- thymus, pbl - peripheral blood 
leukocytes, bm - 
bone marrow, fl - foetal liver 
# very weak signal 
* very high level of expression 
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a) kb b) 
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Figure 4.3 
Representative Northern blot analysis of (a) I. M. A. G. E. cDNA A3B02, and (b) 
I. M. A. G. E. cDNA 240080. The MTN blots included 2pg of poly (A+) RNA from; 
spleen (1), lymph node (2), thymus (3), peripheral blood leukocytes (4), bone 
marrow (5), and foetal liver (6). Sizes of RNA marker bands (kb) are indicated 
approximately. 
123456 
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4.3.5 Dot blot analysis 
Dot blot analysis showed 14/20 (70%) of 'positive' clones had similar signal 
intensities with the positive control following hybridisation with cDNA probe 
Cdy-17a06, see Figure 4.5. Six clones with the largest inserts were selected for 
further analysis. Direct sequencing of these 'positives' as single-stranded 
templates showed they did not contain their EST sequence from which they were 
derived, and therefore did not overlap with clone Cdy-17a06. These clones were 
discarded from this point. A dot blot of clone Bda-87b11 showed 14/20 (70%) of 
'positive' clones had similar signal intensities with the positive control following 
hybridisation with cDNA probe Bda-87b11. 
4.3.6 Direct sequencing 
The cDNA clones selected for further analysis were sequenced as single or double- 
stranded templates. Two out of the seven cDNAs (4885953 and 143772) showed 
100% homology with the Homo sapiens CCR4-associated factor 1 CNOT8 
(previously POP2) gene over their entire sequence. The POP2 gene had been 
previously cloned in our laboratory (Fidler et al., 1999). These two ESTs therefore 
represented part of the POP2 gene and were discarded from the study at this 
point. 
cDNA clone 240080 was highly expressed in foetal liver according to Northern 
analysis. Gene dosage analysis had shown it not to map to chromosome 5. Direct 
sequencing of clone 240080 as a double-stranded template generated 478bp of 
sequence. A FastA nucleotide homology search utilising the GenEMBL databases 
showed cDNA 240080 to have 100% homology with the Homo sapiens H19 gene 
over 416bp. 
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Figure 4.5 
Representative results from dot blot analysis following hybridisation with cDNA 
probe Cdy-17a06. The true positives are shown as strong black signals. The false 
positives are the faint or non-existent signals. YAC 176D01 (positive for clone 
Cdy-17a06) was used as the positive control. YAC 15DB10 (from the opposite end 
of the contig) was used as the negative control. 
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This result confirmed both the Southern and Northern data, and the EST was 
discarded at this point. 
The remaining 3 cDNA clones (A3B02,43911, and 199067) were selected for 
further analysis based on tissue expression, transcript size, and probability of 
completing their full coding sequence. 
4.3.7 Southern analysis 
Southern blot analysis identified a rearrangement in the granulocyte DNA of one 
patient with the 5q- syndrome following hybridisation with cDNA clone A3B02 
when the patient granulocyte DNA and DNA from 18 normal controls was 
digested with restriction enzyme PstI, see Figure 4.6. No rearrangements were 
seen with the probes from cDNA clones 43911 and 199067 when patient 
granulocyte DNA and DNA from normal controls was digested with restriction 
enzymes EcoRV, PvuII, EcoRI, HindIII, and BgIII, suggesting the rearranged band 
seen in the patient granulocyte DNA digested with PstI, was a polymorphism. 
4.3.8 Overlapping cDNA clones 
A GenBank homology search on the sequence of cDNA clones A3B02,43911 and 
199067 showed the cDNAs to be completely novel. A db(EST) search using the 
sequence of each cDNA clone identified several overlapping clones. Direct 
sequencing of approximately 60% of these overlapping clones generated sequence 
that overlapped with the cDNA clone sequence from which it was obtained with 
100% homology over part of the cDNA. The remaining 40% of clones either did 
not contain their EST sequence and/or did not overlap with their respective 
cDNA. 
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The first db(EST) search on the sequence of cDNA clone 43911 identified 4 
overlapping clones. Therefore, the clone with the largest insert was the one 
selected for further analysis. 
4.3.9 cDNA library screening 
The collaboration with the Resource Centre of the German Human Genome 
Project identified one positive clone from a gridded cDNA library filter 
containing; liver, spleen, whole brain, skin, eye, ovary, lung, tonsil, melanocyte, 
pregnant uterus, heart, colon, prostate, kidney, thyroid, pancreas, and adrenal 
gland, following hybridisation with probe A3B02. The sequence generated from 
positive clone B1 overlapped with clone A3B02 with 100% homology. 
Fourteen positive clones were identified with probe 43911. Direct sequencing of 
the five positive clones with the largest inserts showed them all to overlap with 
clone 43911 with 100% homology. However, none of the 5 clones extended the 
sequence of clone 43911 and were discarded from this point. 
4.3.10 RACE PCR 
Two RACE PCR products were generated from the human small intestine and 
human testis cDNA libraries with gene specific primers designed from the 5' end 
sequence of cDNA clone A3B02, see Figure 4.7. Direct sequencing of both 
products generated sequence that overlapped with clone A3B02 with 100% 
homology and extended the cDNA. 
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Figure 4.7 
Representative 3' RACE PCR analysis of I. M. A. G. E. cDNA clone A3B02. 
Marathon-ReadyTM cDNAs were primed with GSP A3B02R3 and AP1, then nested 
with GSP A3BO2R1 and AP2. Products were analysed on a 1% agarose gel. The 
arrow indicates the 929bp product from the human small intestine cDNA library. 
The PCR products were sized with the Low Mass DNA marker (M). 
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Two RACE PCR products were generated from the human pituitary gland and 
human testis cDNA libraries with gene specific primers from the 3' end sequence 
of cDNA clone 43911. The RACE PCR products included a 13bp Poly-(A)+ tail. 
This confirmed the 3' end of the cDNA. A 5' RACE PCR product was 
subsequently generated from the human foetal skeletal muscle cDNA library to 
extend the sequence at the 5' end. 
Four 5' RACE PCR products were generated to complete the full coding sequence of 
novel cDNA H82831. The products were generated from the human pituitary gland, 
human testis, human placenta, and human skeletal muscle cDNA libraries. 
4.3.11 Localisation to the YAC contig 
All three novel cDNAs were shown to be sublocalised to YAC 816D6 
encompassing the critical region of the 5q- syndrome at 5q31.3-q33. 
4.3.12 Expression analysis 
Subsequent RT-PCR analysis showed all three novel cDNAs to be amplified in RNA 
extracted from CD34+ cells. 
4.3.13 Database analysis using the Genetics Computer Group (GCG) software 
package 
FastA nucleotide and BlastX protein homology searches utilising the 
GenEMBL 
and SWISS-PROT databases respectively, showed the novel cDNAs to 
have no 
known homology with any gene, identifying them as completely novel. 
The 
sequence generated from original cDNA clone A3B02 was submitted to 
GenBank, 
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and assigned the Accession number AF010242 (Boultwood et al., 1997). The 
sequence generated from original cDNA clone 43911 was submitted to GenBank, 
and assigned the Accession number AF156165 (Boultwood et al., 2000). 
4.3.14 Novel cDNA AF010242 
The 2410bp sequence of novel cDNA AF010242 was generated firstly from two 
cDNA clones and secondly from two RACE PCR products. A FastA nucleotide 
homology search showed the second RACE PCR product to have 100% homology 
with the human synaptopodin gene over 169bp. This result confirmed novel 
cDNA AF010242 to be the 3' untranslated region (UTR) of the human 
synaptopodin gene. The localisation of the human synaptopodin gene to 
chromosome 5 and the critical region of the 5q- syndrome has subsequently been 
mapped by others at the HGP using the Ensembl program. 
4.3.15 Novel cDNA AF156165 
The 2167bp sequence of novel cDNA AF156165 was generated from two cDNA 
clones and two RACE PCR products and submitted to GenBank as a Homo sapiens 
putative tumour suppressor mRNA. Until recently, the Human Gene Map and 
the UniGene set described cDNA AF156165 as a novel transcript. However, a 
subsequent database analysis showed novel cDNA AF156165 to be the 3' 
UTR of 
the human dynactin p62 gene (Karki et al., 2000). The localisation of dynactin p62 
to chromosome 5q has been confirmed by others at the HGP using the 
Ensembl 
program. 
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4.3.16 Novel cDNA H82831 
The 1845 bp sequence of novel cDNA H82831 was generated from one cDNA 
clone and four RACE PCR products. Subsequently, H82831 was blasted against 
the Ensembl database. The 1845bp sequence of H82831 was found within contig 
AC034205, with 100% homology, proximal to the MEGF1 gene at 5q32. Contig 
AC034205 contains 148198bp of 'working draft' sequence currently consisting of 13 
ordered pieces (contigs). Novel gene H82831 lies within contig 11. However, 
Ensembl had not predicted H82831 as a novel gene. This may be due to the 
MER19 repeats in the sequence that may mask any motifs preventing it from being 
predicted. Alternatively, it may not be predicted because it is not a homologue, 
and does not have any protein motifs, i. e. is completely novel. 
4.3.17 Summary 
Twenty-three novel cDNAs were identified from the approximate 5Mb critical 
region of the 5q- syndrome at 5g31-q33 flanked by the genes FGFI and IL12ß. 
During the study a new patient with MDS and a 5q deletion was identified. This 
narrowed the critical region to approximately 3Mb at 5g31.3-q33 flanked by the 
genes ADRJ32 and IL12ß. Twenty-two percent of the cDNAs were then shown to 
map outside the new region, and excluded from the study. 
The three novel cDNAs selected for further analysis fulfilled the following criteria: 
localisation to the critical region of the 5q- syndrome at 5g31.3-q33, expression in 
haematological tissues, and transcript sizes 54.4kb. 20/23 (87%) did not fulfil 
these criteria, and therefore not selected for further analysis. 
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4.4 Discussion 
4.4.1 Mapping of chromosome 5-specific ESTs to the YAC contig 
The collaboration with Professor Charles Auffray at Genethon was used as the 
primary resource to identify novel genes mapping to the approximate 5Mb critical 
region of the 5q- syndrome at 5g31-q33, flanked by the genes FGF1 and IL12ß. Six 
chromosome 5-specific ESTs were PCR localised to the YAC contig spanning the 
critical region of the 5q- syndrome (Boultwood et al., 1997). 
4.4.1.1 Novel gene AF010242 
Novel gene AF010242 was shown to map to the critical region of gene loss by gene 
dosage analysis. The cDNA was then sublocalised to YAC 816D6 from the YAC 
contig spanning the critical region of the 5q- syndrome (Li et al., 1994; Kostrzewa 
et al., 1998). Northern analysis showed AF010242 to possess a single transcript of 
4.4kb and to be expressed in heart and skeletal muscle, and highly expressed in 
bone marrow, suggesting a possible role in leukaemogenesis. Further 
investigation showed novel gene AF010242 to have 100% homology with the 3' 
UTR of the human synaptopodin gene. Synaptopodin represents a novel, proline- 
rich, actin-associated protein that may play a role in modulating actin-based shape 
and mobility of dendritic spines and podocyte foot processes (Mundel et al., 1997). 
4.4.2 Novel gene identification from the Human Chromosome 5 GeneMap'98 
In 1998, Jaju et al., used FISH on the two 5q- syndrome patients that defined the 
CDR, along with a new, third patient with the 5q- syndrome and a small deletion, 
del(5)(q33q34), to refine further the critical deleted region. This resulted in the 
narrowing of the CDR within 5g31.3-5g33 to approximately 3Mb, flanked 
by the 
ADRß2 and IL12ß genes. 
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Following the identification of patient 3, the Human chromosome 5 GeneMap'98 
at NCBI was accessed to identify novel genes mapping to the 'new' approximate 
3Mb critical region of the 5q- syndrome at 5g31.3-q33, flanked by the genes ADRß2 
and IL12ß. Five transcripts represented by EST sequences were identified. 
4.4.2.1 Novel gene AF156165 
Novel gene AF156165 was accessed from the GeneMap'98 at DNA marker D5S470. 
It was sublocalised to YAC 816D6 from the YAC contig by PCR screening. The 
2167bp novel cDNA sequence was generated from two cDNA clones and two 
RACE PCR products. Novel gene AF156165 was submitted to GenBank as a Homo 
sapiens putative tumour suppressor mRNA. However, an updated UniGene 
search showed we had identified the 3' UTR of the human dynactin p62 gene. 
Dynactin is a multisubunit complex and a required cofactor for most, or all, of the 
cellular processes powered by the microtubule-based motor cytoplasmic dynein 
(Karki et al., 2000). The p62 subunit of dynactin was recently isolated using a 
dynein affinity column. Sequence analysis of the p62 polypeptide revealed a 
highly conserved N-terminal cysteine-rich domain, of which part of it fits a Zn2+- 
binding RING domain (Karki et al., 2000). 
4.4.3 Novel gene identification from the Human Chromosome 5 GeneMap'99 
Following the increase of deposited human sequences into db(EST), the 
GeneMap'99 was accessed between DNA markers D5S410 and D5S487 to identify 
novel genes mapping to the critical region of the 5q- syndrome. Twelve 
transcripts represented by EST sequences were identified. 
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4.4.3.1 Novel cDNAs AA040631, R76720, and H82404 
Novel cDNAs AA040631 R76720 were found to have 100% homology to the 
previously identified human CNOT8 (formerly POP2) gene. The CNOT8 gene was 
previously cloned in this laboratory (Fidler et al., 1999), and may play a role in the 
control of transcription. 
Novel cDNA H82404 was found to have 100% homology to the human H19 gene. 
The H19 gene maps to 11p15.5 and is expressed in differentiating foetal cells (Hao 
et al., 1993). This confirms the lack of signal in hybrid 5 and the very high level of 
expression seen in foetal liver in the Northern analysis. Studies have shown H19 
to be an imprinted gene with an important role in foetal differentiation, as well as 
a postulated function as a tumour suppressor gene (Doyle et al., 1996). This result 
shows the H19 gene to be incorrectly localised on the database and is unlikely to 
be involved in the pathogenesis of the 5q- syndrome. 
4.4.4 Redundancy in the EST database 
The results obtained in this study highlights the enormous value of the Human 
Chromosome 5 GeneMap, db(EST), and the UniGene set at NCBI but reveals the 
redundancy in the data. For example, the twelve transcripts identified from the 
Human GeneMap'99 in this study were assigned to DNA markers D5S410-D5S487 
which flank the critical region of the 5q- syndrome at 5g31.3-q33. However, two 
of these (17%) were shown to be negative for chromosome 5 localisation by 
somatic cell hybrid analysis. One of these ESTs, representing an unidentified 
transcript, was shown to represent the human H19 gene, previously localised to 
11p15.5 (Hao et al., 1993). Moreover, a further two ESTs, representing unidentified 
transcripts, were shown to represent the human POP2 gene (Fidler et al., 1999). 
The inaccuracy of the I. M. A. G. E. consortium distributors was also highlighted 
when screening db(EST) for overlapping cDNA clones. For example, three of nine 
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(33%) overlapping cDNA clones for novel gene C5orf4 (Chapter 3) were found not 
to contain their EST sequence and therefore not the clone requested. 
Others have described similar database errors. Bezieau et al., (1998) showed that 
eleven of fifty (22%) of the ESTs assigned to the critically deleted region at 13q14.3 
in B-CLL from the NCBI Human GeneMap and the Whitehead Institute Centre for 
Genome Research map, did not map to a YAC contig encompassing this critical 
region by PCR amplification. Similarly, nine of fifteen ESTs (60%) assigned to the 
4Mb critical region of the hereditary paragangliomas at 11q23 by the Radiation 
Hybrid Mapping Consortium have been localised outside a YAC contig spanning 
this region (Baysal et al., 1997). 
Physical maps based on YAC clones (and especially CEPH mega-YACs) may be 
unreliable, however, because of high rates of chimaerism and deletions. This may 
explain the conflicting mapping data between the cDNA Radiation Hybrid 
Mapping Consortium and workers utilising YAC contigs at disease loci for EST 
mapping (Baysal et al., 1997; Bezieau et al., 1998; Liu et al., 1998). Gene dosage 
analysis was used in this study to localise ESTs assigned between the DNA 
markers D5S410 and D5S487 prior to mapping within the YAC contig, thus 
reducing the likelihood of such errors. It is therefore important that independent 
mapping studies are performed to produce more refined and accurate EST-based 
transcription maps of a given genomic region. This is of particular importance at 
disease loci where ESTs often represent the first step in candidate gene isolation. 
4.4.5 Human Genome Project progress 
The rapid progression of the Human Genome Project has led to an 
increase in the 
number of ESTs deposited in db(EST) that represent novel coding sequences. 
The 
goal of the HGP to sequence the entire genome and identify the approximately 
30,000 genes has led to the rapid characterisation of these novel cDNAs. 
For 
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example, two novel cDNAs (AF010242 and AF156165) from this study were found 
to represent the 3' UTRs of the synaptopodin and dynactin p62 genes respectively. 
Therefore, the next stage of this study will utilise the data provided by the HGP 
and select candidate genes for mutation analysis with the aim of identifying the 
putative tumour suppressor gene associated with the development of the 5q- 
syndrome. 
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4.5 Conclusion 
The collaboration with Professor Charles Auffray at Genethon, the Human 
Chromosome 5 GeneMaps'98 and '99, and the UniGene set has been successfully 
used to isolate nine novel coding sequences that map to the 5Mb critical region of 
the 5q- syndrome. All nine cDNAs were expressed in haematological tissues and 
represented candidates for the putative tumour suppressor gene associated with 
the development of the 5q- syndrome. Two of the novel cDNAs, AF010242 and 
AF156165 were identified as the human synaptopodin and dynactin p62 genes 
respectively. 
During the study, a new patient with MDS and the 5q- syndrome was identified. 
Cytogenetic analysis defined a small deletion with the proximal breakpoint at 
5q31.3. This patient, therefore, narrowed the critical region from approximately 
5Mb (flanked by the genes FGF1 and IL12ß), at5q3l-q33, to approximately 3Mb 
(flanked by the genes ADRß2 and IL12ß) at 5g31.3-q33. The proximal breakpoint 
of the new critical region of the 5q- syndrome excluded novel cDNAs Cdy-17a06 
and Bda-87b11. 
This study has highlighted the advantages and disadvantages of the EST resource. 
The Human GeneMap at NCBI identified seventeen transcripts that represented 
candidates for the 5q- syndrome putative tumour suppressor gene. Conflicting 
mapping data excluded several of these transcripts while others were incomplete 
due to lack of 5' ESTs. Moreover, eight of seventeen (47%) ESTs represented large 
transcripts over 7.5kb. Transcript sizes less than 4.4kb were considered higher 
priority in the study. 
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There are many already known genes mapping to the approximate 3Mb critical 
region of the 5q- syndrome at 5g31.3-q33 with known/predicted functions that 
make them candidates for the 5q- syndrome putative tumour suppressor gene. 
For example, genes that regulate the cell cycle, have antioxidant properties and 
possess tumour suppressor activity. Therefore, mutation analysis on known genes 
mapping to the critical region of the 5q- syndrome was carried out alongside the 
isolation of novel coding sequences. 
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Chapter 5 
Analysis of species homologous ESTs 
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5.1 Introduction 
5.1.1 Comparative genomics 
The completion of the sequencing of the Saccharomyces cerevisiae and Caenorhabditis 
elegans genomes has aided the understanding of sequence data currently being 
generated by the Human Genome Project. Comparative genomics - the cross- 
referencing of information between species - has been used to determine how the 
function and position of genes has changed over the course of evolution (Graves, 
1998). Fugu rubripes (the Japanese puffer fish) is particularly suited to this kind of 
analysis because whilst its 400Mb genome is eight times smaller than human's, it 
has a similar repertoire of genes. These genome characteristics along with the 
large evolutionary distance between bony fish and mammals make Fugu a useful 
tool for studying gene evolution (Elgar et al., 1999). Moreover, if regions of the 
two genomes exhibited conservation of gene order (i. e., were syntenic), it should 
be possible to dramatically reduce the effort required for identification of 
candidate genes in human disease loci by sequencing syntenic regions of the 
compact Fugu genome. For example, Trower et al., (1996) demonstrated three 
genes (dihydrolipoamide succinyltransferase, S31iii125, and S20i15), which are 
linked to FOS in the familial Alzheimer disease locus (AD3) on human 
chromosome 14, to have homologues in the Fugu genome adjacent to Fugu cFOS. 
The relative gene order of cFOS, S31iii125, and S20i15 was the same in both 
genomes, but in Fugu these three genes lay within a 12.4kb region, compared to 
>600kb in the human AD3 locus. These results demonstrate the conservation of 
synteny between the genomes of Fugu and man and highlight the utility of this 
approach for sequence-based identification of genes in human disease 
loci. 
Drosophila melanogaster has also been used as a model for comparative genomics. 
Rubin et al., (2000) examined 289 human disease genes and found the 
fruitfly to 
have homology to 177 of them providing the foundation for rapid analysis of 
some of the basic processes involved in human disease. Comparisons over vast 
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evolutionary time scales show that the mammalian genome has been highly 
conserved. Thus, information about location and function of genes is directly 
transferable across species and should greatly accelerate the search for genes that 
specify inherited human diseases (Graves, 1998). 
5.1.2 Identifying species homologous genes 
The introduction of molecular biology techniques has allowed the isolation and 
identification of several oncogenes and tumour suppressor genes. Analysis of 
genetic alterations in these genes has enabled the comparison of carcinogenesis 
pathways in humans and rodents at the molecular level (Goodrow, 1996). The 
results from this study showed that most of the oncogenes/tumour suppressor 
genes found to be altered in humans were also altered in rodents. There are still 
many unknown steps in the process of carcinogenesis. However, overall, the 
results indicate that despite the differences between rodents and humans, the use 
and comparison of rodent models with human tumorigenesis is one of the best 
ways to examine the mechanisms of carcinogenesis (Goodrow, 1996). 
D. melanogaster has been the target of extensive genetic analyses over the past 
ninety years and a notable amount of information is known about its gene 
structure, gene regulation and gene function. Banff et al., (1997) utilised the EST 
resource to identify novel human and murine gene transcripts homologous to 
Drosophila mutant genes. Mapping and expression studies were carried out in 
order to characterise these novel genes. The authors state that the comparison 
between these novel genes and their putative partners in Drosophila contributes to 
the understanding of their function in mammals and to the discovery of their 
possible role in disease. 
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5.1.3 Identifying species homologous genes in MDS and leukaemia 
A number of genes involved in the pathogenesis of MDS and leukaemia have been 
shown to have homology to genes from other species. The AML 1 gene which is 
rearranged by the t(8; 21) translocation in AML is highly homologous to the 
Drosophila segmentation gene and the mouse transcription factor PEBP2 alpha 
subunit gene (Miyoshi et al., 1995). This region of homology, called the Runt 
domain, is responsible for DNA-binding and protein-protein interactions. Three 
mouse genomic domains, Fim1, Fim2, and Fim3 were previously described as 
proviral integration regions frequently involved in the early stages of myeloblastic 
leukaemogenesis induced in vivo or in vitro by the Friend murine leukaemia virus 
(Van Cong et al., 1989). The human homologues of these three mouse domains, 
were found to correspond to human loci involved in genetic alterations specific to 
some human leukaemias. Fim2 was identified as the 5' end of the c-FMS 
protooncogene, which encodes the receptor of the macrophage colony stimulating 
factor. The functions of Fim1 and Fim3 are not yet known, but these regions are 
highly conserved among different species. Mapping of these human homologues 
showed that the localisation of FIM2 / c-FMS on 5q was confirmed, while FIM1 and 
FIM3 were localised on human chromosomes 6p22.33-p23 and 3q27 respectively. 
Translocations involving these two regions have been described in various 
haematopoietic malignancies: the t(6; 9) (p23; q34) in acute nonlymphocytic 
leukaemias and the 3q26-q28 translocations in a large variety of leukaemias (Van 
Cong et al., 1989). 
5.1.4 ESTs and the UniGene set 
The EST database is now used by many researchers as the primary resource 
for 
identifying genes localised to a specific chromosomal region. 
UniGene 
(http: //www. ncbi. nlm. nih. gov/UniGene/) is an experimental system 
for 
automatically partitioning GenBank EST sequences into a non-redundant set of 
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gene-oriented clusters. Each UniGene cluster contains sequences that represent a 
unique gene, as well as related information such as the tissue types in which the 
gene is expressed and map location (UniGene homepage). In addition to 
sequences of well-characterised genes, hundreds of thousands of novel EST 
sequences have been included. Human UniGene is updated every week with new 
EST sequences, and bimonthly with new characterised sequences. Currently, 
sequences from the human genome, rat, mouse, cow, zebrafish and clawed frog 
have been processed. These species were chosen because they have the greatest 
amounts of EST data available and represent a variety of species. 
5.1.5 Isolating species homologous ESTs mapping to the critical region of the 
5q- syndrome 
There are three distinctions of similarity that UniGene clusters are assigned to: 
"Highly similar to" means >90% homology in the aligned region; "Moderately 
similar to" means 70-90% homology in the aligned region; and "Weakly similar 
to" means <70% homology in the aligned region, with other species. We selected 
ESTs representing transcripts that were highly similar to genes from other species, 
for further analysis. In addition to these ESTs representing human homologues, 
we selected ESTs representing transcripts that were the complete coding 
sequences of human genes (i. e., human mRNAs). The human genes selected for 
analysis have been implicated in the aetiology of tumours, and therefore represent 
candidates for the putative 5q- syndrome tumour suppressor gene. The ESTs 
selected for further analysis had similarity to the known proteins after translation 
and/or the corresponding clone source was a CGAP library. 
Since the advent of this study, a further resource to identify human genes 
homologous to other species has become available. HomoloGene is a homology 
resource which includes both curated and calculated homologues 
for genes 
represented in UniGene and LocusLink for human, mouse, rat, cow, zebrafish, 
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frog and fly. The calculated homologues are the result of nucleotide sequence 
comparisons between all UniGene clusters for each pair of organisms. These 
homologues are considered putative since they are based only on sequence 
comparisons. Nucleotide sequences for each pair of organisms are compared to 
identify sequences pairs that share the highest degree of nucleotide sequence 
similarity. The best match for a sequence in one organism to a sequence in a 
second organism is based on the percent of identical sequence (%ID) in an 
alignment over a minimum 100 base pairs. 
The EST database and UniGene have been used to identify ESTs mapping to the 
critical region of the 5q- syndrome with homology to known human genes or 
homology to genes from other species. In total, six transcripts were included in 
this study (three of which represented human homologues of yeast and Drosophila 
genes, and three which represented known human genes) each represented by at 
least two ESTs from db(EST) and the UniGene set. These transcripts represent 
candidates for the putative tumour suppressor gene(s) associated with the 5q- 
syndrome. 
5.1.5.1 The Leucyl-tRNA synthetase, cytoplasmic (CDC60) gene 
The yeast cell division cycle gene (CDC60) is indirectly involved in the regulation 
of the cell cycle (Hohmann and Thevelein, 1992). There are several tumour 
suppressor genes known to be involved in the control of the cell cycle that include 
p16, p53, and RB1. 
5.1.5.2 The Regulator of mitotic spindle assembly 1(RMSA-1) gene 
The RMSA-1 gene is essential for mitotic spindle assembly. The assembly of a 
bipolar spindle is essential for the accurate segregation of replicated chromosomes 
during cell division (Waters and Salmon, 1995). The p53 tumour suppressor gene 
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is believed to be involved in the mitotic spindle checkpoint and in the regulation 
of centrosome function (Morgan and Kastan, 1997). 
5.1.5.3 The Goliath protein 
The Goliath protein (g1) is involved in the regulation of gene expression during 
mesoderm formation in Drosophila. It is also thought to have a putative role as a 
transcription factor (UniGene Hs. 9788 data). The nucleotide sequence of its cDNA 
encodes a 32-kDa protein with two putative zinc fingers, and a 
serine/glutamine/proline-rich region. These features indicate a functional role for 
g1. Tumour suppressor genes encoding zinc fingers include the Wilms' tumour 
suppressor gene (WT1) and the Human Kruppel-related 3 (HKR3) gene. WTI 
encodes a zinc finger transcription factor that regulates expression of several genes 
involved in cellular proliferation and differentiation (Bardeesy and Pelletier, 1998). 
The HKR3 gene maps within chromosome subbands 1p36.2-36.3, a region 
postulated to contain a tumour suppressor gene associated with advanced 
neuroblastomas (Maris et al., 1997). 
5.1.5.4 The Protein phosphatase 2A beta subunit (PP2A) gene and the Protein 
phosphatase 1, regulatory (inhibitor) subunit 2 (PPP1R2) gene 
Phosphatases are regulatory enzymes that antagonise the action of kinases within 
the cell (Parsons, 1998). An understanding of the contribution of kinases to cancer 
has emerged during the past two decades. Currently, three phosphatases have 
been implicated in the aetiology of tumours: protein phosphatase 2A (PP2A), 
CDC25A/B, and PT EN (or MMAC1). PP2A and PTEN have been shown to 
function as tumour suppressor genes (Parsons, 1998). 
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5.1.5.5 The Tetratricopeptide repeat protein (tprl) 
The tetratricopeptide repeat (TPR) motif is a protein-protein interaction module 
found in multiple copies in a number of functionally different proteins that 
facilitates specific interactions with a partner protein(s). Most TPR-containing 
proteins are associated with multiprotein complexes, and there is extensive 
evidence indicating that TPR motifs are important to the functioning of chaperone, 
cell-cycle, transcription, and protein transport complexes (Blatch and Lassle, 1999). 
Tumour suppressor genes that harbour this repeat have been identified. Loss of 
heterozygosity in 1p31 is a frequent genetic alteration in breast tumours indicating 
the site of a tumour suppressor gene (Su et al., 1999). Su et al., isolated a new 
member of the human tetratricopeptide repeat-containing family of genes, TTC4, 
which maps to this region. Other members of this gene family have been 
implicated in tumourigenesis suggesting that TTC4 may represent a breast cancer 
tumour suppressor gene (Su et al., 1999). 
5.1.6 Aims of the study 
The aims of this study were to use the EST resource to identify human 
homologues of genes previously identified in other species, and to map them to 
the transcript map currently being generated for the critical region of gene loss in 
the 5q- syndrome. These known genes would be localised in relation to the novel 
coding sequences previously assigned to the transcript map (Chapter 4). 
Over the last ten years, several human genes have been cloned based on their 
homology to genes previously identified in model organisms. For example, 
Bronner et al., (1994) proposed that the hMLH1 (human MutL homologue) was the 
HNPCC (hereditary non-polyposis colon cancer) gene located on 3p because of the 
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similarity of the hMLH1 gene product to the yeast DNA mismatch repair protein, 
MLH1. In relation to this study, Tugendreich et al., (1993) used the EST database 
to identify and positionally map human homologues of yeast genes to cross- 
reference the biological and genetic information known about yeast genes to 
mammalian chromosomal maps. The authors scanned db(EST) for human open 
reading frames related to yeast protein sequences and used the corresponding 
human cDNA to obtain a high-resolution map position on human and mouse 
chromosomes. Their results identified the human homologue of S. cerevisiae 
CDC27 that mapped to human chromosome 17 and mouse chromosome 11. 
The identification and mapping of human homologues to the critical region of the 
5q- syndrome could facilitate the identification of the 5q- syndrome tumour 
suppressor gene. 
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5.2 Materials and Methods 
5.2.1 EST identification 
The Human GeneMap and the UniGene set at NCBI were accessed for species 
homologous ESTs and ESTs representing known human genes, mapping to the 
YAC contig spanning the approximate 5Mb critical region of the 5q- syndrome at 
5g31-q33, flanked by the genes FGF1 and IL 12 ß. The search revealed six 
transcripts. Three transcripts were represented by ESTs 'highly similar' to known 
genes from other organisms (e. g. Drosophila melanogaster, and Saccharomyces 
cerevisiae). The remaining three transcripts were represented by ESTs from the 
complete cds of a known human gene. Two ESTs representing each transcript 
were selected for further analysis. The ESTs selected had similarity to known 
proteins (after translation), contained a polyadenylation signal, contained a 
mapped sequence-tagged site (STS), and its clone source was a CGAP library. 
5.2.2 I. M. A. G. E. cDNA clones 
I. M. A. G. E. cDNA clones of the ESTs were obtained from the UK HGMP Resource 
Centre at Hinxton, Cambridge as stabs in agar. Single colonies were obtained by 
plating onto LB ampicillin (50mg/ml) plates. A single colony was then 
inoculated into a 10ml LB culture containing ampicillin. Plasmid DNA was 
obtained using the QlAprep® Spin Miniprep Kit. The insert was excised using the 
appropriate restriction enzymes and purified for use as a probe with the Wizard® 
PCR Preps DNA Purification System. 
5.2.3 Samples 
Four patients with the classical features of the 5q- syndrome, including the two 
patients that defined the approximate 5Mb critical region of the 5q- syndrome at 
5g31-q33, were included in the study. Granulocyte and mononuclear cells were 
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separated from 40mis of peripheral blood by ficoll gradient centrifugation 
(Boyum, 1984). The granulocytes showed a high level of purity (>_95%). 
Mononuclear cells (specifically T-lymphocytes) were isolated by erythrocyte 
rosetting and showed a purity of >_90%. High molecular weight DNA was 
obtained from the fractionated blood leukocytes by Nucleon® extraction. 
Granulocyte DNA fractions from the peripheral blood of healthy individuals were 
used as controls. High molecular weight DNA was obtained from a 
human/mouse hybrid cell line with human chromosome 5 as its only human 
complement. 
5.2.4 Gene dosage analysis 
Gene dosage analysis was used to confirm the localisation of the EST (represented 
by its I. M. A. G. E. cDNA clone) to human chromosome 5; and to determine the loss 
or retention of the gene in the patient granulocyte DNA (Chapter 3 section 3.2.4). 
Gene dosage experiments were carried out on at least two separate occasions. 
5.2.5 Northern analysis 
I. M. A. G. E. cDNA clones which hybridised to a single fragment in hybrid 5 DNA 
and showed a 50% dosage reduction were hybridised to Multiple Tissue Northern 
(MTN) blots (Chapter 3 section 3.2.5 and Table 3.1). 
5.2.6 Direct sequencing 
I. M. A. G. E. cDNA clones representing each EST were sequenced as either single- 
stranded or double-stranded templates, as previously described, by the 
dideoxy 
chain termination method (Sanger et al., 1977) (Chapter 2 section 2.12.1). 
Clones 
were sequenced using the Cy5 Autoread sequencing kit (Chapter 3 section 
3.2.7). 
Each I. M. A. G. E. cDNA clone was sequenced in full and then subjected to a 
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GenBank homology search to confirm its homology with the known gene, and to 
identify overlapping clones to generate the full-length cDNA. 
5.2.7 Overlapping cDNA clones 
Sequence data from each I. M. A. G. E. cDNA clone was subjected to a homology 
search against the EST database db(EST) at NCBI for overlapping cDNA clones to 
generate the full-length cDNA (Chapter 3 section 3.2.8). Sequence data from the 
overlapping clone was added to the sequence from the I. M. A. G. E. cDNA clone, 
and the 'new' sequence submitted to db(EST). 
5.2.8 cDNA library screening 
If no overlapping clones were identified from db(EST) or UniGene, the cDNA 
clone insert was screened against cDNA libraries. In the first instance, a foetal 
brain cDNA library was selected as this tissue expresses a wide variety of genes. 
Seven high-density gridded cDNA filters were used in the study. Also, a 
collaboration with the Resource Centre of the German Human Genome Project at 
the Max-Planck-Institute for molecular genetics (RZPD) was established (Chapter 
3 section 3.2.9). Positive clones were sequenced and the 'new' sequence submitted 
to db(EST). 
5.2.9 Database analysis using the Genetics Computer Group (GCG) software 
package 
FastA, BlastX and Frames analysis was carried out on the sequence generated 
from the I. M. A. G. E. cDNA clones, as previously described (Chapter 3 sections 
3.2.12.1-3.2.12.3). 
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5.3 Results 
5.3.1 ESTs identified from the Human GeneMap and the UniGene set 
ESTs identified from the Human Chromosome 5 GeneMap at NCBI, and the 
UniGene set are displayed in Table 5.1. I. M. A. G. E. cDNA clones from which each 
EST was originally derived were obtained. 
5.3.2 Gene dosage analysis 
Three out of six (50%) I. M. A. G. E. cDNA clones representing ESTs 'highly similar' 
to CDC60, RMSA-1, and PP2A were shown to map to the 5Mb critical region of the 
5q- syndrome at 5g31-q33. An approximate 50% reduction in the dosage of each 
cDNA clone in the granulocyte patient DNA compared with normal controls, 
confirmed the deletion of one allele. 
Gene dosage analysis with I. M. A. G. E. cDNA clone 308419 derived from EST 
W44992 (Goliath protein) showed that the 308419 probe hybridised to 18 
fragments in the granulocyte DNA from the patients and controls, and 8 
fragments in the Hybrid 5 DNA. Not one of the 18 fragments appeared to show a 
50% reduction in the granulocyte patient DNA, suggesting cDNA clone 308419 
did not map to the critical region of the 5q- syndrome as had been predicted by 
the Human GeneMap and the UniGene set. Moreover, mapping information from 
UniGene showed the gene had been mapped between two sets of DNA markers 
from the transcript map. No further analysis was carried out on EST W44992. 
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ESTs H51264 and R78295 representing the tprl and PPP1R2 genes respectively 
were shown to map outside the distal breakpoint of the critical region by gene 
dosage analysis, see Figure 5.1. A UniGene search later identified PPP1 R2 to map 
to chromosome 3g29. 
Thus the CDC60, RMSA-1, and PP2A genes were selected for further analysis. 
5.3.3 Northern analysis 
Northern analysis showed I. M. A. G. E. clone 33583 (CDC60) to be ubiquitously 
expressed and to possess a transcript of 4.4kb in addition to a faint transcript of 
6.0kb, see Figure 5.2. 
5.3.4 Direct sequencing 
Direct sequencing of clone 33583 (CDC60) generated 1073bp of sequence. A 
GenBank homology search showed the cDNA to be the human homologue of the 
yeast cell division cycle gene CDC60 (leucyl-tRNA synthetase, cytoplasmic). A 
BlastX protein homology search utilising the SWISS-PROT database showed the 
cDNA to have a 46% amino acid match over its entire length with Saccharomyces 
cerevisiae CDC60 protein and a 43% amino acid match with Neurospora crassa 
leucyl-tRNA synthetase, cytoplasmic, see Figure 5.3. 
Direct sequencing of I. M. A. G. E. clone 145513 derived from EST R77718 (RMSA-1) 
generated 561bp of sequence. A FastA nucleotide homology search showed clone 
145513 to have 97.1% identity with a Homo sapiens chromosomal protein, see 
Figure 5.4. 
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1234567 
renin 
194016 
'+' ++++ ++ 
+ ++++ +- 
Figure 5.1 
Representative gene dosage analysis of I. M. A. G. E. cDNA clone 194016 from EST 
H51264 (tprl). DNA obtained from the granulocyte fractions of 3 patients (lanes 1, 
3, and 7), the lymphocyte fractions from 2 patients (lanes 2 and 4), and healthy 
controls (lanes 5 and 6) was digested with EcoRI and simultaneously hybridised to 
a probe for 194016 and a probe for the renin gene. ++ indicates the presence of two 
copies of the tprl gene and +- indicates the deletion of one copy of the gene. 
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Figure 5.2 
Representative Northern blot analysis of I. M. A. G. E. cDNA clone 33583 (CDC60). 
The MTN blot (a) included 2}ßg of poly (A+) RNA from; heart (1), brain (2), 
placenta (3), lung (4), liver (5), skeletal muscle (6), kidney (7), and pancreas (8). 
The MTN blot (b) included 2pg of poly (A+) RNA from; spleen (1), lymph node 
(2), thymus (3), peripheral blood leukocytes (4), bone marrow (5), and foetal liver 
(6). Sizes of RNA marker bands (kb) are indicated approximately. 
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Figure 5.3 BlastX analysis of I. M. A. G. E. cDNA clone 33583 (top) and the yeast 
cell division cycle gene CDC60 (bottom) 
33583: 6 EVKKTIQKKMIDAGDALIYMEPEKQVMSRSSDECWALCDQWYLDYGEENWKKQTSQCLK 
185 
+K ++ MI AG+A +Y EPE QVMSRS D+C+V+L DQWY+DYGEE+WKKQ +CL+ 
CDC60: 505 QAKNKVKADMIAAGEAFVYNEPESQVMSRSGDDCIVSLEDQWYVDYGEESWKKQAIECLE 
564 
33583: 186 NLETFCEETRRNFEATLGWLQEHACSRTYGLGTHLPWDEQWLIESLSDSTIYMAFYTVAH 365 
++ FE+ FE L WL+ A RTYGLGT LPWDE++L+ESLSDSTIY +FYT+AH 
CDC60: 565 GMQLFAPEVKNAFEGVLDWLKNWAVCRTYGLGTRLPWDEKYLVESLSDSTIYQSFYTIAH 624 
33583: 366 LLQGGNLHGQAESPLGIRPQQMTKEVWDYVFFKEAPFPKTQIAKEKLDQLKQEFEFWYPV 545 
LL + +G PLGI QMT EV+DY+F +TIL +L++EFE++YP+ 
CDC60: 625 LL-FKDYYGNEIGPLGISADQMTDEVFDYIFQHQDDVKNTNIPLPALQKLRREFEYFYPL 683 
33583: 546 DLRVSGKDLVPNHLSYYLYNHVAMWPEQSDKWPTAVRANGHLLLNSEKMSKSTGNFLTLT 725 
D+ +SGKDL+PNHL++++y HVA++P++ WP +RANGHL+LN+ KMSKSTGNF+TL 
CDC60: 684 DVSISGKDLIPNHLTFFIYTHVALFPKKF--WPKGIRANGHLMLNNSKMSKSTGNFMTLE 741 
33583: 726 QAIDKFSADGMRLALADAGDTVEDANFVEAMADAGILRLYTWVEWVKEMVANWDSLRSGP 905 
Q ++KF AD R+A ADAGDTVEDANF E+ A+A ILRL+ EW +E + +LR+G 
CDC60: 742 QTVEKFGADAARIAFADAGDTVEDANFDESNANAAILRLFNLKEWAEE-ITKESNLRTGE 800 
33583: 906 ASTFNDRVFASELNAGIIKTDQNYEKMMFKEALKTGFFEFQAAKDKYRELAVEGMHRELV 1085 
+FDF E+NA I KT +Y +K ALK G F+FQAA+D YRE A MH++L+ 
CDC60: 801 ITDFFDIAFEHEMNALIEKTYEQYALTNYKNALKYGLFDFQAARDYYRE-ASGVMHKDLI 859 
33583: 1086 FRFIEVQTLLLAPFCPHLCEHIW-TLLGKPDSIMNASWPVAG-PVNEVLIHSSQYLMEVT 1259 
R+IE Q LLLAP PH E+I+ +LG S+ NA +P A PV++ ++ + YL + 
CDC60: 860 ARYIETQALLLAPIAPHFAEYIYREVLGNQTSVQNAKFPRASKPVDKGVLAALDYLRNLQ 919 
33583: 1260 HDLRLRLKNYNMPAKGKKTDKQPLQKPSHCTIYVAKNYPPWQHTTLSVLRKHFEANNGKL 1439 
+R + KGK + KP T+ +++++P WQ + ++RK FL 
CDC60: 920 RSIREGEGQALKKKKGKSAEID-ASKPVKLTLLISESFPEWQSQCVEIVRKLFSEQT--L 976 
33583: 1440 PDNKVIASELGSMPELKKYMKKVMPFVAMIKENLEKMGPR-ILDLQLEFDE 1589 
DNK ++K MK+ MPF++++K+ LP++ +L+F E 
CDC60: 977 DDNKKVREHIE ----- PKEMKRAMPFISLLKQRLANEKPEDVFERELQFSE 1022 
I. M. A. G. E. cDNA clone 33583 has a 46% amino acid match with the Saccharomyces 
cerevisiae CDC60 protein in a 1090bp overlap. 
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Figure 5.4 Alignment of I. M. A. G. E. cDNA clone 145513 (top) and the Homo 
sapiens chromosomal protein mRNA (the human homologue of 
the Drosophila RMSA-1 gene - GenBank accession No. L26953) 
(bottom) 
50 60 70 80 90 100 
145513 AATATCCTTGTTAGTTATATAAAAATAAACTTTTTTTTGCTTTTTGCAGATTTGAAATTT 
L26953 TTTTTTTTGCTTTTTGCAGATTTGAAATTT 
10 20 30 
110 120 130 140 150 160 
145513 AATTAAGCTATTAACTTCTTAATCATCACATCCTCCAACTCTGTTTTAACTCCCCCCTCC 
L26953 AATTAAGCTATTAACTTCTTAATCATCACATCCTCCAACTCTGTTTTAACTCCCCCCTCC 
40 50 60 70 80 90 
170 180 190 200 210 220 
145513 CCCTCCCCTTTTTTTTTTAAGGAATAAAGGGATTCATTCCTCATTTTAACTGATGTTACA 
{{I{II11 IIII'{I'IIII{I{II{IIIIIIIIIIIIIII{III{IIIIIII{{IIII{{ 
L26953 CCCTCCCC-TTTTTTTTTAAGGAATAAAGGGATTCATTCCTCATTTTAACTGATGTTACA 
100 110 120 130 140 
230 240 250 260 270 280 
145513 GTGAAGATGGGTTCTTGAACTCTTGGAAGCCTGGATGAGCCACCTAATCTGCAAGATAAA 
L26953 GTGAAGATGGGTTCTTGAACTCTTGGAAGCCTGGATGAGCCACCTAATCTCAAAGATAAA 
150 160 170 180 190 200 
290 300 310 320 330 340 
145513 AACCAAAGACCAATGCGTATTGGGGAAAAGAATGCTTAGTACTGCAAGACTGTTGAATAC 
L26953 AACCAAAGACCAATGCGTATTGGGGAAAAGAATGCTTAGTACTGCAAGACTGTTGAATAC 
210 220 230 240 250 260 
350 360 370 380 390 400 
145513 CTGTTGAATATTCCTATTGAGGTTTTTYCCTAAACATACTTCAGTAACATCTTA--GGAC 
L26953 CTGTTGAATATTCCTATTGAGGTTTTTTCCTAAACATACTTCAGTAACATCTTACCGGAC 
270 280 290 300 310 320 
410 420 430 440 450 460 
145513 AATT-CACTGGAGAAATGTTGAT-CCYGGCTGGAATGTCATACCATTGACCCATTTGAAG 
L26953 AATTGCACTGGAGAAATGTTGATCCCTGGCTGGAATGTCATACCATTGACCCATTTGAAG 
330 340 350 360 370 380 
470 480 490 500 510 
145513 AGTTAAAGCTKGGATTTGACYTGCTCTATTCTACCAGG-ATWTTGTTAGGGTAG 
IIIIIIIIII 111111111 IIIIIIIilllllllll 11=111111111111 
L26953 AGTTAAAGCT-GGATTTGAC-TGCTCTATTCTACCAGGAATATTGTTAGGGTAGCCTTTT 
390 400 410 420 430 440 
I. M. A. G. E. cDNA clone 145513 has a 97.1% identity with the Homo sapiens 
chromosomal protein mRNA over a 444bp nucleotide overlap. 
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This result suggests EST R77718 represents the human homologue of the 
Drosophila RMSA-1 gene. A BlastX protein homology showed clone 145513 to 
have an 82%-97% amino acid match over two pieces of sequence with the 
Drosophila regulator of mitotic spindle assembly 1 (RMSA-1) gene. 
5.3.5 Overlapping cDNA clones 
db(EST) searches using the sequence of clone 33583 (CDC60) identified nine 
overlapping clones. Two of these I. M. A. G. E. clones, 567178 and 1173393 
possessed large inserts, and were thus selected for further analysis. Direct 
sequencing of these overlapping clones generated sequence that overlapped with 
CDC60 with 100% homology over part of the sequence. Both clones also 
generated a further 1218bp of sequence. A FastA nucleotide homology search on 
the new 2291bp sequence showed clone 33583 to have 99.7% identity with the 
Homo sapiens mRNA for leucyl transferase, see Figure 5.5. This result suggests EST 
R44866 represents the human homologue of the yeast CDC60 gene. 
5.3.6 cDNA library screening 
The collaboration with the Resource Centre of the German Human Genome 
Project identified seven positive clones from the Soares infant brain and human 
foetal brain cDNA libraries following hybridisation with probe 33583 (CDC60). 
The sequence generated from 3/7 (43%) positive clones overlapped with clone 
33583 with 100% homology but did not add any additional sequence. The seven 
clones were discarded from the study at this point. 
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Figure 5.5 Alignment of I. M. A. G. E. cDNA clone 33583 (top) and the Homo 
sapiens mRNA for leucyl tRNA synthetase (human homologue of 
the yeast CDC60 gene - GenBank accession No. D84223) (bottom) 
10 20 30 
33583 GGCACGAGGTAAAGAAGACTATTCAGAAAAAG 
D84223 TTGGTGGATGGATTTAAAGGACAGAAGGTTCAAGATGTAAAGAAGACTATTCAGAAAAAG 
1510 1520 1530 1540 1550 1560 
40 50 60 70 80 90 
33583 ATGATTGACGCTGGAGATGCACTTATTTACATGGAACCAGAGAAACAAGTGATGTCCAGG 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
D84223 ATGATTGACGCTGGAGATGCACTTATTTACATGGAACCAGAGAAACAAGTGATGTCCAGG 
1570 1580 1590 1600 1610 1620 
100 110 120 130 140 150 
33583 TCGTCAGATGAATGTGTTGTGGCTCTGTGTGACCAGTGGTACTTGGATTATGGAGAAGAG 
D84223 TCGTCAGATGAATGTGTTGTGGCTCTGTGTGACCAGTGGTACTTGGATTATGGAGAAGAG 
1630 1640 1650 1660 1670 1680 
160 170 180 190 200 210 
33583 AATTGGAAGAAACAGACATCTCAGTGCTTGAAGAACCTGGAAACATTCTGTGAGGAGACC 
D84223 AATTGGAAGAAACAGACATCTCAGTGCTTGAAGAACCTGGAAACATTCTGTGAGGAGACC 
1690 1700 1710 1720 1730 1740 
220 230 240 250 260 270 
33583 AGGAGGAATTTTGAAGCCACCTTAGGTTGGCTACAAGAACATGCTTGCTCAAGAACTTAT 
D84223 AGGAGGAATTTTGAAGCCACCTTAGGTTGGCTACAAGAACATGCTTGCTCAAGAACTTAT 
1750 1760 1770 1780 1790 1800 
280 290 300 310 320 330 
33583 GGTCTAGGCACTCACCTGCCTTGGGATGAGCAGTGGCTGATTGAATCACTTTCTGACTCC 
D84223 GGTCTAGGCACTCACCTGCCTTGGGATGAGCAGTGGCTGATTGAATCACTTTCTGACTCC 
1810 1820 1830 1840 1850 1860 
340 350 360 370 380 390 
33583 ACTATTTACATGGCATTTTACACAGTTGCACACCTATTGCAGGGGGGTAACTTGCATGGA 
D84223 ACTATTTACATGGCATTTTACACAGTTGCACACCTATTGCAGGGGGGTAACTTGCATGGA 
1870 1880 1890 1900 1910 1920 
400 410 420 430 440 450 
33583 CAGGCAGAGTCTCCGCTGGGCATTAGACCGCAACAGATGACCAAGGAAGTTTGGGATTAT 
IIIIIIIIIIIIIIillllllllllllllillllllllllllllllllllllýlllllll 
D84223 CAGGCAGAGTCTCCGCTGGGCATTAGACCGCAACAGATGACCAAGGAAGTTTGGGATTAT 
1930 1940 1950 1960 1970 1980 
460 470 480 490 500 510 
33583 GTTTTCTTCAAGGAGGCTCCATTTCCTAAGACTCAGATTGCAAAGGAAAAATTAGATCAG 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
D84223 GTTTTCTTCAAGGAGGCTCCATTTCCTAAGACTCAGATTGCAAAGGAAAAATTAGATCAG 
1990 2000 2010 2020 2030 2040 
520 530 540 550 560 570 
33583 TTAAAGCAGGAGTTTGAATTCTGGTATCCTGTTGATCTTCGCGTCTCTGGCAAGGATCTT 
D84223 TTAAAGCAGGAGTTTGAATTCTGGTATCCTGTTGATCTTCGCGTCTCTGGCAAGGATCTT 
2050 2060 2070 2080 2090 2100 
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580 590 600 610 620 630 
33583 GTTCCAAATCATCTTTCATATTACCTTTATAATCATGTGGCTATGTGGCCGGAACAAAGT 
D84223 GTTCCAAATCATCTTTCATATTACCTTTATAATCATGTGGCTATGTGGCCGGAACAAAGT 
2110 2120 2130 2140 2150 2160 
640 650 660 670 680 690 
33583 GACAAATGGCCTACAGCTGTGAGAGCAAATGGACATCTCCTCCTGAACTCTGAGAAGATG 
II II111II1II111111111111IIlIIIIIIIIIiIIIIIIIIIIIIIIIIIIIIII 
D84223 GATAAATGGCCTACAGCTGTGAGAGCAAATGGACATCTCCTCCTGAACTCTGAGAAGATG 
2170 2180 2190 2200 2210 2220 
700 710 720 730 740 750 
33583 TCAAAATCCACAGGCAACTTCCTCACTTTGACCCAAGCTATTGACAAATTTTCAGCAGAT 
D84223 TCAAAATCCACAGGCAACTTCCTCACTTTGACCCAAGCTATTGACAAATTTTCAGCAGAT 
2230 2240 2250 2260 2270 2280 
760 770 780 790 800 810 
33583 GGAATGCGTTTGGCTCTGGCTGATGCTGGTGACACTGTAGAAGATGCCAACTTTGTGGAA 
D84223 GGAATGCGTTTGGCTCTGGCTGATGCTGGTGACACTGTAGAAGATGCCAACTTTGTGGAA 
2290 2300 2310 2320 2330 2340 
820 830 840 850 860 870 
33583 GCCATGGCAGATGCAGGTATTCTCCGTCTGTACACCTGGGTAGAGTGGGTGAAAGAAATG 
D84223 GCCATGGCAGATGCAGGTATTCTCCGTCTGTACACCTGGGTAGAGTGGGTGAAAGAAATG 
2350 2360 2370 2380 2390 2400 
I. M. A. G. E. cDNA clone 33583 has a 99.7% identity with the Homo sapiens mRNA 
for leucyl tRNA synthetase, over a 2263bp nucleotide overlap. 
5.3.7 Summary 
During this study, two new patients (patient 3 and patient 4) with MDS and a 5q 
deletion were identified which narrowed the critical region of the 5q- syndrome to 
approximately 3Mb at 5g31.3-q33 (patient 3), and then approximately 
1.5Mb at 
5g31.3-q32. The new critical region now excluded the CDC60, RMSA-1, and 
PP2A 
genes. No further analysis was carried out. 
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5.4 Discussion 
The Human Chromosome 5 GeneMap and the UniGene set at NCBI identified six 
transcripts that mapped to the approximate 5Mb critical region of the 5q- 
syndrome at 5g31-q33 flanked by the genes FGF1 and IL12ß. Each transcript was 
represented by ESTs 'highly similar' to known genes from yeast or Drosophila, or 
known human genes. These genes represented candidates for the 5q- syndrome 
tumour suppressor gene. 
Three of the six genes (Goliath protein, trpl, and PPP1R2) were shown to map 
outside the critical region of gene loss by gene dosage analysis. These results, as 
with the novel genes in Chapter 4, highlight the redundancy in the EST database. 
The Goliath protein had been mapped by two independent groups at two 
locations on the Whitehead map, and five locations on the Transcript map 
between two sets of DNA markers. These multiple mappings indicated a 
discrepancy in its localisation. An updated UniGene search shows it has 
subsequently been localised to two regions at 5q35, outside the distal breakpoint 
of the 5q- syndrome at 5q33. 
The tprl gene had been mapped independently by Oxford using the GB4 panel. It 
is beneficial for a gene to be mapped to the same location by two or more 
independent groups to confirm the localisation. Murthy et al., (1996) had 
previously localised the tprl gene to chromosome 5q32-q33.2 flanked by the DNA 
markers D5S2049 and D5S1955. The novel human gene was identified by a two- 
hybrid screen when interacting with the GAP-related domain of neurofibromin, 
the product of the NFl gene. However, tprl was found to map outside the distal 
breakpoint of the critical region, at 5g33, by gene dosage analysis. We 
subsequently mapped it to 5q33-q34 by gene dosage using the granulocyte 
DNA 
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from the newly identified patient 3. Recently, the Ensembl program has mapped 
the gene within contig AC000609 at 5q33.3. 
The PPP1R2 gene, like trill, had been independently mapped using the GB4 panel. 
The gene was shown to map proximal to trpl between the DNA markers D5S410 
and D5S487, according to the EST database. PPP1 R2 was also shown to map 
outside the distal breakpoint, but within 5q33-q34, by gene dosage analysis. The 
Ensembl program has mapped the gene within contig AC011414, also at 5q33.3, 
proximal to the tprl gene. Therefore, the EST database had wrongly localised the 
two genes, but their position relative to each other was correct. Following these 
results, the Homo sapiens genome view showed the PPP1R2 gene to have four 
"hits" in the human genome. Two "hits" were shown to map to 5q, while two 
were shown to map to 3q29, a region encoding many genes including the 
candidate tumour suppressor gene, DLG1, a human homologue of the Drosophila 
disc large tumour suppressor gene (Azim et al., 1995). Subsequently, Permana and 
Mott (1997) determined the authentic PPP1R2 gene to be located on chromosome 
3q29 consisting of six exons, when investigating whether genetic alterations in 
PPP1R2 could contribute to insulin resistance in Pima Indians. Permana and Mott 
showed the gene on chromosome 5 to be a homologue of PPP1R2, and identified it 
as an intronless pseudogene. 
The PP2A gene was correctly mapped to the critical region of the 5q- syndrome at 
5g31-q33, according to the GeneMap and UniGene set at NCBI. The PP2A gene 
had been mapped by two independent groups to the critical region of gene loss. 
Subsequently, the gene was shown to be retained in patient 3, therefore mapping 
the gene outside the new proximal breakpoint at 5g31.3. 
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Two transcripts were identified as the human homologues of the yeast cell 
division cycle gene CDC60, and the Drosophila regulator of mitotic spindle 
assembly, RMSA-1 gene. Our data confirmed that these genes were correctly 
mapped to the critical region of the 5q- syndrome at 5g31-q33, according to the 
GeneMap and UniGene set at NCBI. Like the PP2A gene, the CDC60 gene had 
been mapped by two independent groups to the critical region of gene loss, and 
then subsequently shown to be retained in patient 3, therefore mapping the gene 
outside the new proximal breakpoint at 5q31.3. However, the RMSA-1 gene was 
shown to map to the new critical region of the 5q- syndrome at 5g31.1-q33 by gene 
dosage analysis. A subsequent search on the UniGene and the Homo sapiens 
genome view showed the gene to be localised to three regions on chromosome 5q, 
and one region on chromosome 11cen-g22.3. These multiple mappings indicated a 
discrepancy in the localisation of RMSA-1, therefore no further analysis was 
carried out. Since the end of this study, a new patient (patient 4) with MDS and a 
5q deletion was identified, narrowing the critical region to approximately 1.5Mb at 
5g31.3-q32. The Ensembl program has recently mapped RMSA-1 within contig 
AC021078 at 5q33, thus outside the reduced critical region of the 5q- syndrome. 
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5.5 Conclusion 
The EST resource was successfully used to localise one known human gene and 
identify two human homologues of known genes from S. cerevisiae and 
D. melanogaster, which mapped to the 5Mb critical region of gene loss in the 5q- 
syndrome, at 5g31-q33. These three genes thus represented potential candidate 
genes for the 5q- syndrome. However, during the course of this study, new 
patient data narrowed the 5q- syndrome critical region to approximately 1.5Mb at 
5g31.3-q32, flanked by the genetic marker D5S413 and GLRA1 gene. The three 
candidate genes have been excluded from the reduced critical region. 
The main disadvantage of the EST resource is its high degree of redundancy. Fifty 
per cent of the six genes originally selected for analysis were shown to map 
outside the critical region of gene loss. This was previously highlighted in 
Chapter 4 when mapping novel genes to the 5q- syndrome critical region. The 
high failure rate may be due to redundancy in the sequence data, widely 
dispersed sequences, ambiguous nucleotides within the sequences, the possibility 
of amplifying through introns and the presence of repetitive elements within the 
sequence (Malone et al., 1999). Therefore, gene dosage analysis was used to 
localise the genes to 5q and produce an accurate transcription map of the critical 
region of gene loss in the 5q- syndrome. 
The process of generating a transcript map of the 5q- syndrome critical region has 
been facilitated by the increasing flow of data released by the Human Genome 
Project. In April 2000, researchers at the Department of Energy's Joint Genome 
Institute in California decoded in draft form the genetic information on human 
chromosome 5. Chromosome 5 contains anestimated 194 million bases, or about 
six percent of the human genome. Disease-linked genes on this chromosome 
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include those for colorectal cancer, basal cell carcinoma, acute myelogenous 
leukaemia, and a type of dwarfism. In addition, the approximate 1.5Mb critical 
region of the 5q- syndrome is currently being annotated by members of our group 
using the Ensembl program in collaboration with the Sanger Centre. The Ensembl 
program has used a number of criteria to map a particular gene to a particular 
chromosomal region, thereby decreasing the amount of redundancy in the 
database. For example, genes have only been predicted represented by ESTs that 
are part of a cluster in the UniGene set. ESTs represented as unidentified 
transcripts are not considered to be true genes. It is estimated that there are a total 
number of thirty-six genes, twenty-three known, and thirteen novel mapping to 
the critical region of the 5q- syndrome. 
We have generated a detailed transcript map of the 5q- syndrome critical region 
comprising of known genes and novel coding sequences. Following the success of 
the HGP along with the annotation of the critical region of the 5q- syndrome, we 
will carry out mutation studies with the aim of identifying the 5q- tumour 
suppressor gene(s). 
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6.1 Introduction 
6.1.1 Targeting genes as candidates for disease 
Frequent deletions and loss of heterozygosity in a segment of a particular 
chromosome in association with a malignancy suggest that the disease may be 
caused by inactivation of a tumour suppressor gene located in the commonly 
deleted region (CDR). The identification and targeting of novel genes in such 
regions has followed many approaches including: constructing a high-resolution 
physical map of YAC, PAC, and cosmid contigs covering the genomic region, 
exon trapping, and direct selection as described in the previous chapter. With 
many CDRs being gene-rich, identifying candidate genes for mutation analysis 
requires the need for prioritisation. 
Genes have been isolated as candidates due to their localisation, expression 
patterns, homology with a protein from another species, belonging to a gene 
family, and their predicted/known function. Many genes involved in 
carcinogenesis have been targeted due to their chromosomal localisation. The 
distal portion of chromosome 1p is one of the most commonly affected regions in 
human cancer (Chadwick et al., 2000). A study of hereditary and sporadic 
colorectal cancer identified a region of frequent deletion 32.2 centimorgans (CM) 
from lptel (Chadwick et al., 2000). Results showed deletion breakpoints to cluster 
in the vicinity of or inside the RIZ gene that encodes a retinoblastoma protein- 
interacting zinc finger protein. Moreover, the RIZ1 isoform contains a PR domain 
implicated in tumour suppressor function. The PR domain is a newly recognised 
protein motif that characterises a subfamily of Kruppel-like zinc finger genes. 
Members of the PR domain family have been shown to play important roles in cell 
differentiation and malignant transformation (Liu et al., 1997). Other candidate 
tumour suppressor genes isolated as a result of their chromosomal localisation 
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include the HI C-1 (Hypermethylated in cancer 1) a BTB / POZ transcriptional 
repressor located at 17p13.3, a region hypermethylated or subject to allelic loss in 
many human cancers (Guerardel et al., 2001). 
The technique of screening the human EST database has been used to target genes 
as candidates for disease. db(EST) has recently been used to identify candidate 
genes in respiratory chain deficiency. Disorders of mitochondrial oxidative 
phosphorylation (OXPHOS) are now recognised as major causes of human 
metabolic diseases and several mutations of mitochondrial and nuclear genes 
encoding respiratory chain components have been reported (Rotig et al., 2000). 
While several hundred of these genes have been reported in yeast, only a few 
nuclear genes have been identified in humans. The yeast databases therefore 
present an invaluable tool for identification of human homologues that should be 
regarded as candidate genes in OXPHOS diseases. Yeast protein sequences were 
compared to the GenBank db(EST) database in order to identify the human 
counterparts, using the BLAST program. The study identified one hundred and 
two groups of human ESTs with significant homology to yeast genes (Rotig et al., 
2000). 
6.1.2 Targeting genes in MDS and leukaemia 
The elucidation of the putative tumour suppressor gene(s) involved in the 
pathogenesis of many myeloid and lymphoid malignancies remains a major goal 
in cancer research. Several genes with tumour suppressor activity 
have been 
targeted as candidates for MDS and leukaemia. p53 is one of the most 
frequently 
mutated genes in human cancers (Neubauer et al., 1993). Since p53 
has been 
implicated in lymphatic and some myeloid leukaemias, such as the blastic phase 
of CML, studies have been carried out to address the role of p53 gene mutations 
in 
Page 179 
MDS. The study by Neubauer et al., looked at mutations within exons 4-9 of the 
p53 gene, in patients with MDS. No mutations were found in the seventeen MDS 
patients included in the study suggesting p53 gene mutations do not play a major 
role in the pathogenesis of MDS. However, a study by Kaneko et al., (1995) looked 
at exons 5-8 of the p53 gene. p53 mutations were found in 7/57 (12%) patients 
with MDS. These mutations correlated with both leukaemic transformation and a 
poor prognosis in MDS. 
We decided to target known genes as candidates for the 5q- syndrome. Due to the 
speed and accuracy of the EST database, we used the technique of screening 
db(EST) for the identification of candidate tumour suppressor genes. We have 
analysed the SPARC gene which has been reported to possess tumour suppressor 
activity (Mok et al., 1996); the annexin VI gene which belongs to a family of genes 
of which have been implicated in tumourigenesis (Kataoka et al., 2000); and the 
ATOX1 (previously HAH1) gene which has been predicted to play a role in 
antioxidant defence (Klomp et al., 1997). 
6.1.3 The SPARC gene 
SPARC (secreted protein acidic and rich in cysteine), also termed BM-40,43K- 
protein, and osteonectin is an extracellular, Ca2+ ion-binding, glycoprotein widely 
distributed in human tissues undergoing developmental regulation and repair 
(Lane and Sage, 1994; Ledda et al., 1997). The protein is shown to be expressed in 
haematopoietic cells including megakaryocytes (Kelm Jr et al., 1992). Although 
information concerning the expression, biochemical properties, and cellular 
activities of S PA RC has increased significantly over the last fifteen years, the 
precise function of the protein is unknown. However, a number of studies 
have 
shown SPARC to possess important properties. One such property 
is as an 
antiadhesin causing changes in cell shape by disrupting cell-matrix 
interactions 
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(Lane and Sage, 1994). SPARC has also been shown to function as a cell growth 
regulator by inhibiting progression through the GI-->S phase of the cell cycle (Sage 
and Bornstein, 1991). These functions suggest SPARC may play a role in 
tumourigenesis. Moreover, Mok et al., (1996) showed that downregulation of 
SPARC strongly reduced the growth rate of cancer cell lines in vitro, suggesting 
SPARC functions as a tumour suppressor gene, at least in some malignancies. 
The SPARC gene has been localised to chromosome 5g31-q33 by somatic cell 
hybrid analysis and by in situ hybridisation (Swaroop et al., 1988); within the 
critical region of gene loss in the 5q- syndrome (Boultwood et al., 1994; Jaju et al., 
1998), see Figure 6.1. Its expression in haematopoietic cells along with its 
properties as a cell-cycle inhibitor make SPARC a candidate for the putative 
tumour suppressor gene associated with the 5q- syndrome. The SPARC gene was 
analysed for mutations by direct sequencing in three patients with MDS and the 
5q- syndrome. 
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Figure 6.1 Ideogram of Chromosome 5 illustrating the critical region of the 5q- 
syndrome and the position of the SPARC gene 
6.1.4 The Annexin VI gene 
The annexins were first described as a family of calcium phospholipid-binding 
proteins in 1990 (Crumpton and Dedman, 1990). To date, over twenty members of 
the annexin family have been identified, ten of which have been described in 
mammals, including annexin VI. The annexins are defined by a conserved 
internally repetitive 70-amino acid sequence, present four times in all annexins 
except annexin VI, which has eight repeats (Crompton et al., 1988). Although the 
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biological functions of these proteins have yet to be established, annexin V has 
been proposed to play a role in apoptosis (Rand, 1999). The fact that they are 
highly conserved and present in a variety of cell types suggests that important 
biological roles will be elucidated. Annexin VI is highly expressed in mammalian 
tissues although generally restricted to specialised cell types, in particular 
endocrine cells and certain ductal epithelia (Clark et al., 1991). This pattern of 
expression supports a role for annexin VI in some aspect of secretion, although in 
vitro studies showed annexin VI to inhibit synexin (annexin VII) and calpactin 
(annexin II) driven granule aggregation (Creutz et al., 1992). 
Although no one clear function for the annexins has been established, a number of 
studies suggest a role in tumour suppression. A study of the annexin VI 
expression levels on a melanoma cell line showed the gene to be a marker for the 
less invasive phenotype of malignant melanoma, and suggested a possible role in 
tumour suppression (Kataoka et al., 2000). Moreover, annexin VI, like the SPARC 
gene, has been shown to inhibit progression through the cell cycle, suggesting a 
possible role for annexin VI in cell growth regulation and tumourigenesis 
(Theobald et al., 1994). A subsequent study showed the heterologous expression 
of annexin VI in A431 squamous carcinoma cells caused a marked suppression of 
tumour cell growth (Theobald et al., 1995). 
The annexin VI gene has been localised to the critical region of gene loss in the 5q- 
syndrome by gene dosage analysis, and sublocalised to the YAC contig 
(Boultwood et al., 2000). This localisation, expression pattern, and properties of 
annexin VI as a cell cycle inhibitor make it a candidate for the putative tumour 
suppressor gene associated with the development of the 5q- syndrome. 
The 
annexin VI gene was analysed for mutations by cycle sequencing in nine patients 
with MDS and the 5q- syndrome. 
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6.1.5 The role of antioxidants in cancer 
Genes having known or predicted tumour suppressor activity, for example the 
SPARC and annexin VI genes respectively, represent good candidate genes for the 
5q- syndrome. Also, genes with a predicted function in antioxidant defence have 
been shown to be involved in the pathogenesis of cancer. A gene localised to the 
5q- syndrome critical region predicted to be involved in antioxidant defence is the 
ATOX1 (previously HAH1) gene. 
Reactive oxygen species are widely generated in biological systems. 
Consequently, humans have evolved antioxidant defence systems that limit their 
production. Intracellular production of active oxygen species such as dioxygen 
and hydrogen peroxide is associated with the arrest of cell proliferation. 
Similarly, generation of oxidative stress in response to various external stimuli has 
been implicated in the activation of transcription factors and to the triggering of 
apoptosis. Despite antioxidant defence mechanisms, cell damage from oxygen 
free radicals (OFRs) is ubiquitous. OFR-related lesions that do not cause cell death 
can stimulate the development of cancer (Dreher and Junod, 1996). Reducing the 
avoidable endogenous and exogenous causes of oxidative stress is the current 
strategy at present, but in the future, the action of tumour suppressor genes and 
the DNA repair mechanisms may lead the way to additional tools against 
carcinogenesis from OFR (Dreher and Junod, 1996). 
6.1.6 The HAH1 gene 
The human ATX homologue 1 (HAH1) gene is the human homologue of the ATX1 
gene in Saccharomyces cerevisiae (Klomp et al., 1997). ATX1 encodes a cystolic 
copper-binding protein in S. cerevisiae, functioning to protect cells 
from toxicity in 
a copper-dependent manner (Klomp et al., 1997). The 
ATX1 protein (Atx1p) 
functions as an antioxidant protecting yeast from the toxic effects of superoxide 
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and hydrogen peroxide (Lin and Culotta, 1995). Therefore, it was suggested that 
HAH1 may play an essential role in the antioxidant defence and copper 
homeostasis in humans (Klomp et al., 1997). 
Fluorescence in situ hybridisation had previously localised HAH1 to chromosome 
5q32-q33 (Klomp et al., 1997). It was recently finely mapped to the YAC contig 
encompassing the critical region of the 5q- syndrome, adjacent to the SPARC gene 
(Boultwood et al., 2000). It's localisation, expression pattern, and properties as an 
antioxidant make HAH1 a candidate for the tumour suppressor gene associated 
with the 5q- syndrome. The HAH1 gene was analysed for mutations by cycle 
sequencing in eight patients with MDS and the 5q- syndrome. 
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6.2 Materials and Methods 
6.2.1 Patients 
Three patients with MDS and a 5q deletion were included in the direct sequencing 
study of the SPARC gene. A further 6 patients were included in the molecular 
analysis and cycle sequencing study of the HAH1 and annexin VI genes. 
Classification was according to the FAB criteria (Kouides and Bennett, 1992). At 
the time of investigation, all 9 patients had the characteristic clinical and 
haematological features of the 5q- syndrome (Van den Berghe et al., 1974; Dewald 
et al., 1985) 
6.2.2 Samples 
Mononuclear cells and granulocytes were separated from 40mis of EDTA treated 
peripheral blood by Ficoll gradient centrifugation (Boyum, 1984). The granulocyte 
fraction showed a high level of purity (>_95%). High molecular weight DNA was 
obtained from the fractionated peripheral blood by Nucleon® extraction. 
Granulocyte DNA from one healthy individual was used as the control. 
Total RNA was obtained from the patient granulocyte fractions with the Totally 
RNA Isolation Kit that is based on the disruption of cells in guanidinium 
thiocynate/cationic detergent solutions, followed by organic extraction and 
alcohol precipitation of the RNA. Granulocyte total RNA fractions from the 
peripheral blood of healthy individuals were used as controls. 
6.2.3 Gene dosage analysis 
The SPARC gene had previously been localised to the critical region of the 5q- 
syndrome by gene dosage analysis (Boultwood et al., 1994). cDNA clones 
representing; (1) part of the HAH1 gene, and (2) the annexin VI gene were 
localised 
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to the critical region of gene loss in this study as previously described (Chapter 3 
section 3.2.4). 
6.2.4 Northern analysis 
An I. M. A. G. E. cDNA clone representing part of the HAH1 gene was hybridised to 
an MTN blot as previously described (Chapter 3 section 3.2.5), to determine the 
tissue expression pattern and transcript size of the cDNA. Northern analysis had 
previously been carried out on the SPARC gene (Xavier et al., 1989) and the 
annexin VI gene (Smith et al., 1994). 
6.2.5 Southern analysis 
Granulocyte DNA fractions were obtained from nine 5q- syndrome patients and 
healthy individuals. The DNA was digested with restriction enzymes PstI, 
HindIII, PvuII, and BglII; size fractionated through a 1% agarose gel and Southern 
blotted. Two Southern blot filters were prepared and hybridised with an 
I. M. A. G. E. cDNA clone insert derived from the HAH1 gene to screen for gene 
rearrangements. Southern analysis was carried out on two separate occasions. 
Southern analysis had previously been carried out on the SPARC and annexin VI 
genes in the laboratory. 
6.2.6 Localisation to the YAC contig 
The SPARC, HAH1, and annexin VI genes were sublocalised by PCR screening to 
the YAC contig encompassing the critical region of the 5q- syndrome (Kostrzewa 
et al., 1998) as previously described (Chapter 2 section 2.15). The genes were 
further localised to BACs (Bacterial artificial chromosomes) spanning the critical 
region of gene loss. PCR primer pairs were designed from the coding region of 
each gene. Details of the primer conditions are shown in Table 6.1. 
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Table 6.1 PCR primer conditions for localisation of the SPARC, HAM, and 
annexin VI genes to the YAC contig 
Gene Primer Primer sequence Annealing PCR 
name 5'-3' temp size 
SPARC SPARC-F9 TTCCCTGCAGGTACCTCT 55°C 150bp 
SPARC-R9 ACTCACTCTGCTTGATGC 
HAH1 HAH1-FB GAGGCGCTGCTGACAC 61°C 416bp 
HAH1-RC CAACAAAAGCAGCTTGATTTATG 
Annexin ANX6-F1 GCACTTCTGCCAAGAAATGG 58°C 320bp 
VI ANX6-R1 ACAGACAGAGGTTCAGGATG 
6.2.7 Expression in CD34+ cells by RT-PCR analysis 
CD34+ expression analysis was carried out on the SPARC, HAM, and annexin VI 
genes as previously described (Chapter 2 section 2.17). RT-PCR primer pairs were 
designed flanking the coding regions of each gene. Details of the primer 
conditions are shown in Table 6.2. 
Table 6.2 PCR primer conditions for CD34+ expression analysis in the 
SPARC, HAH1, and annexin VI genes 
Gene Primer Primer sequence Annealing PCR 
name 5'-3' temp size 
SPARC SPARC-RTF1 AAATACATCCCCCCTTGCC 56°C 557bp 
SPARC-RTR1 CAGAACAACAAACCATCCAAAC 
HAH1 HAH1-FB GAGGCGCTGCTGACAC 61°C 440bp 
HAH1-RC CAACAAAAGCAGCTTGATTTATG 
Annexin ANX6-F4 GATGCTCTGAGCTCAGACAC 60°C 700bp 
VI ANX6-R4 AGATAAGAGCCCAACCCAAC 
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6.2.8 Mutation analysis of the SPARC gene 
The method of choice for mutation analysis of the SPARC gene was 
directsequencing of the 9 coding exons since the genomic structure of the gene 
was known. 
6.2.8.1 Polymerase Chain Reaction (PCR) amplification of the SPARC gene 
PCR amplification was performed on patient granulocyte DNA samples and on 
the normal granulocyte DNA from one healthy individual. Primer pairs were 
designed from intronic sequences flanking each of the 9 coding exons (exons 2-10) 
of the SPARC gene. Details of the primer conditions are shown in Table 6.3. PCR 
was performed on a thermal cycler (Biometra Trio Thermoblock) in a 50P1 reaction 
volume in PCR buffer containing 1mM-3mM Mg2+ (Table 6.3), 1.25pM dNTPs, 
2.5U of Taq polymerase, 200ng of template DNA, and 100pmoles of each of the 
primers for 35 cycles under the following conditions: 94°C for 30 seconds, 
annealing temperature (Table 6.3) for 30 seconds, and 72°C for 1 minute. The PCR 
products were run on 1-2% agarose gels (dependent on size of PCR product) and 
purified using Wizard® PCR Preps DNA Purification System (Promega) as 
previously described (Chapter 2 section 2.5.1.3) 
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6.2.8.2 Subcloning of SPARC exon PCR products 
The purified PCR products were cloned into the pGEM®-T Easy Vector System II 
(Promega) as previously described (Chapter 2 section 2.5.1.4). The plasmid DNA 
was extracted using the QIAprep® Spin Miniprep Kit as previously described 
(Chapter 2 section 2.5.1.2. ). 
6.2.8.3 Sequencing of SPARC exon PCR products 
Plasmid DNA was sequenced as a double-stranded template using the Cy5 
Autoread sequencing kit as previously described (Chapter 2 section 2.12.1.3- 
2.12.1.4). 
A minimum of 10 clones from each exon were sequenced from each patient and 
control. 
6.2.9 Mutation analysis of the HAH1 and Annexin VI genes 
In contrast to the SPARC gene, only the cDNA sequence of the HAH1 and annexin 
VI genes were known. The method of choice for mutation analysis of the coding 
regions of the HAH1 and annexin VI genes was RT-PCR followed by cycle 
sequencing. HAH1 has a small coding region (207bp) which could be cycle 
sequenced in one fragment fragment only. The annexin VI gene has a large coding 
region of 2022bp but was split into 4 fragments (approximately 500bp in size) and 
each fragment sequenced individually. 
6.2.9.1 Reverse transcriptase PCR (RT-PCR) 
RT-PCR was carried out using the Reverse-iTTM One-step PCR kit as previously 
described (Chapter 2 section 2.16). Primer pairs were designed flanking the 
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coding regions of HAH1 and annexin VI. Details of the primer conditions are 
shown in Table 6.4. 
6.2.9.2 Purification and quantification of RT-PCR products 
Purification and quantification of each patient and control RT-PCR product from 
each gene was carried out as previously described (Chapter 2 section 2.16.1). 
6.2.9.3 Cycle sequencing on the ALFexpress automated sequencer 
All cycle sequencing reactions were carried out using the Thermo SequenaseCyTM5 
Dye Terminator Kit (Amersham Pharmacia Biotech, Uppsala, Sweden), for use on 
the Alfexpress automated sequencer as previously described (Chapter 2 section 
2.18). Nested primers were used for sequencing of the coding regions of the 
HAH1 and annexin VI genes. Nested primers add specificity to the annealing and 
sequencing reactions. The increase in specificity results from the nested primer 
not annealing to any primer dimers or oligomers created in the PCR reaction. The 
primers were diluted in distilled water to a final concentration of 2pmol/ 1. 
Details of the primers are shown in Table 6.5. 
6.2.10 Database analysis using the Genetics Computer Group (GCG) software 
package 
Sequence data generated from each patient and control of the three candidate 
genes: SPARC, HAH1, and annexin VI, was compared with the published 
sequences using BestFit analysis, as previously described 
(Chapter 3 section 
3.2.14.1). 
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6.3 Results 
6.3.1 Patients 
Nine patients with the classical features of the 5q- syndrome and a deletion of 
chromosome 5 as the sole karyotypic abnormality were included in the molecular 
and mutation analysis of the SPARC, HAH1, and annexin VI candidate genes. 
Cytogenetic details of the patients are shown in Table 6.6. 
6.3.2 Gene dosage analysis 
Gene dosage analysis with cDNA clones derived from the HAH1 and annexin VI 
genes and the renin gene showed both probes hybridised to a single fragment. An 
approximate 50% reduction in the dosage of each cDNA clone in the granulocyte 
patient DNA compared with normal controls, confirmed the deletion of one allele. 
6.3.3 Northern analysis 
Northern analysis showed I. M. A. G. E. cDNA clone 416547 derived from the HAH1 
gene to possess a single transcript of 0.8kb and to be ubiquitously expressed, see 
Figure 6.2. 
6.3.4 Southern analysis 
No rearrangements were observed in the granulocyte fractions of nine patients 
with the 5q- syndrome digested with restriction enzymes PstI, Hindill, PvuII, and 
BgIII, following hybridisation with I. M. A. G. E. cDNA clone 1883868 derived from 
the HAH1 gene. 
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Table 6.6 Clinical details of 5q- syndrome patients included in the study 
Patient Sex/age Cytogenetic karyotype Sample type 
1 F/66 46, XX, del(5)(g31g33) Granulocyte fraction 
DNA + RNA 
2 F/22 46, XX, del(5) (q31 q33) Granulocyte fraction 
DNA + RNA 
3 F/65 46, XX, del(5)(q33-q34) Granulocyte fraction 
DNA + RNA 
4 F/60 46, XX, del(5)(g13-q33) Granulocyte fraction 
RNA 
5 F/81 46, XX, del(5) Granulocyte fraction 
RNA 
6 M/48 46, XY, del(5)(g13-q33) Granulocyte fraction 
RNA 
7 F/78 46, XX, del(5) Granulocyte fraction 
RNA 
8 F/61 46, XX, del(5)(g13-q33) Granulocyte fraction 
RNA 
9 F/83 46, XX, del(5)(g13-q33) Granulocyte fraction 
RNA 
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Figure 6.2 
Representative Northern blot analysis of I. M. A. G. E. cDNA clone 416547. The 
MTN blot included 2pg of Poly-(A)+ RNA from; spleen (1), lymph node (2), 
thymus (3), peripheral blood leukocytes (4), bone marrow (5), and foetal liver (6). 
Sizes of RNA marker bands (kb) are indicated approximately. 
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6.3.5 Localisation to the YAC contig 
The SPARC, HAH1, and annexin VI genes were sublocalised by PCR screening to 
YAC 816D6 from the YAC contig spanning the critical region of the 5q- syndrome 
(Kostrzewa et al., 1998), see Figure 6.3. The SPARC and HAH1 genes were further 
localised to the 200kb BAC 113P19. The annexin VI gene was shown to map to the 
136kb BAC 119C17, distal to the SPARC and HAH1 genes, at 5q32. 
6.3.6 Expression in CD34' cells by RT-PCR analysis 
The SPARC, HAH1 and annexin VI genes were all expressed in RNA from CD34+ 
cells upon analysis by RT-PCR, see Figure 6.4. 
6.3.7 Mutation analysis of the SPARC gene 
No mutations were found in the 9 coding exons (exons 2-10) of the SPARC gene in 
the 3 patients with the 5q- syndrome included in the study. AC to G substitution 
in exon 10 of patient 3 was observed at nucleotide 998. This single base 
substitution was also observed in the normal control, suggesting this was a 
polymorphism, see Figure 6.5. Patients 1 and 2 had aC at nucleotide 998, 
consistent with the published sequence (Villarreal et al., 1989). Furthermore, in 
exon 10, aT was observed at nucleotide 960 in all 3 patients and the normal 
control. This is in contrast to the published sequence (Villarreal et al., 1989) that 
has aG at nucleotide 960. This base change does not affect the amino acid 
sequence at this position. 
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5q- syndrome critical region 3Mb 
ANX6 
CDX1 
ADRß2 CSF1R 
CENT ýýý 
5g31 
RPS14 
L, I II 
D5S4ý5S1419 D5S2416 D5S1838 D5S2 
SPARC HAH1 
_I 113P19 (200kb) 65D22 (70kb) 
54C21 (215kb) 90G13 (70kb) 262H11 (110kb) 
5q32 
YAC 816D6 
(1600kb) 
BAC clones 
Figure 6.3 
Fine physical mapping of the SPARC, HAH1 and annexin VI (ANX6) genes 
(boldface) within the critical region of the 5q- syndrome at chromosome 5q32. All 
three genes were localised to YAC 816D6. The SPARC gene was sublocalised to 
BAC 113P19, adjacent to the HAH1 gene. The ANX6 gene was sublocalised to 
BAC 119C17. The size of the YAC and BACs shown is indicated in the brackets. 
IL12(3 
TEL 
6.3.8 Mutation analysis of the HAH1 gene 
No mutations were observed in the 207bp coding region of the HAH1 gene in the 8 
patients with the 5q- syndrome included in the study. 
MFAP3 
SPARC GRiA1 
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Figure 6.4 
Representative CD34+ expression analysis of the annexin VI gene. Total RNA 
obtained from CD34+ cells 1: 10 dilution (lane 1), 1: 100 dilution (lane 2), and 
mononuclear cells of a normal healthy control (lane 3) was amplified with annexin 
VI gene specific primers. A negative control (lane 4) was included in the 
experiment. 
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Figure 6.5 
Representative sequence analysis of exon 10 of the SPARC gene. AC to G 
substitution in patient 3 (a) was observed at nucleotide 998. This single base 
substitution was also observed in the normal control suggesting this was a 
polymorphism. Patient 2 (b) shows aC at nucleotide 998, consistent with the 
published sequence. An asterisk (*) indicates the position of the base change. 
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6.3.9 Mutation analysis of the annexin VI gene 
No mutations were found in the four fragments encompassing the 2022bp coding 
region of the annexin VI gene in the 9 patients with the 5q- syndrome included in 
the study. AT to C substitution in fragment 4 in 6/9 patients was observed at 
nucleotide 1778. This single base substitution was also observed in the normal 
control, suggesting this was a polymorphism. 
6.3.10 Database analysis using the Genetics Computer Group (GCG) software 
package 
Sequence data from each patient was compared with the published sequence and 
the normal control using BestFit analysis, see Figure 6.6. 
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1 aggacctggtacaacaggatgtccaggacctatacgaggcaggggaactg 50 
IIIIIIII11111 N I1 N IIlII1111111I1IIIII111II111I11I 
691 aggacctggtacaacaggatgtccaggacctatacgaggcaggggaactg 740 
51 aaatggggaacagatgaagcccagttcatttacatcttgggaaatcgcag 100 
1111111IIIIIII N 111IIII11111I11111 N1111IIIIIIIIi1l 741 aaatggggaacagatgaagcccagttcatttacatcttgggaaatcgcag 790 
101 caagcagcatcttcggttggtgttcgatgagtatctgaagaccacaggga 150 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIiIiIIIIIIIIIIIIII 
791 caagcagcatcttcggttggtgttcgatgagtatctgaagaccacaggga 840 
151 agccgatgaaggccagcatccgaggggagctgtctggggactttgagaag 200 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII'IIIIIIIIIII'II 
841 agccgatgaaggccagcatccgaggggagctgtctggggactttgagaag 890 
201 ctaatgctggccgtagtgaagtgtatccggagcaccccggaatattttgc 250 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIil1III111111I11111111 
891 ctaatgctggccgtagtgaagtgtatccggagcaccccggaatattttgc 940 
251 tgaaaggctcttcaaggctatgaagggcctggggactcgggacaacaccc 300 
IIIIIIIiIfIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
941 tgaaaggctcttcaaggctatgaagggcctggggactcgggacaacaccc 990 
301 tgatccgcatcatggtctcccgtagtgagttggacatgctcgacattcgg 350 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
991 tgatccgcatcatggtctcccgtagtgagttggacatgctcgacattcgg 1040 
351 gagatcttccggaccaagtatgagaagtccctctacagcatgatcaagaa 400 
1041 gagatcttccggaccaagtatgagaagtccctctacagcatgatcaagaa 1090 
401 tgacacctctggcgagtacaagaagactctgctgaagctgtctgggggag 450 
Illllllllllllllllllllllllllllillllllllllllllllllll 
1091 tgacacctctggcgagtacaagaagactctgctgaagctgtctgggggag 1140 
451 atgatgatgctgctggccagtt 472 
IIIIIIIIIIIIIIIIIIIIII 
1141 atgatgatgctgctggccagtt 1162 
Figure 6.6 
Representative BestFit analysis of patient 1 (top) and the published sequence 
(bottom) from fragment 2 of the annexin VI gene. The analysis shows no 
ambiguities between the two sequences suggesting no mutations or 
polymorphisms exist in this patient. 
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6.4 Discussion 
The SPARC, HAHI and annexin VI genes have been localised and finely mapped 
to the critical region of the 5q- syndrome at 5g31.3-q32, flanked by the DNA 
marker D5S413 and the GLRA1 gene (Boultwood et al., 1994,2000). Their 
localisation, expression patterns in CD34+ cells and haematological tissues, and 
their predicted functions suggest they represent candidates for the putative 
tumour suppressor gene associated with the development of the 5q- syndrome, 
and warrant further analysis. 
Fine physical mapping of the three candidate genes demonstrated they mapped 
within YAC 816D6 within 5q32, with HAHI mapping immediately adjacent to the 
SPARC gene flanked by the genetic markers D5S1838 and D5S1419 (Boultwood et 
al., 2000). Annexin VI was shown to map proximal to SPARC and HAH1. 
The SPARC gene has been shown to regulate cell growth by inhibiting the cell 
cycle and to possess tumour suppressor activity making it a good candidate. An 
example of a gene involved in the cell cycle and which possesses tumour 
suppressor activity is the p27 (Kip1) gene. A major function of p27 is to bind and 
inhibit cyclin/cyclin-dependent kinase complexes, thereby blocking cell cycle 
progression (Philipp-Staheli et al., 2001). The central role of p27 makes it 
important in a variety of disease processes that involve aberrations in cellular 
proliferation and neoplasia. A large number of studies have reported that p27 
expression is frequently downregulated in human tumours. In addition, murine 
and tissue culture models have shown that p27 is a potent tumour suppressor 
gene for multiple epithelially derived neoplasias. 
To investigate the proposal that SPARC may be mutated in the 5q- syndrome, we 
directly sequenced three patients with the 5q- syndrome for mutations 
in the nine 
coding exons of SPARC. A previously unidentified polymorphism 
in exon 10 was 
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seen in patient 3 and in normal control DNA. No mutations were found in the 
nine coding exons of the SPARC gene in the three patients with the 5q- syndrome 
included in the study. Consequently, SPARC is unlikely to be the putative tumour 
suppressor gene associated with the development of the 5q- syndrome. 
The annexin VI gene has also been shown to possess tumour suppressor activity 
making it a good candidate for the 5q- syndrome tumour suppressor gene. A 
member of its family (annexin VII) may also play a role in tumour suppression. 
Other examples of family members both possessing tumour suppressor activity 
comes from the p53 family members, p63 and p73. The p73 and p63 genes share 
similarities in transcription activation and apoptosis induction (Tan et al., 2001), 
and possess 63% amino acid identity in the DNA-binding domain (Levero et al., 
2000), with p53. Like p53, the p63 and p73 genes have been found to be mutated in 
human cancer, although mutations are rare (Irwin and Kaelin, 2001). 
We screened the annexin VI gene for mutations in the coding region by cycle 
sequencing. No mutations were found in the coding region of the annexin VI gene 
in nine patients with the 5q- syndrome included in the study. A previously 
unidentified polymorphism in fragment 4 at nucleotide position 1778 of the 
coding region, was seen in six out of nine patients and in normal control DNA. 
Annexin VI is unlikely to be the putative tumour suppressor gene associated with 
the 5q- syndrome. 
6.4.1 The role of antioxidants in MDS and leukaemia 
Certain dietary (chemical) and endogenous (enzymatic) antioxidants have been 
cited in the literature as fighting oxidative stress specifically in MDS and 
leukaemia. A study by Peddie et al., (1997) demonstrated the use of the 
antioxidant Amifostine in MDS. Amifostine (Ethyol) is an important 
drug in 
clinical use which selectively protects normal tissues of various organs 
from the 
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effects of radiation and multiple cytotoxic chemotherapeutic drugs (Capizzi and 
Oster, 2000). Ineffective haematopoiesis in MDS is mediated, at least in part, by 
apoptosis, though the mechanisms of apoptotic induction are unclear. The 
authors found that Tumour necrosis factor-alpha (TNF-alpha) promotes apoptosis 
via intracellular OFR production, oxidation of DNA and proteins, and is 
increasingly implicated in the pathogenesis of ineffective haematopoiesis in MDS. 
This data implies a role for intracellular OFR production, mediated by TNF-alpha, 
in the pathogenesis of ineffective haematopoiesis in MDS, and provides a rationale 
for the bone marrow stimulatory effects of antioxidants such as Amifostine in 
MDS. 
Arsenic trioxide (As2O3) induces remission in a high proportion of patients with 
acute promyelocytic leukaemia (APL) via induction of apoptosis (Bachleitner- 
Hofmann et al., 2001). Results suggest that the apoptotic effect of As2O3 is not 
specific for APL but can also be observed in non-APL acute myeloid leukaemia 
cells. Ascorbic acid has recently been demonstrated to enhance the apoptotic 
effect of As2O3, suggesting a possible future role of As2O3/ascorbic acid 
combination therapy in patients with AML (Bachleitner-Hofmann et al., 2001). 
An example of an antioxidant possessing tumour suppressor activity comes from 
the mitochondrial antioxidant enzyme, manganese-containing superoxide 
dismutase (MnSOD). Li et al., (2001) showed that reconstitution of MnSOD 
expression in several human cancer cell lines leads to reversion of malignancy and 
induces a resistant phenotype to the cytotoxic effects of TNF and hyperthermia, 
thereby functioning as a tumour suppressor gene. 
The HAH1 gene is thought to play a role in antioxidant defence, suggesting it may 
be involved in the development of the 5q- syndrome. Eight patients with the 5q- 
syndrome were sequenced for mutations in the small open reading frame of the 
HAH1 gene. No mutations or polymorphisms were found in the 204bp HAH1 
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coding region in the eight patients with the 5q- syndrome included in the study. 
Consequently, HAH1 is unlikely to be the gene involved in the pathogenesis of the 
5q- syndrome. 
6.4.2 Future work 
The technique of direct sequencing (cycle sequencing) as the primary method for 
mutation detection is time-consuming and costly. Since the beginning of this 
mutation analysis study, the sequencing goals of the HGP have been achieved 
ahead of schedule. This new sequence data along with the annotation of the 
critical region of the 5q- syndrome has changed the approach to mutation analysis 
on candidate genes considered to be associated with the development of the 5q- 
syndrome. 
Future mutation analysis work in this study will be carried out on genomic DNA 
on the coding exons of each gene mapping to the critical region of gene loss. Each 
coding exon will be screened by the primary method of DHPLC (denaturing high- 
performance liquid chromatography). Any sequence changes observed will be 
confirmed by cycle sequencing. This new approach will save time, money, and 
valuable patient material. 
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7.1 Introduction 
7.1.1 Identifying mutations in genes implicated in disease 
Over the past two decades there has been a greater understanding of the 
molecular genetics of human cancer. It is now known that cancer is essentially a 
genetic disease arising from inherited and/or somatically acquired mutations at 
different genetic loci, and that tumourigenesis is a multistep process (Pearson and 
Van der Luijt, 1998). Since the discovery of the cellular basis of hereditary; the 
chromosome, and the molecular basis of hereditary; the DNA double helix, there 
has been a quest to decipher first genes and then entire genomes. The plan to 
determine the complete human genome sequence was established by a consortium 
in 1995. The first two goals of the Human Genome Project were to; identify all the 
approximately 100,000 (now believed to be approximately 30,000) protein-coding 
genes in the human genome; and to determine the sequences of the three billion 
chemical bases that make up human DNA. This information will help to 
understand which genes are implicated in disease and to determine which 
nucleotide(s) changes have functional consequences. 
7.1.2 Techniques for mutation detection 
There are currently a number of sensitive methods for the detection of changes in 
the nucleic acid sequence. The introduction of the Polymerase Chain Reaction, 
which allows specific in vitro amplification of a particular target DNA sequence 
(Saiki et al., 1988), has greatly facilitated the development of techniques to identify 
genetic alterations. 
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7.1.2.1 Single-strand conformation polymorphism (SSCP) 
Single-strand conformation polymorphism (SSCP) analysis is a rapid method for 
the detection of minor sequence changes in DNA (Hayashi and Yandell, 1993). 
Over the last decade, the technique has been widely used to detect mutations in 
oncogenes, tumour suppressor genes, and genes responsible for genetic diseases 
(Hayashi and Yandell, 1993). SSCP is particularly useful when searching for small 
deletions or insertions, single base mutations, and polymorphisms. Large 
insertions or deletions greater than 1kb are likely to go undetected. Another major 
disadvantage of the technique is its sensitivity. SSCP is believed to have an 85% 
detection rate of fragments shorter than 300bp. The sensitivity depends on a 
number of factors, including the mutation pattern in the target sequence and the 
temperature. Excessive heat may result in the disappearance of mobility shifts 
(Glavac and Dean, 1993). 
SSCP has been widely used in the mutation analysis of disease genes. HNPCC is 
one of the most common cancer predisposition syndromes (Yuasa, 2000). 
Mismatch repair genes, such as hMSH2 and hMLH1 have been identified as 
causative genes for most HNPCC mutations detected by SSCP (Yuasa, 2000). 
SSCP is more often used as the technique prior to direct sequencing. Mok et al., 
(1993) used these two techniques to detect mutations in the p53, ras, and NF1 
genes. SSCP has also been used in conjunction with the protein truncation test 
(PTT) in the screening of mutations in the APC gene. Twenty-nine different 
mutations in thirty-four cases were identified, that all lead to the formation of 
premature stop codons (Giarola et al., 1999). 
7.1.2.2 Protein truncation test (PTT) 
The protein truncation test works by targeting mutations that generate shortened 
proteins, mainly premature translation termination. The PTT has several 
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advantages over other mutation detection methods; it has good sensitivity, a low 
false-positive rate, and can pinpoint the site of the mutation. However, a 
disadvantage is its use of RNA as the target (Den Dunnen and Van Ommen, 1999). 
The PTT has been used widely in the discovery of mutations, particularly in 
tumour suppressor genes. Tuberous sclerosis (TSC) is an autosomal dominant 
trait characterised by the widespread development of benign tumours (Sampson 
and Harris, 1994). LOH has been shown for the regions of chromosomes 9q34 and 
16p13 known to harbour TSC genes (Mayer et al., 1999). The authors screened the 
entire coding regions of the TSC1 and TSC2 genes with the PTT. They identified a 
high proportion of TSC2 splicing aberrations that strengthens the importance of 
intronic disease-causing mutations (Mayer et al., 1999). More recently, Wimmer et 
al., (2000) identified two novel mutations in the NF1 tumour suppressor gene 
using the PTT. 
7.1.2.3 Heteroduplex analysis (HDA) 
Heteroduplex analysis (HDA) is a gel electrophoresis based technique that 
distinguishes double-stranded heteroduplex molecules that form between a 
mutant and wild-type DNA strand, from homoduplex molecules. An advantage 
for the use of this method is that it does not require specialised equipment. The 
method has been modified in recent years to increase the sensitivity of single-base 
pair alterations. HDA has been used on its own, or more often, in conjunction 
with another technique (mainly SSCP) in mutation detection. Like SSCP, HDA 
has been used to screen for mutations in tumour suppressor genes. HDA was 
used with temperature gradient gel electrophoresis (TGGE) when screening for 
mutations in exon 15 of the TSC1 gene (Hass et al., 2000). Three novel mutations 
were identified in nine unrelated cases. Furthermore, Hass et al., showed HDA 
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had a higher sensitivity in detecting frameshift mutations, while TGGE was more 
sensitive in the detection of base changes. HDA has also been used as the sole 
technique in the screening of heterozgyous germline mutations in the RB1 gene of 
patients with bilateral retinoblastoma (Zhang and Minoda, 1995). 
7.1.2.4 Denaturing gradient gel electrophoresis (DGGE) 
Denaturing gradient gel electrophoresis (DGGE) allows the rapid screening of 
single base changes in enzymatically amplified DNA (Fodde and Losekoot, 1994). 
The technique is based on the migration of double-stranded DNA molecules 
through polyacrylamide gels containing linearly increasing concentrations of a 
denaturing agent (urea and formamide). The denaturing gradient can also be 
generated by temperature; this method is termed temperature gradient gel 
electrophoresis. DGGE has several advantages; high sensitivity (>95%), improved 
detection of heterozygotes, and easy isolation of the mutant allele for subsequent 
sequence determination. Disadvantages of the technique include; the need for 
special equipment, cost, and being time-consuming. 
A number of mutations in genes implicated in disease have been identified by 
DGGE. Analysis of ten exons of the APC gene led to the identification of eight 
novel germline mutations resulting in frameshifts or stop codons (Fodde et al., 
1992). Blanquet et al., (1993) identified germline mutations in the RB1 gene that 
also resulted in the generation of stop codons, amino acid substitutions, and 
alterations in splice sites. 
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7.1.2.5 Non-isotopic RNase cleavage assay (NIRCA) 
NIRCA is an RNase-cleavage-based method for mutation screening that detects 
mutations as double-stranded cleavage products in duplex RNA targets. This 
method is reasonably quick, can detect base-pair changes, and the cleaved 
products can be analysed on agarose gels. The technique is useful for screening 
large fragments (500bp - 1kb). Smaller fragments (<500bp) may have a mismatch 
that may not be resolved if cleavage occurs close to one end of the target fragment. 
As with most other methods NIRCA has been used to screen for mutations in the 
p53 gene (Macera et al., 1999). The authors identified two point mutations along 
with an Apal restriction site polymorphism located in intron 7 within p53. The 
polymorphism allowed the authors to detect LOH in informative samples in a 
population of patients with prostate cancer. LOH was detected in 10/31 patients 
(32.4%) suggesting the p53 tumour suppressor gene may play a more active role in 
prostate cancer than was previously believed (Macera et al., 1999). 
7.1.2.6 Direct sequencing 
The most sensitive screening technique for genes that predispose patients for 
particular cancers is direct sequencing (Gross et al., 1999). However, sequencing of 
complex genes is technically demanding, costly, and time-consuming. Direct 
sequencing (cycle sequencing) is often used to confirm and determine the nature 
of the mutation/polymorphism, following screening by one of the aforementioned 
methods. p53 is the most commonly mutated gene in cancers (Bharaj et al., 1998). 
Several studies have used SSCP followed by cycle sequencing as a method for p53 
gene mutation screening. For example, Wang-Gohrke et al., (1998) identified 
eleven mutations from forty-four SSCP-negative frozen ovarian cancer samples, 
and 17/61 (28%) patients with hairy cell leukaemia harboured p53 mutations 
in 
exons 5-8 of the p53 gene (Kong et al., 2000). Cycle sequencing has also 
identified 
mutations in patients with neurofibromatosis type 1 (Luria et al., 1997), and other 
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tumour suppressor genes, for example p15 and p16, in patients with bladder 
cancer (Orlow et al., 1995). 
7.1.2.7 Denaturing High Performance Liquid Chromatography (DHPLC) 
The most recently developed technique for detecting mutations in genes involved 
in carcinogenesis is DHPLC, also known as Temperature Modulated 
Heteroduplex Analysis (TMHA). The technique was first pioneered by 
Transgenomic and named the WAVETM Nucleic Acid Fragment Analysis System 
(Transgenomic, Inc., San Jose, CA). DHPLC employs the formation of 
heteroduplexes between wild-type (reference) and mutated DNA which are 
efficiently separated on a unique, polymer-based separation matrix with detection 
by UV/Vis and/or fluorescence. DHPLC has significant advantages over past 
techniques; experimental time is greatly reduced due to full system automation, 
parameter prediction and control features of the WAVEMAKERTM utility software; 
detection of unknown mutations in heterogeneous samples; and fragments are 
immediately available for direct sequencing, PCR amplification, and cloning. 
Moreover, there is significant reduction in the number of samples sequenced, and 
sensitivity has been reported to approach 100%. This non-gel, high-throughput 
technology provides the ideal platform for cancer research projects. 
Genes implicated in cancer and disease, including tumour suppressor genes, are 
now being screened for mutations by DHPLC. Studies include DHPLC analysis 
on the TSC1 gene. DHPLC detected 27/28 (96%) known TSC1 sequence 
variations. The only sequence variation not identified was a mosaic case (Roberts 
et al., 2001). Other studies include blind analysis of exon 16 of the NF1 gene where 
55/55 (100%) individuals were correctly identified (O'Donovan et al., 1998). 
DHPLC is now being used for new studies, for example, mutation analysis of the 
entire mitochondria genome has recently been reported (van den 
Bosch et al., 
2000). 
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DHPLC has been compared with other techniques to clarify its superiority. Gross 
et al., (1999) conducted a study of BRCA1 mutation analysis comparing DHPLC 
with SSCP and direct sequencing. Sequencing is the most sensitive technique, but 
is time-consuming. SSCP is one of the most frequently used pre-screening 
methods but its sensitivity and efficiency are unsatisfactory. The DHPLC 
technique resolved 100% of the DNA alterations that were observed in cycle 
sequencing. In contrast, mutation analysis by SSCP accounted for 94% of the 
detected variations. In addition, DHPLC allowed the discrimination between 
different alterations in a single fragment. 
7.1.3 The WAVETM DNA Fragment Analysis System 
The need for automated and high-throughput systems for DNA analysis has 
increased due to the demands of several genome projects. Many human diseases 
result from defects in genetic information leading to pathological symptoms and 
changed phenotypes. Thus, DNA sequence variants (polymorphisms) may be 
used in the analysis and diagnosis of genetic disease. 
The Transgenomic WAVETM DNA Fragment Analysis System is an accurate, 
automated, rapid and economical tool to screen for manifestations of changes in 
DNA sequence and analysis of DNA fragments. Transgenomic's approach for 
analysis of nucleic acids with the WAVETM system is based on a liquid 
chromatography principal. 
Analysis on the WAVETM system is performed at a temperature sufficient to 
partially denature the DNA heteroduplexes. The melted heteroduplexes are 
resolved from the corresponding homoduplexes by ion-pair reversed-phase liquid 
chromatography (DHPLC or TMHA). The differential retention times on the 
DNAsep® matrix allow for high sensitivity and rapid single nucleotide and short 
tandem repeat polymorphism (SNP and STR, respectively) detection. 
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In conclusion, the WAVETM Fragment Analysis System is the first commercially 
developed automated technology for DNA sequence variation detection and 
fragment sizing. It offers considerable advantages for high-throughput screening 
of SNPs and STRs in the human genome. 
7.1.4 Mutation analysis on genes mapping to the critical region of the 5q- 
syndrome, by DHPLC 
We decided to use DHPLC as the primary screening method for mutation 
screening of coding exons from candidate genes (known and predicted) mapping 
to the approximate 1.5Mb critical region of the 5q- syndrome at 5g31.3-5g32, 
flanked by the genetic marker D5S413 and the GLRA1 gene. 
The coding exons for each candidate gene have been predicted using the Ensembl 
gene prediction program, available from the Sanger Centre 
(http: //www. ensembl. org/). Thirty-six genes (twenty-three known, thirteen 
predicted (novel)) represented by approximately five hundred coding exons have 
been predicted to map to the critical region of the 5q- syndrome. This represents a 
gene-rich region making priority of importance. To coincide with the publication 
of the draft public Human Genome Sequence on February 15 2001, the Ensembl 
site has been updated to the October 7 data set, which was the main data set used 
in the publication and covers 94% of known genes. 
We selected genes for analysis that represent good candidate tumour suppressor 
genes for the 5q- syndrome, i. e. they possess tumour suppressor activity, have 
antioxidant properties, and have already been implicated in leukaemogenesis. 
The five candidate genes included in the study were the human plasma 
glutathione peroxidase (GSHPx-3) gene, human homologue of the Drosophila 
tumour suppressor gene fat2 (MEGF1) gene, the human platelet-derived growth 
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factor receptor, beta (PDGFRf3) gene, and two novel genes ENSG00000145872, and 
ENSG00000086589. 
7.1.4.1 The GSHPx-3 gene 
GSHPx-3 is one of a family of selenium-dependent glutathione peroxidases that 
reduce hydrogen peroxide and organic hydroperoxides in the presence of reduced 
glutathione. The essential role of GSHPx-3 is its ability to protect haemoglobin 
from oxidative breakdown in erythrocytes. Many forms of active oxygen such as 
hydrogen peroxide, lipid hydroperoxides, superoxide, hydroperoxy and hydroxyl 
radicals, and single oxygen are implicated in human disease (Chu et al., 1992). 
Evidence exists to support a role for oxidant damage in the pathogenesis of 
rheumatoid arthritis, cardiovascular disease, immune injury and cancer (Cerutti, 
1985; Cross et al., 1987). The antioxidant activity of the glutathione peroxidases, 
including GSHPx-3, may have a protective role in the development of many 
diseases, including atherosclerosis and carcinogenesis (Halliwell, 1987). 
7.1.4.2 The MEGF1 gene 
The MEGF1 gene is the human homologue of the Drosophila tumour suppressor 
gene fat2 and has been localised to the critical region of the 5q- syndrome by gene 
dosage analysis, and sublocalised to YAC 816D6 and BAC clone 17D7 (Fidler et al, 
2001). Previous studies identified fat2 as a tumour suppressor gene when two 
recessive lethal mutations in the fat2 locus caused hyperplastic, tumour-like 
overgrowth of larval imaginal discs in Drosophila (Mahoney et al., 1991). 
7.1.4.3 The PDGFRß gene 
The PDGFRf3 gene encodes a cell surface tyrosine kinase receptor 
for members of 
the platelet-derived growth factor family. These growth 
factors are mitogens for 
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cells of mesenchymal origin (Gronwald et al., 1988). PDGFRß has been implicated 
in the t(5; 12)(g33; p13) balanced translocation in a subgroup of patients with 
CMML (Golub et al., 1994). The consequence of the translocation is expression of a 
fusion transcript in which the tyrosine kinase domain of PDGFRß is coupled to a 
novel ets-like leukaemia gene, tel. The tel-PDGFRß fusion demonstrates the 
oncogenic potential of PDGFRß and may provide a paradigm for early events in 
the pathogenesis of AML (Golub et al., 1994). 
7.1.5.4 Novel gene ENSG00000145872 
Novel gene 145872 was selected for mutation analysis because it was shown to be 
expressed in CD34+ cells, and to be the human mitochondrial homologue of the 
bacterial heat-shock protein (hsp70) co-chaperone, GrpE. Molecular chaperones 
are defined as proteins that interact with non-native states of other protein 
molecules (Burston and Clarke, 1995). This activity is important in the folding of 
newly synthesised polypeptides and the maintenance of proteins in unfolded 
states suitable for translocation across membranes. The tumour suppressor genes 
p53 and RB1 have been shown to act as chaperones (Lane et al., 1993). 
7.1.5.5 Novel gene ENSG00000086589 
Novel gene 86589 was selected for mutation analysis because it was shown to be 
expressed in CD34+ cells and to possess an RNA-binding domain RNP-1 (RNA 
recognition motif). The RNA recognition motif (RRM) is one of the most common 
eukaryotic protein motifs. RRM sequences form a conserved globular structure 
known as the RNA-binding domain (RBD) or the ribonucleoprotein 
domain. 
Many proteins that contain RRM sequences bind RNA in a sequence-specific 
manner (Crowder et al., 2001). A tumour suppressor gene whose protein 
possesses an RBD is the WTI gene (Kennedy et al., 1996). 
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7.1.6 Aims of the study 
The primary aim of the study was to analyse the coding exons of five candidate 
genes for the 5q- syndrome, for mutations, by DHPLC. DHPLC is an accurate, 
rapid method for detecting changes in the DNA sequence, and has been used 
successfully to detect mutations in genes implicated in cancer and disease. The 
first step was to use the Ensembl program to identify known and novel genes 
predicted to map to the critical region of the 5q-syndrome. Secondly, Ensembl 
was used to establish the number of predicted coding exons for each known and 
novel gene, and to select the genes that were expressed in human bone marrow 
and CD34+ cells. Expression in CD34+ cells was carried out because MDS is a stem 
cell disorder. Mutation studies were then carried out on these candidate genes by 
DHPLC followed by direct sequencing with the aim of identifying the 5q- 
syndrome gene. 
During this study, we found one candidate gene, MEGF1, to be downregulated in 
a number of patients with the 5q- syndrome and AML compared to normal 
controls. Tumour suppressor genes and growth regulatory genes are frequent 
targets for methylation defects that can result in aberrant expression. The p16 
gene is one of several tumour suppressor genes that has been shown to be 
inactivated by DNA methylation in various human cancers (Woodcock et al., 
1999). Therefore, the second aim of the study was to establish a methylation map 
of the promoter region of the MEGF1 gene and evaluate the methylation status of 
CpG islands within the promoter region. 
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7.2 Materials and Methods 
7.2.1 Candidate gene selection 
Candidate genes for the 5q- syndrome gene were selected based on the following 
criteria; their localisation to the approximate 1.5Mb critical region of the 5q- 
syndrome at 5q31.3-q32 flanked by the DNA marker D5S413 and the GLRA1 gene; 
their expression in CD34+ cells and haematological tissues; and their predicted 
function, i. e. has antioxidant properties, or functions as a tumour suppressor gene. 
7.2.2 Ensembl exon prediction 
The coding exons for each candidate gene were either predetermined and 
accessible on the GenBank database at NCBI, or predicted by the Ensembl 
program. The genes were predicted by the Ensembl analysis pipeline from either 
a Genewise or Genscan prediction followed by confirmation of the exons by 
comparisons to protein, cDNA and EST databases. Novel genes predicted by 
Ensembl were confirmed experimentally in our laboratory. 
7.2.3 Samples 
Fifteen patients with the classical features of the 5q- syndrome, including a 5q 
deletion as the sole karyotypic abnormality were included in the study. In 
addition to the 5q- syndrome patients, one patient in transformation to AML, two 
patients previously with MDS that had transformed to AML, plus five AML 
patients (for the MEGF1 gene only), were included in the study. Whole peripheral 
blood, usually 5mls, was spun down and the plasma removed. Alternatively, 
granulocyte cells were separated from 40mis of peripheral blood by ficoll gradient 
centrifugation (Boyum, 1984). The granulocytes showed a high level of purity 
(>95%). High molecular weight DNA was obtained from either whole peripheral 
blood or from the fractionated blood leukocytes by Nucleon® extraction- Whole 
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peripheral blood DNA and granulocyte DNA fractions from healthy individuals 
were used as controls. Details of patient samples are shown in Table 7.1. 
7.2.4 PCR amplification 
The exon-specific primers were designed flanking the coding exons of each gene. 
The primers were approximately 50% GC and at least 19 bases in length. 
Additionally, the primers contained either aG or C residue as the last 3'-base, and 
did not have any regions that could self-anneal or form "hair pin" loops. The 
primers were dissolved in RNase-free water to a concentration of 100pmol/pl. 
7.2.4.1 Exon optimisation 
Exon optimisation was carried out using BioTaq DNA polymerase (Bioline UK 
Ltd., London, UK) (Chapter 2 section 2.5.2 steps 1-5). 
1. For each 50pl PCR reaction the following were added to a sterile 0.6ml PCR 
tube; 
sterile distilled water 
10x reaction buffer 
50mM MgC12 
dNTP mix 
primer 1 
primer 2 
template DNA (=200ng) 
Taq polymerase (2.0-2.5 units) 
up to 50p1 
5p1 
1.5p1 
4pl 
100pmo1 
100pmo1 
1}ßl 
0.5pl 
2. Details of each primer set are shown in Tables 7.2,7.3,7.4 and 7.5. Primers 
designed to generate a PCR product in the range approximately 150-450bp. 
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Table 7.1 Clinical details of 5q- syndrome and AML patients included in 
the study 
P ti a ent Sex/age Cytogenetic karyotype Sample type 
1 F/66 46, XX, del(5)(g31g33) Peripheral blood 
DNA 
2 F/22 46, XX, del(5)(g31g33) Granulocyte 
fraction DNA 
3 F/65 46, XX, del(5)(q33-q34) Granulocyte 
fraction DNA 
4 F/70 46, XX, del(5)(g22-q35) Granulocyte 
fraction DNA 
5 F/60 46, XX, del(5)(g13-q33) Peripheral blood 
DNA 
6 F/81 46, XX, del(5) Peripheral blood 
DNA 
7 M/48 46, XY, del(5)(g13-q33) Granulocyte 
fraction DNA 
8 M/66 46, XY, del(5) (q13-q31) Granulocyte 
fraction DNA 
9 F/78 46, XX, del(5) Granulocyte 
fraction DNA 
10 F/61 46, XX, del(5)(g13-q33) Granulocyte 
fraction DNA 
11 F/83 46, XX, del(5)(g13-q33) Granulocyte 
fraction DNA 
12 F 46, XX, del(5) Granulocyte 
fraction DNA 
13 F 46, XX, del(5) Peripheral blood 
DNA 
14 F 46, XX, del(5) + myelorna Peripheral blood 
DNA 
15 F 46, XX, del(5) Granulocyte 
fraction DNA 
16 F 46, XX, del(5) Granulocyte 
transforming fraction DNA 
17 F/52 46, XX, del(5)(g13-q33) Blast cells DNA 
RAEB -* AML 
18 M/58 46, XY, del(5)(g15-q35) Peripheral blood 
RAEB -* AML DNA 
19 A AML Blast cells DNA 
20 B AML Blast cells DNA 
21 C AML Blast cells DNA 
22 D AML Blast cells DNA 
23 E AML Blast cells DNA 
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Table 7.3 Exon primer conditions for the PDGFRß gene 
ne G E P i e xon r mer name Primer sequence Annealing PCR 
5'-3' temperature Product 
size 
PDGFRß 1 PDGFR-Ex1-F2 CTGCCACCAGCACACATC 60°C 220bp 
PDGFR-Exl-R2 GGCTCATTCTGCAGGAGCC 
2 PDGFR-Ex2-F2 AGCACTCTCTGGACTTCCC 62°C 481bp 
PDGFR-Ex2-R2 GTGGCCTCCTCGCAGGC 
3 PDGFR-Ex3-F AGAATCCACTGGGAAGTG 57°C 430bp 
PDGFR-Ex3-R GGGATGGCCAGAAACCG 
4-5 PDGFR-Ex4-5F GTATCAAAAATGCAACTC 57°C 571bp 
PDGFR-Ex4-5R GCTGGTGGTGACTTCCC 
6 PDGFR-Ex6-F3 TCTAGGAGGGATGAACTGTC 55°C 477bp 
PDGFR-Ex6-R3 ACTCCATGGCTGGCACGG 
7 PDGFR-Ex7-F2 ACTCCTCCCATGGGTGGG 60°C 266bp 
PDGFR-Ex7-R2 GGGAGAACTGTAAGAGTCC 
8 PDGFR-Ex8-F GGGACTAGATAACCTTCACG 58°C 261bp 
PDGFR-Ex8-R AGGACCTGTCCTGTTAACTG 
9 PDGFR-Ex9-F GGTAGGGATTGGGATCGTC 58°C 316bp 
PDGFR-Ex9-R AGTTTCCCTGTCTGCAAGG 
10 PDGFR-ExlO-F GCCAGATCACGCAGCATTC 60°C 269bp 
PDGFR-Ex10-R ATCTATGATGCCAAAGATGGG 
11 PDGFR-Exll-F CAGACCTCAGAGAGTCTTC 60°C 275bp 
PDGFR-Ex11-R AGACGGACGAACCTAATGG 
12-13 PDGFR-Ex12-13F CTGGGAGAGGCTAAGTGTG 60°C 228bp 
PDGFR-Ex12-13R GCAGCTTCCTGGTAGGCC 
14 PDGFR-Ex14-F GTGTGCTGTTGTGCAAGGC 60°C 282bp 
PDGFR-Ex14-R AGAATAGGCTCCTGTGGTG 
15 PDGFR-Ex15-F CTCCTCAGGTATCCCAAAG 60°C 263bp 
PDGFR-Ex15-R TTGAAGGGACGCCTGAGG 
16 PDGFR-Ex16-F AAGAGCATCAGCCTGTTTGG 60°C 299bb 
PDGFR-Ex16-R GAGAAGAAATTCATGAGTGGC 
17-18 PDGFR-Ex17-18F TCACAGGCACTGTGACTGC 60°C 536bp 
PDGFR-Ex17-18R CCTGTGGGCCAGAAGGAG 
19 PDGFR-Ex19-F ATGAGTGGTCGAGGTAGAC 60°C 218bp 
PDGFR-Ex19-R GAGGTCCTTCCTTGCACTC 
20 PDGFR-Ex20-F AGCCAGTAGAGTTGGATATC 60°C 250bp 
PDGFR-Ex20-R CTCTCCTTGTCCTGTAGAAG 
21 PDGFR-Ex21-F CTTGTACTCGGTGTCTGAC 60°C 269bp 
PDGFR-Ex21-R CCTTGTTCTGAGAGGCAGC 
22 PDGFR-Ex22-F CTGTGCACAATTTCCTTGGC 60°C 336bp 
PDGFR-Ex22-R ATCCCTGAAGGCATTTCTGG 
23a PDGFR-Ex23a-F CGAGAGAGACCACAAAGTC 60°C 508bp 
PDGFR-Ex23a-R CCCCAAGAAGGATGTGAG 
23b PDGFR-Ex23b-F CTCACATCCTTCTTGGGG 60°C 449bp 
PDGFR-Ex23b-R GTATTCCAGGTGGTTGCAC 
23c PDGFR-Ex23c-F GTGCAACCACCTGGAATAC 60°C 429bp 
PDGFR-Ex23c-R CTGGGGCCATTAGGCAGC 
23d PDGFR-Ex23d-F GCTGCCTAATGGCCCCAG 62°C 437bp 
PDGFR-Ex23d-R GAAGAAAACTGCAGGGGCC 
23e PDGFR-Ex23e-F GGCCCCTGCAGTTI"TCTTG 58°C 440bp 
PDGFR-Ex23e-R ACTGCTGCTGGAATCCTCC 
NB. Exons 12 and 13 have now been predicted as one exon. This change 
does not 
affect the results in any way. 
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Table 7.4 Exon primer conditions for 15/23 exons of the MEGF1 gene 
Gene Exon Primer 
name 
MEGF1 12 
4 
5 
6 
7 
8 
11 
14 
15 
16 
17 
18 
19 
21 
r 
Primer sequence 
5'-3' 
MEG2-F CCACCATTGTAGAGATCCC 
MEG2-R GGAATGGTGGGTAAGGGTG 
MEG3-F 
MEG3-R 
MEG4-F 
MEG4-R 
MEG5-F 
MEG5-R 
MEG6-F 
MEG6-R 
MEG7-F 
MEG7-R 
MEG8-F 
MEG8-R 
MEG11-F 
MEG11-R 
MEG14-F 
MEG14-R 
MEG15-F 
MEG15-R 
MEG16-F 
MEG16-R 
MEG17-F 
MEG17-R 
MEG18-F2 
MEG18-R2 
MEG19-F 
MEG19-R 
MEG21-F2 
MEG21-R2 
TATCTTCCTCCCTGAACCC 
TTGCCTCAGTAAAGTGGCC 
AAGGCCACTAACCAGCATG 
TGCAATTGTCAGCTCAGGTG 
GAGCTGGTGTATAAGGATGG 
GTCTTCCTGTCTCTTGGCC 
AAGAAGGCCTTCCATCTCC 
CTAAATCACTGAGGTTGTGG 
TCAGCATGTCTCCAAGCATG -I 
GGCTTGCAGTGCACCTTCTC 
ATCTTGACCCATCCTCTGAG 
CTTACCCTAACCCTGCCTC 
TGGATCTGAATGCAGTCCC 
CATGGCACTGGGCACTTG 
GGCCCAACTGCCTCATTG 
GTTCTTGTCCCACAAAGAGC 
ACCCCACCGCAGGTATC 
ATTCATCTTCTGGACCTGC 
GCTACCTCATTGCTAACCTC 
GCATCTTCTGCTAGAAGGG 
GGGACTCATTCTGCTCTTTG 
CCATGGTCACCACCAGAAG 
TAGCCCGTTTGATGTCCAG 
TCCATGTCACAGAGCAGAG 
CAGAGTACAGAGCGCATTC 
CAGTCTGCCAATGCCAGG 
Annealing PCR 
temp Product 
size 
63°C 439bp 
60°C 
65°C 
60°C 
60°C 
63°C 
60°C 
60°C 
60°C 
60°C 
60°C 
60°C 
58°C 
63°C 
63°C 
NB: The remaining eight MEGF1 exons were analysed by direct sequencing 
239bp 
411bp 
323bp 
240bp 
398bp 
318bp 
276bp 
296bp 
234bp 
250bp 
279bp 
438bp 
244bp 
289bp 
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7.2.4.2 High-fidelity PCR 
High-fidelity PCR was carried out using a Hot-start Taq polymerase, namely 
AmpliTaq Gold® DNA polymerase (Applied Biosystems, UK), for the GSHPx-3 
gene and Thermo-StartTM DNA polymerase (ABgene®, UK), for the MEGF1, 
PDGFRJ3, ENSG00000145872 and ENSG00000086589 genes. This enables a clean, 
single PCR product to be produced. The primers and conditions used were from 
the exon optimisation experiments. 
la. For each 50pl PCR reaction using AmpliTaq Gold® DNA polymerase, the 
following were added to a sterile 0.6m1 PCR tube or 96-well plate; 
sterile distilled water 
10x reaction buffer 
25mM MgC12 
8mM dNTP mix 
primer 1 
primer 2 
template DNA (=200ng) 
Taq polymerase (1.25 units) 
up to 50}xl 
5}xl 
3}xl 
1.25}xl 
10pmo1 
10pmo1 
1}x1 
0.25}xl 
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1b. For each 501xl PCR reaction using Thermo-StartTM DNA polymerase, the 
following were added to a sterile 0.6m1 PCR tube or 96-well plate; 
sterile distilled water 
10x reaction buffer 
25mM MgC12 
2mM dNTP mix 
primer 1 
primer 2 
template DNA (=200ng) 
Taq polymerase (1.25 units) 
up to 50P1 
5p1 
3}z1 
5V1 
100pmo1 
100pmol 
1Pl 
0.25Vl 
7.2.5 Hybridisation of PCR products to form heteroduplexes 
This step is required to optimise the formation of heteroduplexes and 
homoduplexes. The patient sample is mixed with a sample of the wild-type DNA, 
denatured then reannealed under partially denaturing conditions. PCR products 
were hybridised on the GeneAmp® PCR System 9700 (Applied Biosystems UK) 
under the following conditions; 
Initial denaturation 
42 cycles of, 
95°C for 4 minutes 
95°C minus 1.6°C per cycle for 1 minute 
15 °C hold 
7.2.5.1 Ratio of wild-type to mutant DNA 
PCR products amplified from patient granulocyte DNA were mixed with PCR 
products amplified from homozygous wild-type DNA in a 50: 50 ratio. This was 
due to the granulocyte fractions having >95% purity. PCR products amplified 
from patient peripheral blood DNA did not require mixing. 
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7.2.6 The WAVETM DNA fragment analysis system 
The reagents required for running the WAVE TM system are shown in the 
Appendix. The data can be rapidly generated due to the TMHA parameter 
prediction capabilities of the WAVEMAKERTM utility software. 
7.2.6.1 WAVEMAKERTM prediction software for mutation detection 
The WAVEMAKERTM 4.0 prediction software allows the automated gradient and 
temperature prediction for discovery of SNP's and other mutations. The Mutation 
Detection application is used to determine the presence of a mutation in the 
sample fragment under partially denaturing conditions. 
1. Each PCR product from each exon was predicted to have a particular Tm. 
2. The temperature(s) required to separate the partially double-stranded DNA 
were predicted for each exon. For mutation discovery, it is desirable to 
analyse fragments at several temperatures. 
3. Based on the Tm of each fragment, the gradient is calculated for each 
temperature. The gradient template provides an approach to create a 
gradient between Buffer A (0.1M TEAA) and Buffer B (O. 1M TEAA in 25% 
acetonitrile). Gradients for mutation detection comprise a DNA loading step, 
the linear separation gradient, a clean-off step and finally, equilibration. 
4. A method is created for each individual temperature required for each exon. 
5. A project is constructed combining methods from each exon. The project has 
to begin with the lowest temperature working up to the highest temperature. 
7.2.6.2 Loading of samples 
1. For freshly made buffers, the two standards that are used to assess and 
calibrate the performance of the instrument prior to actual experimental 
sample analysis are run. They are used to optimise certain parameters, such as 
temperature, elution gradient, and buffer composition to ensure optimum data 
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acquisition. The first standard is the DNA Digest Standard. It consists of a 
restriction digest of plasmodia pUC18 by HaeIII and represents a pool of 9 
DNA fragments with the following sizes (bp): 80,102,174,257,267,298,434,458, 
587. The DNA digest standard is used to assess instrument performance for 
size-based DNA fragment separations. The second standard is the Mutation 
Standard. This consists of a combination of two defined 209bp fragments 
representing A and G alleles at position 168 of the polymorphic DYS271 locus. 
Upon heating and renaturation, this fragment mixture forms two 
homoduplexes and two heteroduplexes that are used to check instrument 
parameters for heteroduplex-based mutation screening. 
2. The hybridised samples were aliquoted into a 96-well plate. Usually, 2-10Pl of 
the sample, per temperature, is injected onto the column. 
7.2.7 Sequencing of heterozygotes 
Patient samples that produce a heteroduplex on analysis should be directly 
sequenced to identify the sequence change(s). Cycle sequencing reactions were 
carried out on the ABI PRISM 3100 Genetic analyser (Applied Biosystems) 
(Chapter 2 section 2.17). 
7.2.7.1 Samples 
The original PCR product, prior to hybridisation, should be used as the template 
in the sequencing reactions. If 5iil of the PCR product was 
loaded on the WAVE, a 
1: 10 dilution of the PCR product should be made and 1p1 of the 
dilution used as 
the template in the sequencing reaction. If 10}ßl of PCR product was 
loaded, 2}ßl of 
the dilution should be used as the template. 
7.2.7.2 Sequencing reactions 
Sequencing reactions were carried out using both the forward and reverse exon 
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specific primers to sequence the whole exon, including flanking intronic sequence, 
to rule out sequencing ambiguities. 
7.2.7.3 Data analysis using the Genetics Computer Group (GCG) software 
package 
The position of the sequence change(s) could often be predicted depending on 
which temperature on the WAVETM the change(s) was seen. The patient sequence 
would be compared with the homozygote wild-type sequence and published 
sequence, using BestFit analysis (Chapter 3 section 3.2.14.1) to determine the 
nature of the sequence alteration. 
7.2.8 RACE PCR 
The technology of 5' RACE PCR (Chapter 2 section 2.13) was used to determine 
the true 5' end of the MEGF1 gene. This data would then be used to identify the 
location of the MEGF1 promoter, and determine its methylation status. The 
libraries chosen for the RACE PCR were tissue-specific to the MEGF1 gene. 
1. Gene-Specific Primers were designed from the 5' end of the MEGF1 cDNA. 
Details of the primers, including their melting temperature (Tm) are shown in 
Table 7.6. 
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Table 7.6 5' RACE PCR primer conditions for candidate gene MEGF1 
Gene Primer GSP primer sequence Tm of 
name 5'-3' rimer 
MEGF1 MEGR3 (GSP1) CAGAGATGATCCGGTACCTCACTG 64°C 
MEGR2 (GSP2) AGCTCTCCACATAGGTCTTGGGAG 64°C 
MEGR4 (GSP1) AATTACCTCCCACTGGATCCCTCC 64°C 
MEGR6 (GSP2) ACAGCCAAACCATATCAGCCCTGC 64°C 
MEGR7 (GSP1) ACATGCAGAGGCTGCAGGAAAGC 64°C 
MEGR8 (GSP2) AGCCCTGCCTCTGTCATTTGCTAG 64°C 
MEGR10 (GSP1) GTGGCATCAGGCTGCCTGGCTG 64°C 
MEGR11 (GSP2) GTAGAATAAGGATAAGAAAATCATCAATC 64°C 
2. The Marathon-ReadyTM cDNA templates used in the 25}ßl RACE PCR reaction 
included; human pituitary gland, skeletal muscle, testis, whole brain, and 
placenta. 
3. The RACE PCR products were purified with Wizard preps as previously 
described (Chapter 2 section 2.5.1.3, steps 2-13), and prepared for sequencing 
as previously described (Chapter 2 section 2.19). 
7.2.8.1 Database analysis using the Genetics Computer Group (GCG) software 
package 
The sequence generated from each RACE PCR product was 
first compared with 
the MEGF1 cDNA sequence, using BestFit analysis (Chapter 3 section 
3.2.14.1) to 
determine the homology of the overlap. The sequence was then subjected to a 
BLAST protein search as previously described (Chapter 3 section 
3.2.12.2) 
utilising the Mammalian sequences database and the 
Genome sequences (gss and 
htg) database. A translation was carried out on the complete RACE sequence as 
previously described (Chapter 3 section 3.2.12.4) to 
determine if the sequence was 
in-frame or untranslated. 
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7.2.9 Genomic PCR 
A genomic PCR (Chapter 2 section 2.5.2) was carried out for the MEGF1 gene to 
confirm the genomic sequence order of the contig that included the MEGF1 gene, 
was correct according to the GenBank database. This was achieved by amplifying 
across the genomic sequence from the RACE sequence using the reverse RACE 
gene specific primer 
1. PCR primers were designed from the part of the contig containing the MEGF1 
gene that was approximately 1kb upstream of the 5'end of the true cDNA (as 
determined by RACE PCR (section 7.2.8). The approximately 1kb fragment 
was split into two overlapping PCR products using genomic sequence-specific 
primers and the 5' RACE gene-specific primer. Details of the primers are 
shown in Table 7.7. 
Table 7.7 Genomic PCR primer conditions for candidate gene MEGF1 
Gene Primer 
name 
GSP primer sequence 
5'-3' 
Tm of 
primer 
PCR 
size 
MEGF1 MEG-Fl ATGGGCTCTGTGGGAAACAGCAAG 64°C 580bp 
MEGR9 CCTCATGAGCCTTCATTTCACCTTC 63°C 
MEG-F2 GAAGAATCTGCCACCTTCCTGCC 64°C 547bp 
MEGR12 GTAAGAACTAGTCCCTGGGAGTTG 63°C 
2. The PCR products were purified with Wizard preps as previously described 
(Chapter 2 section 2.5.1.3, steps 2.13), and prepared for sequencing as 
previously described (Chapter 2 section 2.19). 
3. The sequence generated from the PCR products was compared with the 
genomic sequence from the contig containing the MEGF1 gene using BestFit 
analysis as previously described (Chapter 3 section 3.2.14.1). 
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7.3 Results 
7.3.1 Candidate gene selection 
Five candidate tumour suppressor genes; human plasma glutathione peroxidase- 
encoding (GSHPx-3) gene, human homologue of the Drosophila tumour suppressor 
gene fat2 (MEGF1) gene, human platelet-derived growth factor receptor, beta 
(PDGFRß) gene, and novel genes ENSO00000145872 and ENSG00000086589, were 
selected for mutation analysis by DHPLC. The known candidate genes had 
previously been mapped to the approximate 1.5Mb critical region of the 5q- 
syndrome at 5g31.3-q32 by gene dosage analysis. All candidate genes had 
previously been shown to be expressed in haematological tissues including 
human bone marrow, and CD34+ cells. Moreover, all five genes had putative 
functions that made them candidates for the 5q- syndrome gene. 
7.3.2 Ensembl exon prediction 
7.3.2.1 The GSHPx-3 gene 
The genomic structure of the GSHPx-3 gene had previously been determined 
(Yoshimura et al., 1994). Therefore, sequence data from the 5 exons of GSHPx-3 
was accessed from GenBank at NCBI under the accession numbers: D16360 (exon 
1); D16361 (exon 2); and D16362 (exons 3,4, and 5). The exons had a combined 
length of 681bp. 
7.3.2.2 The MEGF1 gene 
The Ensembl program had predicted the MEGF1 gene to contain twenty-three 
coding exons from its 14536bp cDNA. Fifteen of these 23 exons were analysed for 
mutations by DHPLC. The 8 MEGF1 exons not analysed by DHPLC were analysed 
by direct sequencing as the size of these exons were greater than 450bp. 
Page 235 
7.3.2.3 The PDGFRß gene 
The full cDNA sequence of the PDGFRß gene was known and was accessed from 
GenBank at NCBI under the accession number NM_002609. The Ensembl 
program predicted 23 coding exons comprising a total length of 5216bp. The latest 
Ensembi prediction has predicted exons 12 and 13 to be one exon, making 22 
PDGFRß coding exons. This has not affected the results in any way. 
7.3.2.4 Novel gene ENSG00000145872 
The Ensembi program predicted novel cDNA 145872 to have 3 coding exons with 
a total length of 600bp. 
7.3.2.5 Novel gene ENSG00000086589 
The Ensembl program predicted novel cDNA 86589 to have 12 coding exons with 
a total length of 2300bp. The latest Ensembl prediction has predicted exons 4 and 
5 to be one exon, making eleven 86589 coding exons. This has not affected the 
results in any way. 
r 
7.3.3 Samples 
Ten patients with the 5q- syndrome were selected from the pool of patients used 
in the study, see Table 7.1. In addition, the two MDS cases that had transformed 
to AML were included in the analysis for each gene. Five AML cases with a 
5q 
deletion were included in the mutation analysis of the MEGF1 gene. 
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7.3.4 PCR amplification 
The PCR conditions for each coding exon from the 5 candidate genes were 
optimised with BioTaq DNA polymerase. A more specific PCR product was 
obtained using one of the high-fidelity Taq polymerases. 
7.3.4.1 Exon optimisation 
Each coding exon from the 5 candidate genes was successfully optimised using 
BioTaq DNA polymerase, see Figure 7.1. 
7.3.4.2 High-fidelity PCR 
Each coding exon from the five candidate genes was successfully amplified with 
AmpliTaq Gold@ DNA polymerase or ThermoStart 
M DNA polymerase, see Figure 
7.2. 
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Figure 7.1 
Representative agarose gel analysis of the 358bp product of GSHPx-3 exon 1. 
Genomic DNA obtained from normal healthy controls (tracks 1 to 5) was 
amplified with exon-specific primers, and PCR performed on a thermal cycler. 
The PCR products were sized with the HyperLadder IV DNA marker (M). 
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Ml 234567 
449bp --ý 
449bp --º 
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Figure 7.2 
Representative agarose gel analysis of the 449bp PCR product of PDGFRf3 exon 
23b. Genomic DNA obtained from normal healthy controls (lanes 1 to 10) was 
amplified with exon-specific primers, and PCR performed on a thermal cycler. A 
negative control (lane 11) was carried out alongside. The PCR products were 
sized with the SuperMid DNA marker (M). 
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7.3.5 Hybridisation of PCR products to form heteroduplexes 
Each PCR product was hybridised to form heteroduplexes, see Figure 7.3. 
Figure 7.3 Creation of a mixture of heteroduplexes and homoduplexes 
through hybridisation 
wild-type mutant heteroduplexes homoduplexes 
+ 
heat 
cool 
AT GC ACGT AT GC 
IHI 1( 1( II II 
7.3.6 The WAVE'" DNA fragment analysis system 
The amplified PCR products from patient and control DNA for each coding exon 
from each candidate gene were optimised for DHPLC analysis. 
7.3.6.1 Temperature prediction 
The nucleotide sequence of each coding exon from the 5 candidate genes was 
analysed using the WAVEMAKERTM utility software. The Tm of the sequence was 
calculated and a melting curve obtained, see Figure 7.4a. 
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Figure 7.4a 
Graphical representation of the melting curve of MEGFI exon 19. The 243bp 
sequence has a Tm of 62°C and is 53% GC rich. 
Figure 7.4b 
Graphical representation of the temperatures required to partially denature 
MEGF1 exon 19. A polymorphism /mutation should only be detected if the DNA 
retains >_75% helicicity. Three temperatures are required to cover the 243bp size 
fragment. 
The temperature(s) required to partially denature the DNA of each fragment was 
then calculated using the WAVEMAKERTM utility software, see Figure 7.4b. The 
temperatures required for each exon from each candidate gene are shown in 
Tables 7.8,7.9 and 7.10. 
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Table 7.8 Temperature predictions for DHPLC analysis on the WAVETM 
system, for candidate gene MEGF1 
G ene Exon PCR 
product size 
Tm of 
PCR 
fragment 
Temperatures predicted for 
mutation analysis 
MEGF1 2 439bp 58°C 58°C/60°C/61°C/62°C 
3 239bp 61°C 61°C/63°C 
4 411bp 62°C 61°C/62°C/63°C 
5 323bp 63°C 61°C/63°C/64°C 
6 240bp 62°C 61°C/62°C/63°C 
7 398bp 61°C 61°C/62°C/63°C 
8 318bp 61°C 61°C/62°C/64°C 
11 276bp 59°C 59°C/60°C/61°C 
14 296bp 62°C 61°C/62°C/63°C 
15 234bp 61°C 61°C/62°C/64°C 
16 250bp 60°C 59°C/62°C 
17 279bp 62°C 62'C/63'C/64'C 
18 438bp 62°C 61°C/63°C/64°C/65°C 
19 244bp 62°C 61°C/62°C/63°C 
21 289bp 62°C 62°C 
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Table 7.9 Temperature predictions for DHPLC analysis on the WAVETM 
system, for candidate genes PDGFRß and ENSG00000086589 
G ene 
PDGFRß 
Exon 
1 
2 
PCR 
product size 
220bp 
Tm of PCR 
fragment 
65°C 
Temperatures predicted for 
mutation analysis 
65°C/66°C 
3 
4-5 
481bp 
430bp 
571bp 
63°C 
61'C 
62°C 
62°C/63°C/64°C 
61'C/62'C 
61°C/62°C/64°C 
6 477bp 65°C 65°C/66°C 
7 266bp 64°C 64°C/65°C 
8 261bp 64°C 64°C/65°C/66°C 
9 316bp 66°C 66°C/68°C 
10 269b 61°C 62°C/63°C/64°C 
11 2175b 62°C 63°C/65°C 
12-13 228 b 63C 63°C/64°C/66°C 
14 282b 65°C 65°C/66°C 
15 263bp 63°C 63°C/64°C/66°C 
16 299bp 61°C 61°C/63°C/64°C 
17-18 536bp 63°C 62°C/63°C 
19 218b 63°C 62°C/64°C 
20 250b 61°C 61°C/63°C/64°C 
21 269b 63°C 63°C 
22 336bp 63°C 63°C/64°C/65°C 
23a 508b, 55°C 55°C/57°C/61°C/64°C 
23b 449bp 60°C 57°C/59°C/62°C/63°C/64°C 
23c 429b 60°C 57°C/59°C/62°C/64°C 
23d 437bp 61°C 60°C/62°C/63°C 
23e 440bp 63°C 62°C/63°C/65°C/66°C 
86589 1 302bp 66°C 65°C/66°C 
2 180b 61°C 61°C/62°C 
3 213bp 55°C 55°C/56°C 
4-5 243bp 60°C 59'C/61'C/63'C 
6-7 491b 57°C 55°C/57°C/60°C/61°C 
8 404bp 55°C 56°C/57°C/59°C 
9 333bp 55°C 55°C/58°C/62°C 
10-11 494bp 60°C 60°C/61°C/62°C 
12a 455bp 55°C 54°C/55°C/57°C/60°C 
12b 453bp 56°C 55°C/57°C/58°C/60°C 
12c 325bp 59°C 57°C/58°C/62°C/63°C 
NB. PDGFRß exons 12 and 13 have now been predicted as one exon. 86589 exons 4 
and 5 have now been predicted as one exon. These changes do not affect the results 
in any way. 
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Table 7.10 Temperature predictions for DHPLC analysis on the WAVET"" 
system, for candidate genes GSHPx-3 and ENSG00000145872 
Gene Exon PCR 
product size 
Tm of 
PCR 
fragment 
Temperatures 
predicted for mutation 
analysis GSHPx-3 1 358bp 65°C 63'C/65'C/67'C 
2 251bp 60°C 58'C/62'C 
3 306bp 61°C 56°C/61°C/62°C 
4 361bp 61°C 60°C/61°C/66°C 
5 363bp 60°C 60°C/63°C 
145872 1 364bp 54°C 55°C/59°C/63°C 
2 383bp 56°C 56°C/57°C/58°C 
3 458bp 60°C 59°C/60°C/62°C 
7.3.6.2 Mutation analysis results by DHPLC 
The 5q- syndrome and AML patients, plus the normal controls were shown to be 
homozygous or heterozygous for each coding exon of the candidate genes, by 
DHPLC. A single peak on the WAVE TM chromatogram represented the patients 
and controls that were homozygous for a particular exon, see Figure 7.5a. Two to 
four peaks represented the heterozygous patients and controls, see Figure 7.5b. 
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Figure 7.5a 
Representative DHPLC chromatogram of exon 1 of the ENSG00000145872 novel 
gene. A single, homozygous peak in patient 3 (a) was observed at 59°C (one of the 
temperatures predicted by the WAVEMAKERTM software). The amplified PCR 
product from the patient DNA was mixed with the amplified PCR product from 
the homozygous wild-type DNA in a 50: 50 ratio. This single, homozygous peak 
was also observed in the normal control (b). 
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Figure 7.5b 
Representative DHPLC chromatograms of heterozygotes. A single, homoduplex 
and single, heteroduplex peak in patient 5 (a) was observed at 64°C in exon 22 of 
the PDGFRß gene. The large arrow indicates the homoduplex peak. The small 
arrow indicates the heteroduplex peak. 
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A single, homoduplex peak and double, heteroduplex peak in patient 11 (b) was 
observed at 62°C in exon 19 of the PDGFRf3 gene. The large arrow indicates the 
homoduplex peak. The small arrows indicate the two heteroduplex peaks. 
Figure 7.5b 
A double, homoduplex and double, heteroduplex peak in patient 12 (c) was 
observed at 61°C in exon 2 of the MEGF1 gene. The amplified PCR products from 
the patient DNA was mixed with the amplified PCR products from the 
homozygous wild-type DNA in a 50: 50 ratio. The large arrows indicate the 
homoduplex peaks. The small arrows indicate the heteroduplex peaks. 
c) 
1 2 
7.3.7 Sequencing of heterozygotes 
34 
Time (Minutes) 
S 6 7 
No mutations were found in the coding exons of the candidate genes in the ten 5q- 
syndrome and seven AML patients included in the study. Several nucleotide 
changes in the coding exons of the patients were observed. These substitutions 
were also observed in the normal control(s), indicating that they were 
polymorphisms, see Tables 7.11 and 7.12, and Figure 7.6. A heterozygous pattern 
in exon 23e of the PDGFRf3 gene was observed in patient 11. No 
heterozygous 
pattern or nucleotide substitutions were found upon direct sequencing of patient 
11, i. e . the patient was 
homozygous. 
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Figure 7.6 
Representative sequence analysis of exon 14 of the MEGF1 gene. A heterozygous 
pattern of C and T alleles in patient 21 (a) was observed at nucleotide 44226. This 
heterozygous pattern was also observed in the normal control (b). An asterisk (*) 
indicates the position of the heterozygote. 
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Direct sequencing of the wild-type DNA that had been mixed with patient 11 
showed aG to A substitution at nucleotide 72432 when compared with the 
published sequence. Patient 11 has aG at nucleotide 72432. Therefore, patient 11 
and the normal control were homozygous for alternate alleles at nucleotide 72432, 
see Figures 7.7a and 7.7b. 
7.3.8 Data analysis using the Genetics Computer Group (GCG) software 
package 
Sequence data from each patient was compared with the published sequence and 
the normal control using BestFit analysis, see Figure 7.8. 
7.3.9 RACE PCR 
RACE PCR was used in this study to determine the true 5' end of the MEGF1 
gene. This was needed in order to accurately identify the promoter, upstream of 
the 5' end. Three 5' RACE PCR products were generated from the human 
pituitary gland, skeletal muscle, testis, and whole brain cDNA libraries with gene- 
specific primers designed from the 5' sequence of the MEGF1 cDNA. Direct 
sequencing of the first RACE PCR reaction generated products of various sizes. 
The largest product (865bp) was generated from the skeletal muscle cDNA 
library, and selected for further analysis. The second (501bp) and third (-240bp) 
RACE PCR reactions generated products of the same size in all tissues. Direct 
sequencing of the first two RACE products generated sequence that overlapped 
with the MEGF1 cDNA with 100% homology and extended the 5' end of the gene. 
The third RACE product only generated 130bp of sequence despite the PCR 
product being sized at ~240bp. This suggested the true 5' end of the MEGF1 gene 
had been determined. In total, 1256bp of 5' RACE sequence had been generated 
and added to the 5' end of the MEGF1 gene. 
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Figure 7.7a 
Representative DHPLC analysis of exon 23e of the PDGFRß gene. A heterozygous 
pattern was observed in patient 11 (a) at 66°C. The amplified PCR product from 
the patient DNA was mixed with the amplified PCR product from the wild-type 
DNA. A large arrow indicates the homoduplex peak. A small arrow indicates the 
heteroduplex peak. 
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A single, homozygous peak was observed in the normal control (b) at 66°C. 
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Figure 7.7b 
Representative sequence analysis of exon 23e of the PDGFRJ gene. AG was 
observed in patient 11 (a) at nucleotide 72432. This was consistent with the 
published sequence. 
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An A was observed in the normal control (b) at nucleotide 72432, suggesting 
patient 11 and the normal control were homozygous for alternate alleles in exon 
23e of the PDGFRß gene. An asterisk (*) indicates the position of the alternate 
alleles. 
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1 cttaaatctgtctcagtaatggtatcacctagaccaccaacatatagtgt 50 
1 cttaaatctgtctcagtaatggtatcacctagaccaccaacatatagtgt 50 
51 ggtgatagttttatcctctggtgggtccagccgaggcattgttgaagccc 100 
IIIIIIIIIililllllliillllllllliililllllilllllllllll 
51 ggtgatagttttatcctctggtgggtccagccgaggcattgttgaagccc 100 
101 gctttagaagcttgtcagctacaggatcattgattccgtaataacggtct 150 
11111illllll11111111111111111111111111111111111111 
101 gctttagaagcttgtcagctacaggatcattgattccgtaataacggtct 150 
151 ttaatattctgatcagcaagggggtcatctggatctgtaggctt 194 
151 ttaatattctgatcagcaagggggtcatctggatctgtaggctt 194 
Figure 7.8 
Representative BestFit analysis of patient 13 (top) and the published sequence 
(bottom) from exon 8 of the ENSG00000086589 novel gene. The analysis shows no 
ambiguities between the two sequences suggesting no mutations or 
polymorphisms exist in this patient. 
7.3.10 Database analysis using the genetic Computer Group (GCG) software 
package 
7.3.10.1 BestFit analysis 
The 1256bp of 5' RACE sequence was shown to overlap with 
the MEGF1 cDNA 
sequence with 100% homology over 135bp. 
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7.3.10.2 BLAST analysis 
A BlastX protein homology searches utilising the Mammalian sequences database 
showed the 1256bp RACE sequence to have 100% homology with the Homo sapiens 
protocadherin FA T2 mRNA (human homologue of the Drosophila tumour 
suppressor gene, fat2) - GenBank accession number AF231022, over a 135bp 
overlap (MEGF1 cDNA overlap). A BlastX protein homology search utilising the 
Genome sequences database showed the 1256bp RACE sequence to have 99% 
homology with the AC011374 Homo sapiens chromosome 5 clone CTB-113P19, 
working draft sequence, 37 unordered pieces over the whole 1256bp, see Figure 
7.9. The Ensembl program had previously shown the MEGF1 gene to map within 
contig AC011374 at 5q32. 
7.3.10.3 Translate 
The 1256bp RACE sequence could not be translated into one of the six open 
reading frames, suggesting the sequence was the 5' UTR of the MEGF1 gene. 
7.3.11 Genomic PCR 
The GenBank database has shown the genomic sequence of contig AC011374 to be 
in 37 unordered pieces. Therefore, a genomic PCR was carried out to determine if 
the sequence of contig AC011374, upstream of the 5' end of the MEGF1 gene, was 
in the correct order. Two overlapping PCR products (580bp and 547bp) were 
generated when genomic DNA was amplified across the genomic sequence of 
contig AC011374 containing the MEGF1 gene, from the 5' RACE sequence. Direct 
sequencing of the two PCR products generated 580bp and 547bp of sequence 
respectively that showed 100% homology with the genomic sequence of contig 
AC011374 over the whole 1127bp. This confirmed the sequence upstream of the 5' 
end of the MEGF1 gene was correct according to the GenBank database. 
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Figure 7.9 BlastX analysis of 5' RACE sequence (top) and the Homo sapiens 
chromosome 5 working draft sequence, contig AC011374 (bottom) 
RACE: 1 taagtcatttacctttattatttcactgaattttcacaacaatcctaagagattgatgat 
60 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII'IIIIIIIIIIIIIIIIIII'IIIII 
AC0113: 70985 taagtcatttacctttattatttcactgaattttcacaacaatcctaagagattgatgat 
71044 
RACE: 61 tttcttatccttattctacagaaggtgaaatgaaggctcatgaggttaaataacttgctc 
120 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
AC0113: 71045 tttcttatccttattctacagaaggtgaaatgaaggctcatgaggttaaataacttgctc 
71104 
RACE: 121 taaaagtcacctacctagcaaatgacagaggcagggctgacagccaggcagcctgatgcc 
180 
II1111111iIIIIIIIIIIIIIIIIIIfIIIII'I1f111'I11111111111111I11111 
AC0113: 71105 taaaagtcacctacctagcaaatgacagaggcagggctgacagccaggcagcctgatgcc 
71164 
RACE: 181 acgcctgggatcttggtcactttgctttcctgcagcctctgcatgtgcggaaacagctca 240 
IIII11111111I11111111111111111III111I1111IIIlIIIIIIIIIIIIII! 
AC0113: 71165 acgcctgggatcttggtcactttgctttcctgcagcctctgcatgtgcggaaacagctca 71224 
RACE: 241 gtttggctagagctcagccccagtggaaaggccttgtaggaaggagagagaatagtagtt 300 
III11111111111111111111IIIfIfI1111111111111111111111111111i1 
AC0113: 71225 gtttggctagagctcagccccagtggaaaggccttgtaggaaggagagagaatagtagtt 71284 
RACE: 301 tagaaccagatagctaaacttggttcctggctaagagttgggactatctcaccatcgccc 360 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIlIIIIIII 
AC0113: 71285 tagaaccagatagctaaacttggttcctggctaagagttgggactatctcaccatcgccc 71344 
RACE: 361 aaggagtcacagaaagtttttgggaaaaaagagtaaagagttcaggactgtgttctagct 420 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIilillll ýýýýýýýýýýýýýýýýýýýýýýý 
AC0113: 71345 aaggagtcacagaaagtttttgggaaaaaagagtaa-gagttcaggactgtgttctagct 71403 
RACE: 421 gctgagtgtctttgagagagcatttttgaactagtctgctattcttcagccacggggttt 480 
IIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
AC0113: 71404 gctgagtgtctttgagagagcatttt-gaactagtctgctattcttcagccacggggttt 71462 
RACE: 481 ctcaaccatggcactattgacattggggctggataattctgttgcagggctgatatggtt 540 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
AC0113: 71463 ctcaaccatggcactattgacattggggctggataattctgttgcagggctgatatggtt 71522 
RACE: 541 tggctgtgttcccacccaaatctcatcttgaattgtggctcccataatcccccagtatca 600 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIiIIIIIIIIIIIIIIIIII IIIIII 
AC0113: 71523 tggctgtgttcccacccaaatctcatcttgaattgtggctcccataatccccctgtatca 71582 
RACE: 601 tgggagggatccagtgggaggtaattgaatcataggggtgtgtttttcccatgctgttct 660 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIII IIIIIIIIIII 
AC0113: 71583 tgggagggatccagtgggaggtaattgaatcatgggggtgtgtttttctcatgctgttct 71642 
RACE: 661 cgtgatagtgaataagtctcatgagatctgatggttttacaaaggggagttcccctgcct 720 
IIIIIIfII'Iltl'flllllf(IIIIIIIIIfllflllllillll(IIII(IIIII(I(II 
AC0113: 71643 cgtgatagtgaataagtctcatgagatctgatggttttacaaaggggagttcccctgcct 71702 
RACE: 721 acgcgctcttgcctgctgccaagtaagatatgactttgcttttcctttgccttctgccat 780 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
AC0113: 71703 acgcgctcttgcctgctgccaagtaagatatgactttgcttttcctttgccttctgccat 71762 
RACE: 781 gattatggggcctccccagtcatgtggaacggtgagtccattaaacctcattcctttata 840 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII! IIIIIIIIIIII 
AC0113: 71763 gattatggggcctccccagtcatgtggaacggtgagtccattaaacctcattcctttata 71822 
RACE: 841 aattacccagtctcaggtatgtctttattctcagtgtgagaactgactcacacaaaggca 900 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
AC0113: 71823 aattacccagtctcaggtatgtctttattctcagtgtgagaactgactcacacaaaggca 71882 
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RACE: 901 ctgtcctatgcattgtaggttgtttagcagtatccccagcctctacctgccagatgccat 960 
IIIIIIIIiIIIII'I'lltllllll'IIIIIIIIIIIIIIIIIIIIIIIIIIIIJlIIIIII 
AC0113: 71883 ctgtcctatgcattgtaggttgtttagcagtatccccagcctctacctgccagatgccat 71942 
RACE: 961 tagcaccaccacccccaagctgggtcagccaaaagtatcttcagacattgccaagtgtcc 1020 
1I'1 111111111 14141I11111144I1I11I11414114I{111411V14111Hill 
AC0113: 71943 tagcaccaccactcccaagctgggtcagccaaaagtatcttcagacattgccaagtgtcc 72002 
RACE: 1021 cttgagggtcaaaatcacctccagttaagaatcacagcagtagaaaccattttttccccc 1080 
III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII9III 
AC0113: 72003 cttgagggtcaaaatcacctccagttaagaatcacagcagtagaaaccattttttccccc 72062 
RACE: 1081 taacttgcgccctgtcttttattttctgcccagggtttcgggagttttccaccatgacta 1140 
IIIIIIII I'{III'NIIIIIIIIIIII'I IIIII1111111411'Illlllll411'Ill'll 
AC0113: 72063 taacttgcaccctgtcttttattttctgcccagggtttcgggagttttccaccatgacta 72122 
RACE: 1141 ttgccctgctgggttttgccatattcttgctccattgtgcgacctgtgagaagcctctag 1200 
IIII{II111111I1I{I{IIIIIIIIIII9IIIII{I{{IIIIIIIIIII{III'{IIII 
AC0113: 72123 ttgccctgctgggttttgccatattcttgctccattgtgcgacctgtgagaagcctctag 
72182 
RACE: 1201 aagggattctctcctcctctgcttggcacttcacacactgcccattacaatgccac 
1256 
IIIIIIIIIIIIIIIIIIIIIIIIIII'111N IIIIIII IIIII{I{{IIIIIII 
AC0113: 72183 aagggattctctcctcctctgcttggcacttcacacact-cccattacaatgccac 
72237 
The 1256bp 5' RACE sequence has a 99% nucleotide match with the Homo sapiens 
chromosome 5 working draft sequence, contig AC011374. 
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7.4 Discussion 
The completion of the draft sequence of chromosome 5 by the Human Genome 
Project has enabled a collaboration with the Sanger Centre, using the Ensembl 
program, to predict the number of genes mapping to the approximate 1.5Mb 
critical region of the 5q- syndrome at 5g31.3-q32. The Ensembl program has 
predicted, in total, thirty-six genes of which twenty-three are known and thirteen 
are predicted (novel). The GSHPx-3, PDGFRf3, MEGF1 and novel genes 145872 
and 86589 represent candidates for the 5q- syndrome gene, and were analysed for 
mutations by DHPLC. 
The MEGF1 gene is the human homologue of the Drosophila tumour suppressor 
gene fat2 (Nakayama et al., 1998). The fat2 gene in Drosophila encodes a novel 
member of the cadherin superfamily (Mahoney et al., 1991). The cadherins 
function as calcium-dependent adhesion molecules. The fat2 tumour suppressor 
gene was identified because recessive mutations in the fat2 locus cause 
hyperplastic, tumour-like overgrowth of larval imaginal discs, defects in 
morphogenesis and differentiation and death during the pupal stage. Other 
members of the cadherin family have been shown to function as tumour 
suppressor genes in human cancer. An example is the E-cadherin tumour 
suppressor gene that is frequently inactivated by mutation in human breast and 
gastric cancer (Berx et al., 1998) 
Human homologues of other tumour suppressor genes from Drosophila have been 
shown to possess tumour suppressor activity. STIM1 (where STIM is stromal 
interaction molecule) is a candidate tumour suppressor gene that maps to human 
chromosome 11p15.5, a region implicated in a variety of cancers, particularly 
embryonal rhabdomyosarcoma (Williams et al., 2001). 
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To investigate the proposal that MEGF1 may be associated with the development 
of the 5q- syndrome, we analysed ten patients with the 5q- syndrome and seven 
patients with AML, for mutations in the twenty-three coding exons of the MEGF1 
gene. No mutations were found in the twenty-three coding exons of the MEGF1 
gene in the seventeen patients with the 5q- syndrome/AML included in the study. 
Sixteen previously unidentified polymorphisms were identified in the patient and 
normal control DNA from the M£GF1 exons analysed by DHPLC. 
During this study, the MEGF1 gene was shown to be inactivated by 
downregulation of gene expression in a number of patients with the 5q- syndrome 
and AML. Hypermethylation of the promoter region of tumour suppressor genes 
may lead to tumour suppressor gene inactivation in cancer. For example, Mancini 
et al., (1999) established a methylation map of the promoter region of the NF1 
tumour suppressor gene, and demonstrated functional sensitivity for methylation 
at specific sites for the SP1 and CRE binding (CREB) proteins in the NF1 
regulatory region. 
To identify the promoter and methylation status of the CpG islands within the 
promoter region of the MEGF1 gene, we determined the true 5' end of the MEGF1 
gene and identified the sequence upstream of the 5' end. To date, the promoter 
region and CpG islands cannot be identified using database promoter programs. 
Experimental studies will need to be carried out in order to identify the MEGF1 
promoter and to establish the methylation map of the promoter region of 
the 
MEGF1 gene. 
The GSHPx-3 gene, like the HAH1 gene, has been thought to play a role 
in 
antioxidant defence in cancer. An example of an antioxidant that may play a 
role 
in tumourigenesis is the superoxide dismutase (SOD2) gene, located on 
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chromosome 6q. A study by Bravard et al., (1998) showed SOD2 to have a lower 
activity in human melanoma cell lines with deletions of the 6q arm compared to 
the same cell lines without the 6q deletion. 
Ten patients with the 5q- syndrome were sequenced for mutations in the five 
coding exons of the GSHPx-3 gene. No mutations were found in the five coding 
exons of the GSHPx-3 gene in the ten patients with the 5q- syndrome included in 
the study. A previously unidentified polymorphism in exon 5 was seen in patient 
3 and in normal control DNA. 
The PDGFRß gene has been shown to have a proven role in leukaemia. PDGFRJ3 is 
a receptor tyrosine kinase that is disrupted by the t(5: 7), t(5: 12), and t(5: 14) in 
myeloid disorders, resulting in the fusion of PDGFRß to HIP 1, TEL / ETV6, and 
CEV14, respectively (Kulkarni et al., 2000). The identification of these fusion genes 
involving PDGFRJ3 strengthens the association between myeloproliferative 
disorders and deregulated tyrosine kinases. Other members of the type III 
receptor tyrosine kinase family include FMS (colony-stimulating factor 1R) and 
stem cell tyrosine kinase 1 (STK-1). Normal expression of STK-1 is limited to 
CD34+ stem/progenitor cells (Carow et al., 1996). However, in a study of primary 
bone marrow (BM) samples from patients with leukaemia, STK-1 was found to be 
expressed at a higher level in human leukaemias including AML, T-ALL, B- 
lineage acute leukaemia, and blast crisis CML, than in normal BM controls. 
Moreover, the STK-1 protein was found to be overexpressed in the leukaemic BM 
samples, suggesting STK-1 may play a role in the survival and/or proliferation of 
malignant clones in acute myeloid and lymphoid leukaemias (Carow et al., 1996). 
The PDGFRß gene was analysed for mutations by DHPLC in ten patients with the 
5q- syndrome and two patients with AML. No mutations were found in the 
twenty-three coding exons of the PDGFRJ3 gene in the twelve patients included in 
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the study. Sixteen previously unidentified polymorphisms were identified in 
patient and normal control DNA. 
The novel gene ENSG00000145872 was identified as a human mitochondrial 
homologue of the bacterial co-chaperone GrpE (Ensembl gene report, 2001). 
Mitochondria contain a set of molecular chaperones, including hsp70, which are 
essential for the import of proteins from the cytoplasm into the mitochondrial 
matrix (Hartl et al., 1992). Novel gene 113696 was selected as a candidate for the 
5q- syndrome gene as it was expressed in CD34+ cells, and some proteins of 
known tumour suppressor genes have previously been seen to act as chaperones. 
The p53 and RB1 tumour suppressor genes, the most commonly inactivated genes 
in human cancer, have been shown to act as powerful negative regulators of cell 
division (Lane et al., 1993). The RB1 gene achieves this by complexing to a variety 
of specific transcription factors and then inactivating their function. The capacity 
of the RB1 protein to bind these factors is regulated by phosphorylation. The RB1 
proteins can therefore be seen to act as a chaperone for these factors (Lane et al., 
1993). The p53 protein has also been shown to regulate transcription, but may also 
be regulated by its interaction with members of the hsp70 chaperone family (Lane 
et al., 1993). 
To investigate the proposal that novel gene ENSG00000145872 may be mutated in 
the 5q- syndrome, we analysed ten patients with the 5q- syndrome and two 
patients with AML, for mutations in the three coding exons of 
113696. No 
mutations were found in the three coding exons of the novel gene 
in the twelve 
patients included in the study. 
Novel gene ENSG00000086589 has been shown to have the 
RNA-binding domain 
(RNA recognition motif), RNP-1 (Ensembl gene report, 2001). 
This novel gene 
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was selected for mutation analysis as it is expressed in CD34+ cells and there have 
been reports of tumour suppressor genes encoding proteins that contain these 
binding domains. The WT1 tumour suppressor gene encodes four C2H2 zinc 
finger-containing proteins critical for normal mammalian urogenital development 
(Kennedy et al., 1996). WTI can bind specific DNA targets within the promoters of 
many genes and both transcriptional repression and activation domains have been 
identified (Kennedy et al., 1996). Therefore, it has been assumed that regulation of 
transcription is the basis of WT1 tumour suppressor activity. 
We therefore decided to analyse novel gene ENSC00000086589 by DHPLC in ten 
patients with the 5q- syndrome and two patients with AML, for mutations in the 
twelve coding exons of 86589. No mutations were found in the twelve patients 
included in the study. Five previously unidentified polymorphisms were 
identified in patient and control DNA. 
Results from this study have shown DHPLC using the WAVETM DNA Fragment 
Analysis System to be an accurate mutation detection technique. The major 
advantages it has over other screening methods is its sensitivity, which we found 
to be 100%, a major reduction in laboratory time, and a reduced number of 
samples to be sequenced. One disadvantage is the necessity for high-fidelity PCR, 
although that is true for all mutation detection techniques. Its major disadvantage 
is the cost to the researcher in the maintenance and running of the machine which 
is more expensive than previous mutation detection techniques. 
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Chapter 8 
Conclusion 
The 5q- syndrome is a myelodysplastic disorder characterised by refractory 
anaemia, hypolobulated micromegakaryocytic hyperplasia and a clonal 
cytogenetic anomaly consisting of an interstitial deletion of the long arm of 
chromosome 5 (5q-) (Mathew et al., 1993). It is widely believed that a gene(s) 
located on 5q may function as a leukaemia suppressor gene (Le Beau, 1992). 
In order to identify the putative 5q- syndrome tumour suppressor gene, we used 
the EST resource to generate a transcription map of the approximate 5Mb critical 
region of gene loss at 5g31-q33, flanked by the genes FGF1 and IL12ß. In the first 
instance we identified, isolated and mapped ten novel coding sequences to the 
YAC contig spanning the critical region. This included the cloning of novel gene, 
C5orf4, and the identification and mapping of the human synaptopodin and 
dynactin p62 genes, see Figure 8.1. This was followed by the identification and 
localisation of the human homologues of the Drosophila melanogaster RMSA-1, 
Saccharomyces cerevisiae CDC60, and Goliath protein genes, and the localisation of 
known human genes PP2A, tpr1, PPP1R2, and HAH1 to the transcript map, see 
Figure 8.1. These known and novel genes have contributed to the overall 
mapping of this genomic region and represent candidates for the 5q- syndrome 
gene. During the course of this study, however, several of these genes were 
eliminated from further analysis when the commonly deleted region of the 
5q- 
syndrome was narrowed to approximately 1.5Mb at 5g31.3-q32, 
flanked by the 
DNA marker D5S413 and the GLRA1 gene. 
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From the 1.5Mb critical region, we selected six known and two novel candidate 
genes for further analysis. We analysed the coding region/exons of the SPARC, 
annexin VI, and HAH1 genes for mutations by direct sequencing, and the coding 
exons of the GSHP x- 3, MEGF1, PDGF RJ3, ENSG00000145872, and the 
ENSGO0000086589 genes for mutations by DHPLC. No mutations were found in 
the coding exons of these genes in the 5q- syndrome/AML patients included in 
the study. 
I, and members of our research unit are currently analysing the remaining 
seventeen known and eleven novel genes mapping to the critical region of the 5q- 
syndrome for mutations in the coding exons of these genes. In addition, the 
expression level of each gene in the patients with the 5q- syndrome will be 
determined using TaqMan analysis to look for downregulation. 
Further studies should also be carried out on the methylation status of the 
promoter of each candidate gene if the gene is shown to be downregulated by 
TaqMan analysis. Methylation is the main epigenetic modification in mammals 
and abnormal methylation of the CpG islands located in the promoter region of 
the genes leads to transcriptional silencing (Esteller, 2000). Examples include the 
deleted in colorectal cancer (DCC) gene. Sato et al., (2001) found that DCC is 
frequently silenced, probably by epigenetic mechanisms instead of sequence 
mutations in gastric cancer. Other tumour suppressor genes that have been 
shown to be silenced by methylation are p16 (Tannapfel et al., 2000), NF1 (Mancini 
et al., 1999), HIC1 (Melki et al., 1999)/ Von Hippel-Lindau (VHL) gene (Clifford et 
al., 1998), and the first tumour suppressor gene described, RB1 (Robertson et al., 
2000). 
During this study we found the MEGF1 gene to be downregulated in a number of 
patients with the 5q- syndrome and AML compared to normal controls. The 
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identification of the MEGF1 promoter to evaluate the methylation status of CpG 
islands within the promoter region is in progress. 
It is possible that Knudson's two-hit hypothesis may not be relevant in the 
development of the 5q- syndrome and that haploinsufficiency may be the 
underlying mechanism. It is generally assumed that most mammalian genes are 
transcribed from both alleles. Hence, the diploid state of the genome offers the 
advantage that a loss-of-function mutation in one allele can be compensated for by 
the remaining wild-type allele of the same gene (Nutt and Busslinger, 1999). It is 
well known that the vast majority of human disease-causing genes are recessive, 
indicating that recessiveness is the 'default' state. However, a minority of genes 
are semi-dominant, as heterozygous loss-of-function mutation in these genes leads 
to phenotypic abnormalities. This condition is known as haploinsufficiency. 
Haploinsufficiency is believed to be the underlying mechanism in many diseases. 
Song et al., (1999) demonstrated that haploinsufficiency of the AML1 gene is the 
genetic basis of a form of familial thrombocytopenia which predisposes the 
affected individuals to the development of acute myeloid leukaemia. p27Kip is a 
candidate human tumour suppressor protein as it is able to inhibit cyclin- 
dependent kinases and block cell proliferation (Fero et al., 1998). However, a 
causal link between p27 and tumour suppression has not been established as 
homozygous inactivating mutations of the p27 gene in human tumours is a rare 
occurrence. Thus, p27Kipl does not fulfil Knudson's 'two-mutation' criterion for a 
tumour suppressor gene. Fero et al., demonstrated that molecular analyses of 
tumours in p27 heterozygous mice showed the remaining wild-type allele to be 
neither mutated nor silenced, suggesting p27 is haploinsufficient for tumour 
suppression. 
Knudson's hypothesis (the inactivation of two alleles) or haploinsufficiency are 
the two possibilities as the underlying mechanism in the 5q- syndrome. Extensive 
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studies need to be carried out on all candidate genes mapping to the approximate 
1.5Mb critical region at 5g31.3-q32. 
In recent years, the use of mouse models has greatly contributed to the 
understanding of the role of tumour suppressor gene function. Novel insights into 
the role of tumour suppressors in development, differentiation, cell cycle control, 
and tumour suppression have been obtained from the studies on these 'knockout' 
mice. In addition, such mice may serve as disease models for humans with 
inherited cancer predisposition syndromes. The advantage of many mouse 
tumour suppressor models is that they facilitate the study of the roles of tumour 
suppressor gene loss in tumour initiation and progression in vivo. Moreover, the 
extraction of primary cells from tumour suppressor-deficient mice has provided 
an important resource for in vitro studies on the role of targeted genes in cell cycle 
regulation, DNA damage response, regulation of apoptotic pathways, and 
preservation of genomic stability (Ghebranious and Donehower, 1998). For 
example, a knockout mouse has contributed to the understanding of the role of 
p53 in tumour suppression. Mice homozygous for a deletion in the p53 gene 
develop tumours at high frequency, providing essential evidence for the 
importance of p53 as a tumour suppressor in several human cancers (Attardi and 
Jacks, 1999). 
The ability to manipulate the mouse genome via overexpression, underexpression 
or deletion of genes using transgenic expression systems and embryonic stem cell 
(ES) technology has led to the identification and definition of the precise function 
of several tumour suppressor genes in vivo. This group 
includes mice with 
mutations in the RB1 gene. In contrast to the role of the 
RBI gene in human 
retinoblastomas, mice heterozygous for a mutant 
RB allele do not develop 
retinoblastoma, but develop pituitary tumours instead 
(Kumar et al., 1995). The 
tumour susceptibility phenotype of mutant mice has unveiled the tumour 
suppressor activity of specific genes that were not expected 
to have such a 
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function. Transgenic and knockout mice will have an increasingly important role 
in the identification of novel tumour suppressor genes (Kumar et al., 1995). This 
could be important in the identification of the putative 5q- syndrome tumour 
suppressor gene. The generation of a knockout mice for the 5q- syndrome is 
currently in progress. This method will address either a 'one-hit' 
(haplolinsufficiency) or 'two-hit' hypothesis as the underlying mechanism in the 
pathogenesis of the 5q- syndrome. 
The targeting of genes involved in the pathogenesis of cancer and disease is now 
being carried out on a global scale using DNA microarrays. The advent of cDNA 
microarray technology now allows the efficient measurement of expression for 
almost every gene in the human genome. Novel molecular-based sub-classes of 
tumours in breast carcinoma, colon carcinoma, lymphoma, leukaemia, and 
melanoma have been revealed using global expression profiling (Alizadeh et al., 
2001). DNA microarray analysis has already been shown to be of value in MDS. 
Despite the relatively high incidence of MDS in the elderly, differentiation of MDS 
from de novo AML still remains problematic. Through the use of oligonucleotide 
arrays, the gene encoding the protein Delta-like (Dlk) that is distantly related to 
the Delta-Notch family of signalling proteins, was found to be selectively 
expressed in patients with MDS compared to patients with AML and 
CML. Thus, 
Dlk could be the first candidate molecule to differentiate 
MDS from AML 
(Miyazato et al., 2001). We are currently using DNA microarray technology 
to 
identify genes that may be over or underexpressed in patients with 
the 5q- 
syndrome. 
The Human Genome Project originally was planned to last fifteen years, 
but 
effective resources and technological advances 
have accelerated the expected 
completion date to 2003. Several types of genome maps 
have already been 
completed, and a working draft of the entire 
human genome sequence was 
announced in June 2000, with analyses published 
in February 2001. It is most 
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probable that the availability of the complete annotated genomic sequence from 
human chromosome 5q will be the key in identifying and characterising the 5q- 
syndrome gene. 
The identification of the 5q- syndrome gene will enable the study of its protein at a 
functional level. Proteomics has contributed greatly to the understanding of gene 
function in the post-genomic era. Proteomics can be divided into three main 
areas: (1) protein micro-characterisation for large-scale identification of proteins 
and their post translational modifications; (2) 'differential display' proteomics for 
comparison of protein levels with potential application in a wide range of 
diseases; and (3) studies of protein-protein interaction using techniques such as 
the yeast-two-hybrid system. Investigators have used the two-hybrid system to 
directly assay interactions between known proteins and to isolate novel 
interacting partners for a protein of interest. The identification of mutations in 
each partner of an interacting pair of proteins, which disrupt the interaction, can 
be useful for generating genetic tools for characterising in vivo function. The 
functional characterisation of some tumour suppressor genes have been 
ascertained using the yeast two-hybrid system, including the familial breast and 
ovarian cancer susceptibility genes, BRAC1 and BRAC2 (Sharan et al., 1998). This 
system identified several murine Brcal and Brca2 interacting proteins, including 
BARD1. Recently, mutations suggesting a role as a tumour suppressor have been 
identified in the BARD1 gene in primary human tumours. The identification of 
molecules that interact with murine Brcal and Brca2 has greatly enhanced our 
knowledge of how BRCA1 and BRCA2 may function as tumour suppressor genes. 
Transfection studies using transformed NIH3T3 cells should also be carried out 
once the 5q- syndrome gene has been identified to observe any phenotypic 
changes the gene may cause. These studies have been carried out on other genes 
implicated in leukaemogenesis. For example, Kurokawa et al., (1996) 
demonstrated that the AMLb splice variant of the AML1 gene causes neoplastic 
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transformation of NIH3T3 cells. The elucidation of function of the 5q- syndrome 
gene could also be determined with the use of leukaemic cell lines. 
In conclusion, I have been involved in the generation of a transcript map of the 5q- 
syndrome critical region. These newly assigned genes have contributed to the 
detailed mapping of the region and have been investigated as candidate genes. 
Once the 5q- syndrome gene has been identified, it should be investigated to 
ascertain its implications, if any, in the pathogenesis of a wide spectrum of human 
cancers and leukaemias, as for the p53 tumour suppressor gene. 
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Appendix 
Stock solutions and Buffers 
1. Separation of granulocytes and mononuclear cells by density gradient 
centrifugation. 
a. Phosphate Buffered Saline (PBS) 
PBS tablets (Sigma Aldrich) 5 
PBS-EDTA stock 10mIs 
Distilled water up to 1 litre 
Autoclave 
b. PBS-EDTA stock 
PBS tablets 
0.5M EDTA (pH8.0) 
Distilled water up to 1 litre 
Autoclave 
5 
10mIs 
c. 0.5M EDTA (pH8.0)1 litre 
EDTA 186.1g 
Dissolve in 800mls of distilled water using a magnetic plate and flea. Adjust 
pH to 8.0 with NaOH (- 20g NaOH pellets). Make up to 1 
litre with distilled 
water and autoclave. 
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d. Red cell lysis buffer (pH 7.2) 
Sodium bicarbonate 1g 
Ammonium chloride 8.29g 
0.5M EDTA (pH 8.0) 200}1 
Distilled water to 1 litre 
The solution was prepared freshly when required and filter sterilised prior to 
use (0.22pM filter, Falcon). 
2. Standard restriction enzyme digestion of genomic DNA, and gel 
electrophoresis 
a. 10x TBE (1 litre) 
Trisma base 108g 
Boric acid 55g 
EDTA 9.3g 
Distilled water to 1 litre 
b. Gel loading dye (50mis) 
Bromophenol blue 0.25% 
Xylene cyanol FF 0.25% 
Ficoll (Type 400) 15% 
Distilled water to 50mls 
3. Southern blotting 
a. Ethidium bromide solution 
1 ethidium bromide tablet (100mg) was dissolved 
in 10mis of distilled water in 
a fume cupboard. The solution was stored at room 
temperature protected 
from the light. 
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b. Denaturing solution 
NaC1 
NaOH 
c. Alkali transfer buffer 
NaCI 
NaOH 
d. Neutralisation solution 
Tris-HC1(pH 7.5) 
NaC1 
1.5M 
0.5M 
1.5M 
o. 25M 
1M 
3M 
4. Transformation of competent cells 
a. LB (Luria Bertani) media (1 litre) 
Bacto-tryptone 10g 
Bacto yeast extract 5g 
NaCl 10g 
Distilled water to 1 litre 
Autoclave 
b. LB media with agar 
Same as for LB media, but just before autoclaving add 15g/litre bacto-agar. 
Allow to cool to 50°C and add appropriate antibiotics if necessary. Pour 
plates immediately allowing approximately 30-35mis of medium per 90mm 
plate. 
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S. Recovery of the probe from the plasmid 
`f Qx TAE (1 litre) 
Trisma base 242g 
Glacial acetic acid 57.1mis 
0.5M EDTA (pH 8.0) 100mis 
Distilled water to 1 litre 
6. Probe labelling 
a. Sephadex grade G-100 
Sephadex grade G-100 powder was added to sterile distilled water. 10g of 
powder yielded approximately 160m1 of slurry. The swollen resin was 
washed several times with sterile distilled water to remove soluble dextran 
(the volume of water used was at least twice the volume of resin). The resin 
was finally equilibrated in TE buffer (pH 8) and stored at room temperature. 
b. TE buffer (pH 8.0) 
10mM Tris pH 8.0 
1mMEDTApH8.0 
c. 1M Tris (I litre) 
Trisma base 121.1g 
pH adjusted to the desired value by the addition of concentrated HCI. 
Autoclave 
7. Filter hybridisation 
a. 20x SSC 
NaCl 
Tri-sodium citrate 
3M 
0.3M 
Page 307 
b. Hybridisation buffer 
SDS 
Denhardt's solution 
Dextran sulphate 
5x 
1% 
5x 
5% 
Aliquot into 50m1 centrifuge tubes and store at -20°C. Prior to use, defrost 
appropriate volume and add 100mg/ml denatured salmon testes DNA (Sigma 
Aldrich). 
c. SSPE (20x stock solution) 1 litre 
NaCl 
NaH2PO4. H20 
EDTA 
175.3g 
27.6g 
7.4g 
Dissolve in 800mls of distilled water. Adjust the pH to 7.4 with NaOH and 
make up to 1 litre with distilled water and autoclave. 
d. Denhardt's reagent (50x stock solution) 
Ficoll (Type 400) 5g 
Polyvinylpyrollidone 5g 
Bovine serum albumin (BSA) 5g 
Distilled water to 500mls. Filter sterilise with a 0.22ii filter, Falcon, and aliquot 
into 50m1 centrifuge tubes. Store at -20°C. 
Page 308 
8, 
a. 
Preparation of competent E. coli for transformation 
M9 minimal media (500mls) 
Na2HPO4 
KH2PO4 
NH4C1 
NaCl 
Distilled water to 500mls 
Autoclave and cool to 55°C 
6g 
3g 
lg 
0.5g 
IM MgSO4 1m1 
Glucose 2g 
1M CaC12 0.1ml 
Thiamine 0.348 
Adjust volume to 10mis with distilled water and filter sterilise. Add to the 
cooled M9 media. 
b. Minimal media agar plates 
As above but with 8g of bacto-agar. Prepare M9 media in a total volume of 
300mls of distilled water and dissolve 8g bacto-agar in the remaining 200mls. 
Autoclave separately. Mix the solutions together after autoclaving and cool to 
55°C. Add 10mis of filter sterilised solution as above and pour plates. 
c. SOB media (1 litre) 
Bacto-tryptone 20g 
Bacto yeast extract 5g 
NaCI 0.5g 
Distilled water to 1 litre 
Autoclave and add 20mis of sterile 1M MgSO4. 
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d. SOB media with agar 
As above but just prior to autoclaving add 15g/litre of bacto-agar. Cool to 
50°C before pouring plates. 
e. TFB (1 litre) 
Equilibrate a 0.5M solution of MES (2(N-morpholino)ethone sulphonic acid) to 
pH 6.3 using KOH pellets and sterilise by filtration. Store in aliquots at -20°C. 
0.5M K-MES pH 6.3 20mis 
KCl (ultrapure) 7.4g 
MnCl2.4H20 8.9g 
CaC12.2H2O 1.5g 
Hexa-amine cobalt chloride 0.8g 
Make up the solution using the purest available water and add the salts as 
solids. Sterilise by filtration into 50m1 aliquots and store at 4°C. 
9. Transformation of competent cells with ligated M13 
a. 2x YT media (1 litre) 
Bacto-tryptone 16g 
Bacto yeast extract 10g 
NaCl 5g 
Distilled water to 950mis. Adjust pH to 7.0 with NaOH. 
Distilled water to 1 
litre and autoclave. 
b. 2x YT agar 
Same as for 2x YT media, but prior to autoclaving, add 
15g/litre bacto-agar. 
Cool to 50°C before pouring plates. 
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C. 2x YT soft agar 
Same as for 2X YT media, but prior to autoclaving add 7g/litre bacto-agar. 
d. X. <al 
5-Bromo-4-chloro-3-indolyl-ß-D-galactoside. 
Dissolve X-gal in dimethylformamide to make a 2% solution. Cover tube in 
foil to protect from the light and store at -20°C. 
e. IPTG 
Isopropylthio-ß-D-galactoside. Dissolve IPTG in distilled water to make a 2% 
solution. Sterilise by filtration through a 0.22}i disposable filter. Aliquot and 
store at 20°C. 
10. Preparation of single-stranded templates 
a. 3M Sodium acetate 
Sodium acetate. 3H2O 408.1g 
Dissolve in 800mls of distilled water. Adjust the pH to 5.2 with glacial acetic 
acid or to 7.0 with dilute acetic acid. Make volume up to 1 litre with distilled 
water and autoclave. 
11. Preparation of the sequencing gel plates 
a. Bind silane 
Absolute ethanol 2mis 
10% acetic acid 0.5mls 
Bind silane 7.5pl 
Prepare immediately before use 
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2 
a. 
Transformation of competent cells with ligated pGEM®-T Easy 
2mM Mg2* stock 
X12 " 6H 20 20.338 
8304 7H2O 224.65g 
Add distilled water to 100m1. Filter sterilise 
b. SOC media 
Bacto®-tryptone 
Bacto®-yeast extract 
1M Nacl 
1M KCl 
2M Mg2+ stock, filter-sterilised 
2M glucose, filter sterilised 
2. Og 
0.5g 
1m1 
0.25m1 
lm1 
lml 
Add Bacto®-tryptone, Bacto®-yeast extract, NaCi and KCl to 97ml distilled 
water. Stir to dissolve. Autoclave and cool to room temperature. Add 2M 
Mg2+ stock and 2M glucose, each to a final concentration of 20mM. Bring to 
100ml with sterile, distilled water. Filter the complete medium through a 
0.2}ßm filter unit. The final pH should be 7.0. 
13. Precipitation of sequencing reactions with the Thermo SequenaseTM CyTM5 
Dye Terminator Kit (Amersham Pharmacia Biotech) 
a. 7.5M Ammonium acetate (50mis) 
Ammonium acetate 28.905g 
Distilled water to 50mis 
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14" The WAVETM DNA fragment analysis system 
a. Buffer A 
0-1-M Triethylammonium acetate (TEAA) 50mis 
A etonitrile (HPLC Grade) 250}zl 
Milli-Q water to 1 litre 
b. Buffer B 
0.1M Triethylammonium acetate (TEAA) 50mis 
25% Acetonitrile (HPLC Grade) 250m1s 
Milli-Q water to 950mis 
Mix by inversion. Solution undergoes an endothermic reaction when TEAA 
mixes with Acetonitrile. When solution has warmed to room temperature, 
add Milli-Q water to 1 litre. 
c. Buffer C (75% Acetonitrile wash solution) 
75% Acetonitrile (HPLC Grade) 750m1s 
Milli-Q water to 1 litre 
d. Buffer D (8% Acetonitrile syringe wash solution) 
8% Acetonitrile (HPLC Grade) 80mis 
Milli-Q water to 1 litre 
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